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Abstract 
 
The central thesis of this project is that damage caused by reactive nitrogen 
species, e.g. 3-nitrotyrosine (Tyr-NO2), constitutes a marker of disease 
progression/severity. A new sensitive electrochemiluminescence ELISA was 
optimised and validated for Tyr-NO2 measurement, giving a lower limit of 
quantification of 0.04 nM BSA-NO2, intra- and inter-assay CVs of 6.5% and 
11.3%, an average recovery of 106 ± 3% and average linearity 0.998 ± 0.001.  
Nitrative stress, carbonyl stress and C-reactive protein (CRP) concentrations 
were measured before and after major elective surgery. CRP measurements 
confirmed the induction of an inflammatory response. Median serum Tyr-NO2 
levels increased post-surgery to a median (inter-quartile range) value of 0.97 (0 
– 1.7) fmol nitrated BSA (BSA-NO2) equivalents/mg protein compared with a 
pre-surgery level of 0.59 (0 – 1.3) fmol BSA-NO2 equivalents/mg protein 
(p<0.05). Oxidative damage was confirmed by serum protein carbonyl levels 
(p<0.05). 
In a second pre-/post- surgery study, patients who developed sepsis 
postoperatively had significantly higher serum Tyr-NO2 levels one day prior to 
diagnosis (median (IQR) 4.5 (1.65 – 8.21) fmol BSA-NO2 equivalents/mg 
protein) compared to patients without sepsis (1.2 (0.74 – 5.97) fmol BSA-NO2 
equivalents/mg protein; p<0.05). Tyr-NO2 levels have not previously been 
measured before clinical diagnosis. However, Tyr-NO2 did not improve upon 
CRP as a diagnostic marker (area under the curve: Tyr-NO2 0.69 versus CRP 
0.88). 
Nitrate (NO3¯) supplementation in healthy smokers was also studied. Plasma 
Tyr-NO2 levels were unaltered by supplementation or smoking status. Salivary 
nitration was unaffected by smoking and decreased with NO3¯ 
supplementation: the median (IQR) pre-supplementation was 0.67 (0.31-1.14) 
and post-supplementation was 0.43 (0.12-0.61) pmol BSA-NO2 equivalents/mg 
protein. Ozone-based chemiluminescence was utilised for nitrite (NO2¯) and 
NO3¯ measurement as indicators of ˙NO production. Plasma and salivary NO2¯ 
and NO3¯ concentrations increased significantly with NO3¯ supplementation 
(p<0.05).  
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In contrast to published studies, brain frontal lobe Tyr-NO2 levels were not 
higher in dementia: the median (IQR) levels in dementia were 0.29 (0.19-0.57) 
and in non-dementia controls were 0.3 (0.22-0.55) pmol BSA-NO2 
equivalents/mg protein. However, the median brain tissue NO2¯ concentration 
was significantly higher in the Alzheimer’s disease group (p<0.05). Western 
blotting revealed that nitration was predominantly in a few select proteins, with 
TOF-MS/MS analysis suggesting haemoglobin is one of these proteins.  
Measurement of nitrative stress using ozone-based chemiluminescence and an 
electrochemiluminescence-based-ELISA overcomes earlier methodological 
flaws, such as low sensitivity. Detection of total Tyr-NO2 in different 
inflammatory states indicates that its measurement could have potential as a 
marker of disease, but measurement of nitration in specific proteins 
may be more informative than total Tyr-NO2. 
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Chapter 1  
Introduction 
1.1. The Inflammatory Response 
Inflammation is a physiological response to infection or injury and is non-
specific in nature. In particular, acute inflammation acts to remove pathogens 
and repair damaged tissue. The cardinal signs of the inflammatory response are 
heat, redness, swelling, pain and loss of function (Punchard et al, 2004). Many 
non-infectious diseases involve an inflammatory response (e.g. autoimmunity, 
cardiovascular disease, and some neurodegenerative diseases); this 
pathological inflammation often causes tissue damage, exacerbating the 
disease state (e.g. plaque formation in atherosclerosis (Willerson and Ridker, 
2004; Lalkhen and McCluskey, 2008)). 
Inflammatory signals are activated when pattern recognition receptors (PRRs), 
such as Toll-like receptors, found on leukocytes resident in the tissue or 
circulating in the blood, bind either alarmins/danger associated molecular 
patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) (de 
Jong et al, 2010; Newton and Dixit, 2012). Alarmins and DAMPs are host 
molecules that are produced or exposed as the result of tissue or cell damage, 
e.g. heat shock proteins (Castellheim et al, 2009). PAMPs are molecules that 
are found on a variety of pathogens but not within the host, e.g. 
lipopolysaccharide (LPS). Recognised by the toll-like receptor 4, LPS is an 
endotoxin found only on the outside of gram-negative bacteria and can induce a 
lethal immune response in mammals (Salomao et al, 2012). Recognition of 
these molecules is non-specific, i.e. recognition is an innate immune response 
(Castellheim et al, 2009). Activation of PRRs leads to the release of cytokines 
and acute phase proteins (synthesised in the liver and released into the blood 
stream) along with the activation of cascade systems such as complement 
(Figure 1.1) (de Jong et al, 2010). 
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Figure 1.1: Basic overview of the inflammatory response 
Briefly, inflammation is initiated by the presence of pathogens or damaged host tissue. The 
diagram above shows a wound that has penetrated the layers of skin and been infected with 
bacteria. Macrophages and neutrophils have been recruited to the area of injury/infection. These 
cells release pro-inflammatory cytokines (see section 1.2) and reactive oxygen species (see 
section 1.3). Pro-inflammatory cytokines and ROS will then act as signals for further response, 
such as IL-6 activating the acute phase response, and ˙NO causing vasodilatation (Gabay and 
Kushner, 1999; Gruys et al, 2005; Lalkhen and McCluskey, 2008).  
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The innate immune response involves the recruitment of monocytes (e.g. 
macrophages) and polymorphonuclear cells (e.g. neutrophils) to sites of 
infection or damage (Newton and Dixit, 2012). These cells carry out many 
important functions to aid in the removal of pathogens, clearance of dead cells 
and tissue repair (Fujiwara and Kobayashi, 2005; Kolaczkowska and Kubes, 
2013). During pathogen clearance, phagocytic cells (e.g. macrophages and 
neutrophils) undergo an oxidative burst (Slauch, 2011; Chen and Junger, 2012), 
which involves the assembly of the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase complex in the cell membrane, catalysing the 
reduction of oxygen to the free radical superoxide anion (O2˙¯) (Figure 1.2A) 
(Chen and Junger, 2012). O2˙¯ dismutates to hydrogen peroxide (H2O2) by one 
of the three superoxide dismutase (SOD) isoforms (Figure 1.2B) which are 
expressed in different cellular locations; the mitochondria (SOD2), the 
cytoplasm (SOD1) and extracellularly (SOD3) (Fukai and Ushio-Fukai, 2011). 
H2O2 is able to pass through the cell membrane, whereas O2˙¯ cannot, and 
H2O2 acts in a bacteriostatic manner in the surrounding tissue (Dunnill et al, 
2015). H2O2 may also be utilised in reactions that produce further reactive 
oxygen species (ROS) (Costa et al, 2005).  Inflammatory signals also lead to 
the activation of inducible nitric oxide synthase (iNOS), an enzyme that 
catalyses the production of the free radical nitric oxide (˙NO) from the amino 
acid, L-arginine (Figure 1.2C) (Lirk et al, 2002). The production of these free 
radicals/ROS will aid the destruction of the engulfed pathogen (Roos et al, 
2003) and act as secondary messengers, aiding wound healing (Dunnill et al, 
2015). ˙NO also acts as a vasodilator, increasing blood flow to the affected area 
(Salvemini and Marino, 1998) and contributing to the swelling associated with 
inflammation. The ROS and free radicals released during inflammation are 
discussed further in section 1.3. 
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1.2. Inflammatory mediators: cytokines, the acute phase response and 
complement 
Cytokines  
Cytokines are a vital part of inflammation and immunity with a diverse range of 
functions such as inducing fever, stimulating the acute phase response and 
migration of white blood cells (Borish and Steinke, 2003; Dinarello, 2007). 
Cytokines are not purely pro-inflammatory, as some induce the resolution of 
inflammation and promote tissue repair, e.g. IL-10 (Borish and Steinke, 2003). 
There are many families of cytokines, such as interleukins, interferons and 
tumour necrosis factors (Dinarello, 2007).  
The levels of circulating cytokines can be affected by several factors, including 
the time of day and diet. Cytokines typically have a short lifetime and immune 
cells have been shown to continue secreting cytokines in whole blood samples. 
Figure 1.2: Enzymatic production of reactive oxygen species during inflammation 
During inflammation concentrations of the following ROS are increased (A) superoxide anion 
production is catalysed by the NADPH oxidase, (B) hydrogen peroxide production catalysed 
by a SOD isoform and (C) nitric oxide production catalysed by inducible NOS. 
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Both of these factors can lead to over- or under-reporting the levels of 
circulating cytokines present in whole blood (Zhou et al, 2010).  
Acute phase response 
The acute phase response (APR) is a term to describe a systemic innate 
immune response to injury or infection (Gruys et al, 2005). The APR leads to 
increases in circulating pro-inflammatory cytokines and non-specific host 
defences, fever and changes in serum protein concentrations (Suffredini et al, 
1999; Gruys et al, 2005). These proteins, which fluctuate in concentration 
during the course of the inflammatory response, are referred to as acute phase 
proteins (APPs) and are divided into two groups: the positive APPs, which are 
defined as proteins whose plasma concentration increases by at least 25% 
during inflammatory illnesses (Table 1.1 for examples)  and the negative APPs, 
which show a >25% decrease in plasma concentration, such as, albumin, 
transferrin, retinol binding protein and factor XII (Gabay and Kushner, 1999). 
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Table 1.1: Well-known positive acute phase proteins and their roles 
The plasma concentration of the proteins detailed below increases during the acute 
phase response (Suankratay et al, 1998; Gruys et al, 2005; Eklund et al, 2012; 
Murakami et al, 2012). 
Protein Role/s 
Fibrinogen Coagulation 
α1-Protease inhibitor Anti-proteases 
Caeruloplasmin Transport protein 
C-reactive protein (CRP) Binds bacteria/activates complement 
Serum amyloid A 
Induces cytokine 
synthesis/chemotactic for neutrophils 
and mast cells 
Procalcitonin 
Stimulates release of pro-
inflammatory cytokines from 
monocytes 
 
These positive acute phase proteins are often used as biomarkers of 
inflammation, providing information on disease risk, progression or response to 
treatment. However, they are non-specific and will increase with any 
inflammation, not just the pathological inflammation associated with the 
disease.  
C-reactive protein (CRP) is produced by the liver in response to inflammatory 
signals (e.g. IL-6) and binds to PAMPs/DAMPs, such as phosphocholine. It can 
also bind to C1q to activate the complement cascade (Marnell et al, 2005). 
Healthy adult CRP levels are approximately 0.8 mg/L (Povoa, 2002) and these 
levels can increase 1000-fold within 24-48 hours of an inflammatory insult 
(Volanakis, 2001). A study by Colley et al (1983) found that, following surgery, 
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there was a 6-8 hour delay before the acute phase proteins CRP and fibrinogen 
increased in the blood. This was confirmed by Li et al (2004) who found 
increases in CRP were first measurable at 6 hours in patients receiving renal 
angioplasty with a stent. They do however disagree on when CRP levels peak 
in the blood, with Colley et al (1983) reporting 48 hours and Li et al (2004) 
reporting 24 hours, which could be due to the different surgeries patients 
underwent (i.e. elective surgeries, such as unilateral hernia repair, against renal 
angioplasty with a stent). CRP has a half-life of approximately 19 hours and 
levels will decrease rapidly following resolution of the inflammation (Hofer et al, 
2012). Fibrinogen was shown to peak at 96 hours (Colley et al, 1983). An 
elevated erythrocyte sedimentation rate, i.e. the rate at which erythrocytes 
sediment in an hour (the amount of clear plasma at the top of the tube is 
measured), is also considered a marker of inflammation and is often measured 
alongside CRP. However, although measuring erythrocyte sedimentation rate is 
an inexpensive and simple test, it is affected by patient gender and age 
(Olshaker and Jerrard, 1997; Feldman and Sbong, 2014).  
As well as indicating acute inflammation, as the result of trauma or infection, 
CRP can also be used alongside other markers (such as cholesterol) to 
determine a person’s risk of cardiovascular disease, with levels greater than 3 
mg/L indicating a high risk of a heart attack or stroke (Ridker, 2003).  
Complement 
The complement system consists of three activation pathways for 30 plus 
plasma and membrane proteins, which react in a cascade-like manner, 
amplifying the response. These pathways result in (a) opsonisation of 
pathogens (aids phagocytosis), (b) chemoattraction of white blood cells and (c) 
formation of membrane attack complexes in some bacteria (Dunkelberger and 
Song, 2009).  
Complement proteins are also positive APPs (Jain et al, 2011). Complement 
proteins C3 and C4 are measured clinically to diagnose and monitor immune 
complex diseases (such as systemic lupus erythematosus), where a decrease 
in serum levels is observed (Egner, 2000; Birmingham et al, 2010).   
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1.3. Inflammatory mediators: reactive oxygen/nitrogen species  
As has already been described (section 1.1), recruitment and activation of 
immune cells, such as macrophages and neutrophils also leads to the 
production of free radicals and ROS/RNS (see Table 1.2 for examples). Free 
radicals are defined as a species containing at least one unpaired electron. The 
use of the terms ROS and RNS covers both these free radicals and their 
reactive derivatives that do not have an unpaired electron (Halliwell, 2001).  
Table 1.2: Reactive oxygen species produced during inflammation 
Examples of ROS and RNS produced during inflammation (Guzik et al, 2003). These 
ROS and RNS aid in the destruction of pathogens and act as signals for the 
recruitment of more immune cells. However when produced in large amounts (or when 
antioxidant mechanisms are compromised) these species can cause modifications of 
macromolecules in the body, e.g. lipids, DNA and proteins (Pacher et al, 2007). 
 
 
 
 
 
 
 
 
 
 
The ROS and RNS generated during inflammation are involved in redox 
signalling and aid pathogen removal (Winrow et al, 1993; Roos et al, 2003; 
Dunnill et al, 2015). However, these species are also able to react with, and 
modify, cellular components such as the fatty acid membrane and proteins. To 
protect themselves, cells have antioxidant defences which may be enzymatic 
(e.g. catalase and glutathione peroxidase), or scavengers (e.g. glutathione and 
Free radicals  reactive 
oxygen/nitrogen species 
Non-radical reactive 
oxygen/nitrogen species 
N O  
(Nitric oxide) 
 
 
O O  
(Superoxide) 
 
 
H O  
(Hydroxyl radical) 
O
N
O
O
-
 
(Peroxynitrite) 
H
O
OH 
(Hydrogen peroxide) 
OH Cl 
(Hypochlorous acid) 
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coenzyme Q) (Halliwell, 1996; Rizzo et al, 2010). Oxidative stress is the term 
used to describe an imbalance between ROS and antioxidant capacity, leading 
to the oxidative modification of cellular components and tissue damage (Sies, 
1997; Halliwell and Whiteman, 2004). Oxidative stress has been linked to many 
different diseases with an inflammatory component, such as neurodegenerative 
diseases (Giasson et al, 2000; Butterfield et al, 2006a), cardiovascular 
pathology (Beckman et al, 1994b; Shishehbor et al, 2003), autoimmunity 
(Avalos et al, 2007; Szabó-Taylor et al, 2013) and cancer (Reuter et al, 2010; 
De Sanctis et al, 2014).  
Oxidative modifications of proteins can be viewed as just a marker of disease 
activity. However, there is increasing evidence that oxidative modifications are 
an active component of the disease, perpetuating the pathology. For example, 
modifications of proteins may result in a loss or gain of activity, such as; 
impairment of actin polymerization following oxidation of actin (Dalle-Donne et 
al, 2001), a decrease in manganese superoxide dismutase enzyme activity 
following nitration of the enzyme (MacMillan-Crow et al, 1998), increased 
platelet aggregation following the oxidation of fibrinogen (Azizova et al, 2007) 
and increased peroxidase activity following the nitration of cytochrome C 
(Cassina et al, 2000). Another possibility is the generation of an autoimmune 
response to the altered molecule (Cooke et al, 1997; Griffiths, 2008; Kurien and 
Scofield, 2008; Ryan et al, 2014). For example, type II collagen modified by 
ROS can act as an autoantigen in rheumatoid arthritis (Nissim et al, 2005). This 
is thought to be due to modifications forming neo-epitopes that bypass 
tolerance and stimulate lymphocytes (Eggleton et al, 2008; Eggleton et al, 
2013). It has been suggested that this immune response to the neo-epitope 
could then lead to the activation of an immune response against the native 
(unmodified) molecule (Gauba et al, 2011), via the phenomenon of “epitope 
spreading”.  
White blood cell infiltration of a wound (e.g. neutrophils) is at its most rapid in 
the first 12 hours (Kim et al, 2008) and has been shown to peak at 12 hours 
post-surgery (Colley et al, 1983). From this, it can be inferred that the 
respiratory burst and ROS release begins at the site of inflammation within the 
first 12 hours. As there is a 6-8 hour delay in acute phase protein release 
(Colley et al, 1983; Li et al, 2004) that does not peak until at least 24 hours (Li 
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et al, 2004) it can be hypothesised that levels of oxidative stress, and the 
markers associated with it, will peak earlier than markers associated with the 
acute phase response.  
Numerous studies have investigated whether oxidative stress markers could be 
used as biomarkers in disease (reviewed in Griffiths et al (2002); Frijhoff et al 
(2015)) and some of the well-studied markers are discussed in section 1.5.  
1.4. Biomarkers of disease 
The World Health Organisation describe a biomarker as “any substance, 
structure, or process that can be measured in the body or its products and 
influence or predict the incidence or outcome of disease” (WHO, 2001). 
Biomarkers can range from a non-invasive imaging biomarker, e.g. measuring 
brain atrophy by magnetic resonance imaging, to proteins in bio-fluids, e.g. tau 
levels in the cerebrospinal fluid (Anoop et al, 2010). 
Biomarkers are vital not only in obtaining information on aspects of the disease 
process but also in drug development, where they can be used to assess the 
efficacy of treatment. Biomarkers can have clinical utility if they identify human 
individuals at risk of disease, improve diagnosis of disease or allow monitoring 
of disease activity. From a practical stand point, a biomarker also needs to be in 
an easily accessible tissue, something that can be measured on a large scale 
and economically viable.  
A perfect diagnostic biomarker would accurately identify all individuals with the 
disease AND all individuals without the disease. However, many clinical 
diagnostic tests often produce false positives (wrongly identifies healthy 
individuals as diseased) and/or false negatives (wrongly identifies diseased 
individuals as healthy) (Lalkhen and McCluskey, 2008). How well a test 
performs is often described in terms of sensitivity and specificity and these may 
be plotted on a receiver operator characteristics (ROC) curve (Figure 1.3).   
Sensitivity refers to the test's ability to correctly identify diseased individuals, the 
higher the sensitivity the lower the rate of false negatives (Equation 1.1). 
Specificity is the test's ability to correctly identify individuals without the disease, 
the higher the specificity the lower the rate of false positives (Equation 1.2). A 
ROC curve plots sensitivity against 1-specificty, the area under the curve (AUC) 
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is then calculated to determine the test’s overall accuracy, an AUC of 1.0 
represents a perfect test and an AUC of 0.5 represents a test that has no ability 
to discriminate between those with and without disease (Figure 1.3) (Lalkhen 
and McCluskey, 2008). 
Equation 1.1: 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
 
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
 
Equation 1.2:  
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
 
  
Figure 1.3: Receiver operator characteristics (ROC) curves 
ROC curves for an ‘excellent’ biomarker, area under the curve (AUC) = 0.95, a ‘fair’ 
biomarker, AUC =0.7, and biomarker that has no diagnostic ability, AUC =0.5, 
(Brubaker, 2008; Lalkhen and McCluskey, 2008). 
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1.4.1. Markers of oxidative stress and their measurement 
Several pathologies are associated with oxidative stress. To investigate these 
associations, measurements of the redox state of a specific tissue or the whole 
body is required. Due to the transient nature of most ROS and RNS, they 
cannot be measured directly in vivo. Therefore, oxidative stress has been 
investigated by a few different approaches, such as by measuring the 
abundance/activity of enzymes that produce ROS/RNS, by measuring 
antioxidant defences and by measuring ROS/RNS-induced modifications. 
Below is a brief overview of some oxidative stress markers and their 
measurement in human inflammatory diseases. 
Isoprostanes are primarily formed by the peroxidation of the fatty acid, 
arachidonic acid and are isomeric with prostaglandins (Rokach et al, 1997). F2-
isoprostanes are considered one of the most reliable biomarkers of oxidative 
stress in vivo as they are chemically stable and specific for lipid peroxidation 
(Montuschi et al, 2004). It has been suggested that isoprostanes may have a 
pathophysiological function, as they assert biological activity, e.g. 15-F2t-
isoprostane is a potent vasoconstrictor (Montuschi et al, 2004) (Figure 1.4A). 
Immunoassays for isoprostane measurement have been developed 
commercially but validation with mass spectrometry is advised (Frijhoff et al, 
2015). Elevated isoprostanes have been associated with several human 
diseases, such as cardiovascular disease (Davies and Roberts, 2011) and 
Alzheimer’s disease (Montine et al, 2002). 
Protein carbonylation is the result of many reactions that give rise to the 
formation of aldehyde and ketone moieties on proteins (Figure 1.4B). The 
addition of a carbonyl group may be due to direct oxidation of amino acid 
residues or via a secondary reaction, such as binding of aldehydic lipid 
oxidation products (Dalle-Donne et al, 2006a; Frijhoff et al, 2015). The amino 
acids often affected are lysine, arginine, and proline. These residues are often 
located at metal binding sites and are thus prone to metal-catalysed oxidation 
(Stadtman, 1992; Dalle-Donne et al, 2003a). Protein carbonyls are very stable 
and considered a good marker of oxidative stress (Griffiths, 2000). Carbonyls 
are usually detected following derivatization with 2,4-dinitrophenylhydrazine 
(DNP), which can then be detected with an anti-DNP antibody in an ELISA or 
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with spectrophotometry (Frijhoff et al, 2015). Protein carbonyls have been found 
to increase in Alzheimer’s disease (Sultana et al, 2010), chronic obstructive 
pulmonary disorder (Kirkham et al, 2011)  and with major trauma (Winterbourn 
et al, 2000). However, they are a broad marker of oxidation rather than a sign of 
any particular ROS/RNS generation (Dalle-Donne et al, 2003b).  
“Thiols” can refer to low molecular weight thiols (e.g. glutathione, Figure 1.4C) 
or thiol groups (-SH) on the amino acid cysteine. Oxidation of cysteines within a 
protein may affect the protein function; however glutathione (GSH) acts as an 
antioxidant as it scavenges ROS (forming oxidised glutathione; GSSG) (Frijhoff 
et al, 2015). The GSH:GSSG ratio has been used as a marker of oxidative 
stress in several diseases, e.g. paediatric tumours (Zitka et al, 2012), breast 
cancer (Yeh et al, 2006) and amnestic mild cognitive impairment (Sultana et al, 
2008). However, cysteine thiols are unstable as they are readily chemically 
reduced. Additionally, changes in GSH levels may be due to a 
nutritional/metabolic imbalance rather than oxidative stress (Frijhoff et al, 2015).  
Normal cellular metabolism results in background levels of DNA and RNA 
oxidation, which are increased following oxidative stress. DNA/RNA oxidation 
may result in base or sugar modifications, single or double strand breaks or 
cross-linking with proteins (Cooke et al, 2000; Cooke et al, 2003). Single 
deoxynucleotides and DNA chains can both be oxidised. The former will not be 
incorporated into DNA chains and the latter should be removed from the DNA 
chain by DNA glycosylases (to avoid mutagenic potential) (Cooke et al, 2000). 
The guanine moiety is particularly vulnerable to oxidation and 8-oxo-7,8-
dihydroguanine (8-oxoGua) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-
oxodG, Figure 1.4D) are the most studied of the oxidative lesions caused to 
DNA (Loft et al, 2012; Frijhoff et al, 2015). Urinary excretion of 8-oxoGua and 8-
oxo-dG was positively associated with risk of lung cancer and oestrogen 
receptor positive breast cancer respectively (Loft et al, 2012; Loft et al, 2013). 
Urinary excretion of oxidised RNA guanine (8-oxoGuo) has also been shown to 
predict long-term mortality in those with type 2 diabetes (Broedbaek et al, 
2011). These modifications to DNA and RNA are excreted in urine, can be 
measured by ELISA or HPLC-MS and are stable over time, thus achieving 
many of the criteria needed from a clinical biomarker (Cooke et al, 2000; Frijhoff 
et al, 2015). 
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Figure 1.4: Markers of oxidative stress 
The above are the chemical structures for the following oxidative stress markers. (A) 15-F2-isoprostane. (B) Carbonyl 
(aldehyde and ketone). (C) Glutathione. (D) 8-oxo-7,8-dihydro-2′-deoxyguanosine. (E) Nitrite and nitrate. 
A B 
C 
D E 
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Nitrite (NO2¯) and nitrate (NO3¯) are often measured as markers of nitric oxide 
(˙NO) production (Figure 1.4E) (Hood et al, 1998; Kleinbongard et al, 2003). 
NO2¯ is usually measured by employing the Griess reaction. By reducing NO3¯ 
to NO2¯, prior to the Griess reaction, NO3¯ levels can also be measured 
(Tsikas, 2007). The ‘Griess reagents’ are sulfanilic acid and α-naphthylamine. 
Under acidic assay conditions, NO2¯ reacts with sulfanilic acid to form a 
diazonium ion (Figure 1.5). This then couples with α-naphthylamine, creating a 
red azo dye which can be measured by absorbance (Tsikas, 2007).  
 
 
Ozone-based chemiluminescence is considered a more sensitive method than 
the Griess reaction for the measurement of NO2¯ in biological samples, but is 
less widely available (MacArthur et al, 2007; Nagababu and Rifkind, 2010). This 
method measures ˙NO, requiring that both NO2¯ and NO3¯ are chemically 
reduced prior to measurement. ˙NO is subsequently reacted with ozone to form 
“excited state” nitrogen dioxide. As nitrogen dioxide returns to the ground state, 
a single photon is emitted which is detected and measured, by a photomultiplier 
tube (Figure 1.6), allowing the quantification of NO2¯ or NO3¯ (MacArthur et al, 
2007; Piknova and Schechter, 2011).  
An additional consideration, when measuring these markers, is that NO2¯ and 
NO3¯ plasma levels do not just reflect endogenous ˙NO production but also 
dietary ingestion of these metabolites (Miller et al, 2012; Ashworth et al, 2015). 
For example, green leafy vegetables and beetroot are high in NO3¯. Therefore, 
it is important to factor diet into the study design and analysis when using these 
Figure 1.5: Griess reaction for measurement of nitrite. 
Nitrite reacts with sulfanilic acid forming a diazonium ion. The diazonium ion then 
couples with α-naphthylamine to create a red azo dye. 
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metabolites as markers of ˙NO production. Additionally, NO3¯ can be reduced 
to NO2¯ e.g. by NO3¯reductases in oral bacteria (Doel et al, 2005) and NO2¯ 
can be reduced to ˙NO e.g. by xanthine oxidase (Zhang et al, 1998). These 
pathways are discussed further in Chapter 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Ozone-based chemiluminescence for the measurement of nitrite 
and nitrate 
Nitrite and nitrate are reduced to nitric oxide prior to ozone-based chemiluminescence. 
Nitric oxide then reacts with ozone to form “excited state” nitrogen dioxide. As the nitrogen 
dioxide returns to the ground state it releases a photon (light) and this is measured. 
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1.5. 3-Nitrotyrosine as a marker of nitrative stress in inflammation 
Tyrosine (Tyr) nitration is considered a marker of nitrative stress and involves 
the removal of a hydrogen atom and the addition of a nitro group (¯NO2) to the 
third carbon of the aromatic ring (Bartesaghi et al, 2007), i.e. the carbon 
adjacent to the hydroxyl group (Figure 1.7), the possible mechanisms for this 
are described later in pathways 1.1. and 1.2. The amino acids tryptophan, 
histidine and phenylalanine can also be nitrated (Alvarez and Radi, 2003). 
Nuriel et al (2011) have shown that tryptophan nitration is less common than 
Tyr nitration due to the different properties of these amino acids, e.g. Trp is 
more hydrophobic than Tyr, and Tyr nitration is the most studied of these 
modifications. The addition of the nitro group causes an increase in mass of 
+45 Da and drop in pKa (from 10 to ~7.5), which can bring a negative charge 
into a protein  (Alvarez and Radi, 2003). Nitration can occur by many pathways 
but always involves reactive oxygen species and has been described as a two-
step process (Souza et al, 2008); 
1) Tyr is oxidised resulting in the tyrosyl radical 
2) A radical-radical reaction occurs between the Tyr radical and nitrogen dioxide 
(˙NO2) 
It is also possible for the Tyr radical to react with ˙NO, followed by further 
oxidation, to yield nitrotyrosine (Tyr-NO2) but this pathway has not been well 
studied (Bartesaghi et al, 2007).  
 
 
 
 
Figure 1.7: Conversion of tyrosine to 3-nitrotyrosine 
The removal of a hydrogen atom and the addition of a nitro group 
(¯NO2) to the third carbon of the aromatic ring of tyrosine results in 3-
nitrotyrosine. The mechanisms are detailed in pathways 1.1. and 1.2. 
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One widely studied pathway for nitration is the production of the ROS/RNS 
peroxynitrite (ONOO¯). Peroxynitrite is formed by ˙NO and O2˙¯ combining in 
an exceedingly fast radical-radical reaction (rate constant: 1 x 1010 M-1 s-1) 
meaning that ˙NO can outcompete the dismutation of O2˙¯ by superoxide 
dismutases (SODs) (Radi, 2013). ONOO¯ is a nucleophile that can generate 
secondary free radicals, such as ˙NO2. ONOO¯ has a pKa of 6.8 and, as such, 
is present in both the anionic and protonated (ONOOH) form in vivo, making its 
reactivity highly pH dependent (Radi, 2013). The nucleophilic reaction of 
ONOO¯ with carbon dioxide increases the formation of Tyr-NO2 (Alvarez and 
Radi, 2003) via the adduct nitrosoperoxocarbonate (ONOOCO2¯), which 
undergoes homolysis to the secondary free radicals ˙NO2 and carbonate radical 
(CO3˙¯) (Peluffo and Radi, 2007). CO3˙¯ is able to oxidise Tyr, forming a Tyr 
radical that can then react with the ˙NO2 (Pathway 1.1). 
Pathway 1.1: Peroxynitrite mediated tyrosine nitration 
i. ˙NO + O2˙¯           ONOO¯  1 x 1010 M-1 s-1 (Radi, 2013) 
ii. ONOO¯ + CO2     ˙NO2 + CO3˙¯  3 x 104 M-1 s-1 (Lymar and Hurst, 1995) 
iii. CO3˙¯ + Tyr    Tyr˙ + HCO3¯  1.4 x 108 M-1 s-1 (Augusto et al, 2002) 
iv. Tyr˙ + ˙NO2    Tyr-NO2  3 x 104 M-1 s-1 (Lepoivre et al, 2005) 
For a while, Tyr-NO2 was believed to be a specific marker of peroxynitrite 
formation but this has since been disproved (Halliwell, 1997; van der Vliet et al, 
1997), with the major alternate pathway cited involving the enzyme 
myeloperoxidase (MPO – Pathway 1.2). MPO is a haem peroxidase produced 
by immune cells that, in the presence of hydrogen peroxide (H2O2) and nitrite 
(NO2¯), can catalyse the production of both the tyrosyl radical and ˙NO2 
(Bartesaghi et al, 2007).  
Pathway 1.2: MPO mediated tyrosine nitration 
i. H2O2 + MPO  MPO-I + H2O       1.8 x 107 M-1 s-1 (Marquez et al, 1994) 
ii. MPO-I + NO2¯        MPO-2 + ˙NO2      2 x 106 M-1 s-1 (Burner et al, 2000) 
iii. MPO-I + Tyr         MPO-II + Tyr˙      7.7 x 105 M-1 s-1 (Marquez and Dunford, 1995) 
iv. Tyr˙ + ˙NO2  Tyr-NO2  3 x 104 M-1 s-1 (Lepoivre et al, 2005) 
 
Pathways 1.1 and 1.2 are both intrinsically linked to inflammation. ˙NO and O2˙¯ 
production are increased during the phagocytic cells’ oxidative burst (section 
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1.3) and thus ONOO¯ formation is increased during inflammation (Ischiropoulos 
et al, 1992). ONOO¯ has bactericidal activity (Zhu et al, 1992) but is also a 
potent oxidant that not only causes Tyr nitration but lipid peroxidation (Radi et 
al, 1991) and DNA damage (Szabo and Ohshima, 1997). (Szabo and Ohshima, 
1997). MPO is released by activated neutrophils and mediates pathogen killing 
by the production of hypochlorous acid (HOCl), Pathway 1.3 (Hazen and 
Heinecke, 1997; Nauseef, 2014). MPO activity has also been found to cause 
endothelial dysfunction by reducing the bioavailability of ˙NO (Eiserich et al, 
2002). As well as HOCl being involved in 3-chlorotyrosine formation (Domigan 
et al, 1995), HOCl has also been found to cause a loss in both free and protein-
associated Tyr-NO2 in vitro (Whiteman and Halliwell, 1999). The loss occurred 
in a concentration and time dependent manner (Whiteman and Halliwell, 1999) 
and, it has been suggested, that this loss is due to the Tyr-NO2 being 
chlorinated, to form 3-chloro-5-nitrotyrosine (Curtis et al, 2011). If this loss 
occurs in vivo then levels of Tyr-NO2 production could be underestimated when 
HOCl is also being locally generated (Whiteman and Halliwell, 1999). 
Pathway 1.3: MPO generation of hypochlorous acid (HOCl) (Marquez et al, 1994) 
i. H2O2 + MPO    MPO-I + H2O  1.8 x 107 M-1 s-1  
ii. MPO-I + Cl-       MPO-I-Cl-  2.2 x 106 M-1 s-1 
iii. MPO-I-Cl-     HOCl   5.2 x 104 s-1 
When Tyr-NO2 is measured in human samples it is not possible to tell which of 
the above pathways are responsible for the nitration detected. Pfeiffer et al 
(2000) suggested that peroxidase activity may be responsible for more nitration 
than ONOO¯. They showed that, at low concentrations of ONOO¯, the 
formation of dityrosine (a Tyr radical reacting with another Tyr radical) was 
favoured over Tyr-NO2 formation and concluded that this may limit the amount 
of nitration caused by ONOO¯ formation in vivo. ˙NO/O2˙¯ generating systems 
also produced less nitration than bolus addition of authentic ONOO¯ (Pfeiffer et 
al, 2001). When measuring nitration in activated RAW 264.7 macrophages, an 
inconsistency between the time course of ˙NO/O2˙¯ release and Tyr-NO2 
formation was observed, where ˙NO/O2˙¯ peaked far earlier than Tyr-NO2 
formation. Inhibition of nitration by azide and catalase also suggested that 
peroxidase activity was responsible in this system, rather than ONOO¯ (Pfeiffer 
et al, 2001). When Souza et al (1999) nitrated three proteins of a similar size 
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(ribonuclease A, lysozyme and phospholipase A2) in vitro they found that the 
nitration agent they used affected which protein was preferentially nitrated. 
MPO favoured ribonuclease A nitration, whilst ONOO¯ favoured phospholipase 
A2. Bartesaghi et al (2007) observed that ONOO¯-mediated protein nitration 
skews towards Tyr residues deeper in the phosphatidylcholine liposome 
transmembrane than MPO-mediated nitration of protein   residues. They 
suggested that this is due to the difference in where oxidants are formed, as 
ONOO¯ can undergo homolysis within the membrane but MPO oxidants are 
produced outside of the liposome.  
Both of these pathways can nitrate either free Tyr (free Tyr-NO2) or Tyr residues 
within a polypeptide structure (protein-associated Tyr-NO2). It is hard to 
determine whether free Tyr is more susceptible to nitration than Tyr residues in 
vivo, as degradation of nitrated proteins will affect free Tyr-NO2 levels. Free Tyr- 
NO2 levels can affect the levels of protein-associated Tyr-NO2, Eiserich et al 
(1999) found that culturing cells with free Tyr-NO2 (50 µM) led to incorporation 
of the Tyr-NO2 into α-tubulin, as tubulin can be post-translationally modified by 
the removal and addition of Tyr to the carboxyl terminus of the protein (MacRae, 
1997). However, there is no incorporation of the nitrated free amino acid during 
protein synthesis, as Tyr-NO2 cannot be used during this process (Peluffo and 
Radi, 2007). Nitration of tyrosine residues within a peptide appears to show a 
level of specificity, as not all proteins are nitrated and of those that are, only a 
few of the Tyr residues are susceptible to this modification. This does not 
appear to be dictated by the level of aromatic ring exposure (Souza et al, 1999). 
The Tyr residue’s local environment may affect this selectivity and common 
characteristics in this environment are: (1) close proximity to an acidic amino 
acid, (2) the Tyr being positioned on a loop structure and (3) the Tyr being near 
to a transition metal centre (Ischiropoulos, 2003; Bartesaghi et al, 2007). These 
factors may influence the local concentration of nitrating agents and their 
proximity to Tyr residues, for example a metal centre may generate nitrating 
agents that can nitrate proximal Tyr residues (Ischiropoulos, 2003).  
The post-translational modification of proteins by nitration was shown to have 
multiple effects depending on the protein being studied. These effects range 
from being a possible physiological signalling mechanism to being an important 
pathological feature of diseases. Tyr phosphorylation is an important part of 
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signal transduction pathways and some studies have suggested that Tyr 
nitration is also part of cellular signalling (Monteiro, 2002; Yakovlev and 
Mikkelsen, 2010; Jia et al, 2011). For a modification to be considered relevant 
to cellular signalling pathways it must be reversible and some studies have 
found signs of a denitrase activity (Kamisaki et al, 1998; Irie et al, 2003; Deeb et 
al, 2013). Although it is thought to be enzymatic in nature, as the activity is 
decreased by heat and trypsin treatment, the mechanism for this denitration has 
not yet been identified, (Irie et al, 2003; Deeb et al, 2013). Additionally, the 
majority of research describes Tyr-NO2 as a stable product of ONOO¯ 
formation or MPO activity that accumulates during inflammation (Herce-Pagliai 
et al, 1998; Dalle-Donne et al, 2006b). As many studies have shown, and 
continue to show, increased Tyr-NO2 in disease, and without further evidence of 
denitration, the hypothesis that Tyr-NO2 is a cellular signalling mechanism 
cannot yet be upheld.  
There is also evidence to suggest that Tyr-NO2 acts as a ‘signal/tag’ for the 20S 
proteasome, enhancing degradation of modified proteins (Gow et al, 1996; 
Souza et al, 2000b). If the modified protein does indeed experience a higher 
rate of turnover than other, non-modified, proteins then this would affect 
accurate measurement of Tyr-NO2 formation in tissues. However, increased 
Tyr-NO2 levels are observed in many pathologies, suggesting that modification 
of proteins is occurring at a higher rate than protein turnover. This would also 
mean that as inflammation subsides, and the rate of formation decreases, the 
degradation of modified proteins would lead to decreased Tyr-NO2 levels with 
recovery and this has been seen in some studies (Ter Steege et al, 1998; Pirro 
et al, 2007). 
Contrary to the above studies, it has also been suggested that nitration of 
proteins can lead to aggregation of the modified proteins rather than their 
degradation and removal (Souza et al, 2008). The amount of protein oxidation 
occurring has been shown to affect whether proteasome degradation occurs, 
with light damage enhancing degradation and moderate to heavy damage 
inhibiting the proteasome (Davies, 2001; Shringarpure and Davies, 2002; 
Dunlop et al, 2009). Aggregation of nitrated proteins has been seen in 
neurodegenerative diseases, such as Parkinson’s (Giasson et al, 2000) and 
Alzheimer’s disease (Reynolds et al, 2005). Whether nitration of proteins is 
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involved in the disease pathology is unknown, but these studies indicate that 
oxidative and nitrative stress may be a potential therapeutic target. 
Changes to a protein’s 3-dimensional structure and chemical properties may 
also result in a loss of function (Souza et al, 2008) as described for manganese 
superoxide dismutase (MacMillan-Crow et al, 1998). Increased levels of Tyr-
NO2 have been found within cancers (De Sanctis et al, 2014), with one study 
suggesting that the nitration of chemokines within the tumour environment 
hinders their ability to attract tumour specific cytotoxic T cells to the tumour 
(Molon et al, 2011).  However, gain of function has also been observed for 
some proteins, such as cytochrome c (Cassina et al, 2000) and fibrinogen 
(Vadseth et al, 2004). 
Tyr-NO2 has also been linked with autoimmunity (section 1.3), as modified 
proteins can lead to the formation of neo-epitopes that bypass tolerance, i.e. are 
not recognised by the immune system as self (Eggleton et al, 2008; Ryan et al, 
2014). Tyr-NO2 levels in plasma have been found to correlate with disease 
severity or activity in patients with the autoimmune conditions rheumatoid 
arthritis (Misko et al, 2013) and systemic lupus erythematosus (Oates et al, 
1999; Khan et al, 2006) and anti-Tyr-NO2 antibodies have been found in both 
diseases (Khan and Ali, 2006; Khan and Siddiqui, 2006). These observations 
led to the suggestion that Tyr-NO2 may perpetuate the inflammatory response 
and contribute to the pathogenesis of these diseases rather than just being a 
consequence of disease. 
1.5.1. Measuring 3-nitrotyrosine 
In a solution containing only protein, Tyr-NO2 can be measured by UV-visible 
spectrometry. Tyr has an absorption peak (lambda max) at 280 nm. However, 
Tyr-NO2 displays additional peaks at ~357 nm in acidic solutions and at ~430 
nm in basic solutions (Yang et al, 2010). This shift in peak wavelength at 
different pH values is due to the Tyr-NO2 either being in its neutral form at low 
pH or ionized at high pH (De Filippis et al, 2006). 
When dealing with more complex samples (e.g. tissue samples), other 
techniques need to be employed. Published techniques include immunological 
(as anti-Tyr-NO2 antibodies can be raised) and analytical chemistry methods, 
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such as chromatography coupled with various detection systems like mass 
spectrometry. Both these techniques have advantages and disadvantages: 
ELISA methods are high throughput, relatively low cost and do not involve 
extensive sample preparation but have low sensitivity and are semi-quantitative. 
GC/LC-MS/MS is quantitative, highly sensitive and accurate but is low-
throughput, time-consuming and expensive, limiting this method’s usefulness in 
a clinical setting. 
A review of reported Tyr-NO2 levels, in healthy human plasma, is complicated 
due to the methodological differences between studies and a lack of clarity 
when reporting the findings. However, when attempting to compare the healthy 
human plasma levels of Tyr-NO2, it is clear that the literature is highly varied, as 
can be seen in Tables 1.3 and 1.4. 
Table 1.3 details just a small selection of studies measuring Tyr-NO2 in healthy 
human plasma. This comparison is limited, as different units have been used 
across studies making direct comparison near-impossible without further 
details. Furthermore, results may not be directly comparable for ELISA data as 
most studies report a standard equivalence rather than the absolute Tyr-NO2 
concentration, but this is rarely mentioned. It is also important to know whether 
free Tyr-NO2, protein-associated Tyr-NO2 or total Tyr-NO2 is being measured 
and this is not always clearly stated. The two mass spectrometry studies 
produced similar results but are only measuring nitrated albumin rather than 
total protein nitration (Human serum albumin contains 18 Tyr residues 
(Consortium, 2015), Table 1.3). Despite this, nitrated albumin plasma levels of 
approx. 24 nM are higher than the levels reported for total protein-associated 
nitration in three of the five ELISA methods (Table 1.3). Wayenberg et al (2009) 
and Wayenberg et al (2011) measured albumin nitration in the plasma of human 
new-borns by sandwich ELISA and reported results of 7.3 ng nitrated 
albumin/ml and 3.9 ng nitrated albumin/ml respectively. However, due to the 
difference in the units used to report the results (i.e. ng/ml for the ELISA and nM 
for the mass spectrometry) these studies cannot be directly compared. 
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Table 1.3: A comparison of selected studies in which protein-associated 3-
nitrotyrosine levels were measured by ELISA or Mass Spectrometry in the 
plasma of healthy humans 
The studies below are a small example of the literature, selected on the basis that the 
units allowed direct comparison of the results from healthy (i.e. no disease) control 
participants. All the selected studies measured protein-associated Tyr-NO2 in plasma. 
 
 
 
Reference Method 
Plasma protein-
associated Tyr-NO2 
concentrations as 
reported in the original 
paper 
Plasma protein-associated Tyr-
NO2 concentrations expressed 
as nM 
Rossner Jr et al 
(2007) 
Non-
competitive 
ELISA 
856 ± 1989 nmol/l 860 ± 2000 nM 
Sun et al (2007) 
Sandwich 
ELISA 
7.9 ± 7 nmol/l 7.9 ± 7 nM 
Bo et al (2005) 
Sandwich 
ELISA 
Median (range) –  4.78 
(0.04–235.7) nmol/ml 
4800 nM 
(range 40 nM – 235.7 µM) 
Ter Steege et al 
(1998) 
Sandwich 
ELISA 
Undetectable (Limit of Detection 2 nM) 
Ceriello et al 
(2001) 
Indirect ELISA Undetectable ( Limit of Detection 10 nM) 
Tsikas et al 
(2003) 
GC-MS/MS 24 ± 4 nM nitrated albumin 24 ± 4 nM 
Keimer et al 
(2003) 
GC-MS/MS 23.4 nM nitrated albumin 23.4 nM 
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Other ELISA methods have reported high levels of plasma protein nitration, but 
these methods were not included in the table because they measured total 
nitration (i.e. free Tyr-NO2 is also measured) rather than protein-associated 
nitration. Inoue et al (2002) used a competitive ELISA to measure total (free and 
protein-associated) Tyr-NO2 in healthy humans. This study found levels of 
135.4 ± 18.7 nM (35.21 ± 4.87 ng/ml) Tyr-NO2 in healthy humans, contradicting 
three of the five ELISA findings in the table. However, these results represent 
total Tyr-NO2, not just the protein-associated form and this could explain the 
higher levels measured. Bekpinar et al (2005) also used a competitive ELISA, to 
study oxidative and nitrative stress in Behçet’s disease. Tyr-NO2 levels were 
3.67 ± 0.05 ng/ml in healthy controls (approx. 13 nM), this is ten times lower 
than the Inoue et al (2002) findings but comparable to levels of nitrated albumin 
measured in new-borns (Wayenberg et al, 2009; Wayenberg et al, 2011). If the 
higher levels in the competitive ELISA studies are the result of free Tyr-NO2 in 
the plasma, these studies would still not support the data obtained by mass 
spectrometry in Table 1.3. Separate measures of free Tyr-NO2 levels in plasma 
have been obtained by chromatography coupled with several different detection 
methods, such as mass spectrometry, UV detection and electrochemical 
detection (Table 1.4). 
Some investigators have chosen to report the results in relation to total protein 
or Tyr content, allowing for the proportion of nitration to be assessed across 
data sets. Additionally, protein concentration may vary between individuals 
(potentially drastically between those with disease and healthy controls) and 
reporting the results in terms of total protein or Tyr content can account for this 
difference. 
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Table 1.4: A comparison of reported free 3-nitrotyrosine levels in the plasma of 
healthy humans 
The studies below are an example of some of the literature selected on the basis that 
the units allow direct comparison of the results from healthy (i.e. no pathology) control 
participants. All the studies measured free Tyr-NO2 in plasma. (A) Gas chromatography 
separation, (B) Liquid chromatography separation.  
Table 1.4A: Gas chromatography separation 
Authors Method 
Plasma free Tyr-NO2 
concentrations as reported in 
the original paper 
Plasma free Tyr-NO2 
concentrations expressed as 
nM 
Schwedhelm 
et al (1999) 
GC-MS/MS1 2.8 ± 0.84 nM 2.8 ± 0.84 nM 
Keimer et al 
(2003) 
GC-MS/MS1 636.0 (153.0) pM2 0.64 nM (0.15) 
Söderling et al 
(2003) 
GC MS/MS1 0.74 ± 0.30 nM 0.74 ± 0.30 nM 
Tsikas et al 
(2003) 
GC-MS/MS1 
GC-MS1 
GC-MS/MS 
Group aged 51 ± 10 years:  
1.140 ± 0.727 nM 
Group aged 25 ± 3 years: 
2.677 ± 1.540 nM 
Male group aged 26 ± 3 years: 
0.73 ± 0.53 nM 
GC-MS 
Group aged 51 ± 10 years: 
4.463 ± 4.495 nM 
Group aged 25 ± 3 years: 
5.447 ± 2.783 nM 
GC-MS/MS 
Group aged 51 ± 10 years:  
1.1 ± 0.73 nM 
Group aged 25 ± 3 years: 
2.7 ± 1.5 nM 
Male group aged 26 ± 3 years: 
0.73 ± 0.53 nM 
GC-MS 
Group aged 51 ± 10 years: 4.5 ± 
4.5 nM 
Group aged 25 ± 3 years: 
5.5 ± 2.8 nM 
Pannala et al 
(2003) 
GC-MS1 5.44 ± 1.19 nmoles/l 5.4 ± 1.2 nM 
Gaut et al 
(2002a) 
EC-NCI 
GC/MS1 
LC-MS/MS1 
EC-NCI GC/MS 
11 ± 2 nM 
LC-MS/MS  
undetectable 
LOD reported as 39 fmol  
EC-NCI GC/MS 
11 ± 2 nM 
LC-MS/MS 
Not detected 
(Limit of Detection 20 nM) 
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Table 1.4B: Liquid chromatography separation 
Authors Method 
Plasma/serum free Tyr-
NO2 concentrations as 
reported in the original 
paper 
Plasma/serum free Tyr-NO2 
concentrations expressed as 
nM 
Yi et al (2000) LC-MS/MS1 < 4.4 nmol/L 
Not detected 
(Limit of Detection 4.4 nM) 
Thornalley et al 
(2003) 
LC-MS/MS1 6.5 ± 2.5 6.5 ± 2.5 nM 
Ahmed et al 
(2003) 
LC-MS/MS1 9.4 ± 0.4 nM 9.4 ± 0.4 nM 
Ahmed et al 
(2005) 
LC-MS/MS1 <0.4 nmol/l 
Not detected 
(Limit of Detection 0.4nM) 
Kaur and 
Halliwell (1994) 
HPLC – UV 
Undetectable 
(serum) 
Not detected 
(Limit of Detection 200 nM) 
Fukuyama et al 
(1997) 
HPLC – UV Undetectable 
Not detected 
(Limit of Detection 600 nM) 
Fatouros et al 
(2004) 
HPLC-UV 
5.3 ± 0.4 µM 
(older men) 
5300 ± 400 nM 
Ohshima et al 
(1999) 
HPLC 
electrochemic
al detection 
Undetectable 
Not detected 
(Limit of Detection 5 nM) 
Kamisaki et al 
(1996) 
HPLC – 
Fluorescence 
spectrophotom
eter 
31 ± 6 pmol/ml 31 ± 6 nM 
Ohya et al 
(2002) 
853 type 
amino acid 
analyzer 
(Hitachi) 
Undetectable (<0.1 
nmol/mL) 
Not detected 
(Limit of Detection 100 nM) 
Footnotes 
1 Studies took steps to address artefact formation (discussed in the text).  
2 
Data expressed as the median. Values in parentheses represent interquartile 
ranges. 
 
 
28 
 
UV detection has been coupled with chromatography for the detection of free 
Tyr-NO2 and these studies often have a high limit of detection (LOD), 
suggesting low sensitivity (see Table 1.4B). For example Fukuyama et al 
(1997) used HPLC-UV to measure free Tyr-NO2 in plasma taken from healthy 
individuals, as well as renal failure patients (separated into those with septic 
shock and those without). At a wavelength of 274 nm the LOD was 600 nM, this 
is several orders of magnitude higher than the LOD of methods using tandem 
MS (MS/MS) and ELISA methods (although it is protein-associated Tyr-NO2 
measured by ELISA). Perhaps unsurprisingly, free Tyr-NO2 was undetected in 
healthy plasma. The high LOD did not prevent free Tyr-NO2 being measured in 
the renal failure patients, where levels were exceedingly high (118.2 ± 22.0 µM 
with sepsis and 28.0 ± 12.3 µM without). 
Specificity when measuring Tyr-NO2 in tissue can also be an issue with some 
detection methods, e.g. Kaur et al (1998) used HPLC coupled to a photodiode 
array detector to analyse Tyr-NO2 in brain tissue from various neurological 
disorders; a peak with the same retention time as Tyr-NO2 (that was not 
detected in controls) was produced and could be reduced to aminotyrosine by 
dithionite (an often used criterion for identifying Tyr-NO2). However, when mass 
spectrometry was employed as a detection system it was revealed that this 
peak was not true Tyr-NO2 (the compound was not identified). Other detection 
systems, such as UV and electrochemical detection, were unable to make this 
distinction, confirming that mass spectrometry is a more specific detection 
method. 
Mass spectrometry is considered the most accurate method to quantify Tyr-
NO2. However, there are still several factors to take into account. For example, 
Tsikas et al (2003) measured free Tyr-NO2 in the same samples by either GC-
MS or GC-MS/MS and reported levels to be lower with the tandem MS method, 
e.g. for the age group 51 ± 10 years the results for MS vs. MS/MS were 5.5 ± 
2.8 nM and 1.1 ± 0.73 nM respectively (Table 1.4A).  
A principal consideration when measuring Tyr-NO2 by mass spectrometry is 
artefact formation during acidic sample preparation (Frost et al, 2000; Yi et al, 
2000). Yi et al (2000) compared liquid and gas chromatography (LC and GC) 
and concluded that LC was less likely to lead to artificial formation due to a less 
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extreme pH during sample processing. However, Tsikas and Caidahl (2005) 
suggested that this means compromising on sensitivity, and that the 
methodological steps needed to improve sensitivity to a GC standard would 
increase the risk of artefact formation, thus removing its advantage over the GC 
analysis. Gaut et al (2002a) also compared two methods (electron capture 
negative chemical ionization-GC/MS and LC-electrospray ionization MS/MS) 
and found the GC/MS to be not only 100-fold more sensitive than LC-MS/MS 
but also less time-consuming; generation of Tyr-NO2 during analysis was found 
to be negligible for both methods. However, Duncan (2003) suggested that 
Gaut et al (2002a) were mistaken in their conclusion and that the ‘failings of the 
LC assay’ were due to the system they used, rather than LC being less 
sensitive for Tyr-NO2 measurement. Duncan (2003) recommended a triple 
quadrupole system for improved sensitivity. Other methods employed to prevent 
artefact formation include: avoiding acidic conditions (Frost et al, 2000) and 
removing NO2¯, NO3¯ and Tyr from the sample prior to GC-MS/MS sample 
preparation (Schwedhelm et al, 1999).  
Some mass spectrometry studies do not assess the Tyr-NO2 of the entire 
plasma proteome, for example only looking at albumin (Keimer et al, 2003; 
Tsikas et al, 2003). This is presumably done because of the low abundance of 
Tyr-NO2 in serum/plasma (Radi, 2004) and a desire to remove a lot of 
unmodified Tyr from the sample so that Tyr-NO2 can be detected by the MS/MS 
(discussed further in Chapter 5, section 5.4). Therefore, these results are not 
truly representative of the serum nitration levels as they may be missing large 
portions of the Tyr-NO2 present in the proteome. ELISAs however, are able to 
measure whole samples, without any extensive sample preparation (or risk of 
artefact formation). Coupled with lower cost and higher throughput this makes 
ELISA a more appealing method than MS/MS for measuring large numbers of 
clinical samples. 
Many different sample types have been used when measuring Tyr-NO2 in 
samples, e.g. plasma/serum (Shishehbor et al, 2003; Misko et al, 2013), 
synovial fluid (Kaur and Halliwell, 1994), cerebrospinal fluid (Tohgi et al, 1999; 
Korolainen and Pirttilä, 2009), urine (Tsikas et al, 2012), exhaled breath 
condensates (Hanazawa et al, 2000; Bodini et al, 2006) and tissue biopsies 
(Kaminsky et al, 1999; Sultana et al, 2006).  These studies demonstrate that 
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Tyr-NO2 is formed in many different tissue types in vivo, of which many are 
accessible in a clinical setting with minimal invasiveness. This has led to the 
suggestion that Tyr-NO2 could be measured as a marker of oxidative stress, for 
prognosis or disease monitoring, in clinical studies. 
This thesis expands on the above studies by measuring Tyr-NO2, along with 
other inflammatory/oxidative stress markers, in four inflammatory settings: (1) 
inflammation as a result of trauma/tissue injury (i.e. surgery), (2) NO3¯ 
supplementation in smokers (low level, persistent inflammation) and non-
smokers, (3) an acute, infective inflammatory response (i.e. sepsis), and (4) a 
pathology with a chronic inflammatory component (i.e. Alzheimer’s disease).  
1.5.2. Oxidative/nitrative stress following surgery, an example of acute 
inflammation 
Inflammation and oxidative stress are known to occur following surgery and 
oxidative stress has been the subject of investigation as a factor affecting 
recovery (Rosenfeldt et al, 2013). This is of particular importance in surgery that 
involves ischaemia-reperfusion (e.g. abdominal aortic aneurysm and 
transplantation), where excessive ROS generation, such as O2˙¯, has been 
shown to cause tissue damage (Kaminski et al, 2002; Bonder et al, 2004; 
Granger and Kvietys, 2015).  
Ischemia is a reduction in blood flow to a tissue, resulting in hypoxia, and 
reperfusion is the return of normal blood flow to the affected area. Both of these 
stages can cause tissue damage, termed ischaemia-reperfusion injury 
(Dorweiler et al, 2007; Kalogeris et al, 2012). During the hypoxic period of 
ischaemia, anaerobic metabolism is utilised, decreasing cellular pH and rapidly 
depleting ATP, resulting in decreased active transport of calcium leading to 
calcium overload in the cell (Figure 1.8) (Carden and Granger, 2000; Kalogeris 
et al, 2012). If prolonged, necrosis of the ischaemic tissue occurs, making 
prompt return of blood flow vital. However, this reperfusion also causes 
damage. Reperfusion injury is thought to be due to many factors including 
generation of substantial amounts of ROS and a large inflammatory response 
(Figure 1.8) (Carden and Granger, 2000; Kalogeris et al, 2012). 
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˙NO, O2˙¯, and ONOO¯ have all been cited as influencing the myocardial 
damage observed following an ischaemia-reperfusion injury  event in 
cardiovascular surgery (Zweier and Talukder, 2006; Venardos et al, 2007). ˙NO 
is increased by two pathways during this process: NOS activation, i.e. eNOS 
(activated by haemodynamic stimuli) and iNOS (induced following the activation 
of macrophages), and the chemical reduction of NO2¯ by xanthine oxidase (XO) 
(Zweier and Talukder, 2006). O2˙¯ is produced by NADPH oxidase in infiltrating 
polymorphonuclear cells (PMN) and by uncoupling of NOS, observed when 
arginine or BH4 are depleted (Zweier and Talukder, 2006). As well as acting as 
chemoattractants for more PMNs, these free radicals form ONOO¯ (Pathway 
1.1). It has been suggested that, at physiological concentrations, ONOO¯ is 
potentially cardioprotective during reperfusion as it decreases PMN adhesion 
and XO activity (Nossuli et al, 1998; Lee et al, 2000). However, ONOO¯ can 
also modify many cellular targets, such as inducing protein nitration, as 
previously mentioned (Pathway 1.1). Following ischaemia-reperfusion injury, 
Figure 1.8: Cellular changes arising from ischemia and reperfusion 
Ischemia gives rise to anaerobic metabolism and disruption of cell processes that can 
lead to cell death. However, reperfusion can also cause damage to the cells. 
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increased nitration has been measured in rat heart tissue (Bas et al, 2012) and 
human plasma proteins (Troxler et al, 2004; Zhao et al, 2005; Hui et al, 2012).  
Clinical human studies, using therapies targeting oxidative stress induced by 
surgery, have shown that high doses of antioxidants can decrease tissue 
damage or improve recovery time (Bartels et al, 2004; Arato et al, 2010; Leong 
et al, 2010). Tyr-NO2 may be beneficial in these studies as a marker of protein 
modification linked to ˙NO production. 
Measurement of Tyr-NO2 post-surgery is discussed further in chapter 3. 
1.5.3. Oxidative/nitrative stress in smokers, an example of low-level chronic 
inflammation 
The presence of inflammation and oxidative stress induced by smoking has 
been demonstrated in many studies. Smokers have an accumulation of 
neutrophils and macrophages in their airways (Kuschner et al, 1996; van der 
Vaart et al, 2004; Mehta et al, 2008; Mortaz et al, 2010), as well as increased 
pro-inflammatory signals (Rastrick et al, 2013; Wiegman et al, 2015). Increased 
serum levels of peripheral blood cells, such as neutrophils, are also seen in 
smokers compared to non-smokers (Martins et al, 2013). Additionally, isolated 
peripheral blood cells from smokers were found to produce more H2O2 than 
non-smoker cells (Tanni et al, 2012). Mortaz et al (2010) found that cigarette 
smoke induces TLR9 signalling in isolated human neutrophils; in vivo, this 
signalling would lead to further recruitment of neutrophils. However, Mehta et al 
(2008) suggested that, although there is an influx of immune cells, these cells 
had decreased phagocytic and respiratory burst functions. They suggested that 
this is part of the reason why smokers are vulnerable to recurrent infections. 
Increased markers of oxidative stress have also been measured in smokers, 
compared to non-smokers, e.g. the lipid oxidation product malondialdehyde (Isik 
et al, 2007; Waseem et al, 2012). van der Vaart et al (2004) studied the effects 
of acute smoking and found that there was an increase in exhaled ˙NO and 8-
isoprostane, as well as an increase in O2˙¯ and H2O2 in bronchoalveolar lavage 
fluid. This was accompanied by a brief decrease in blood NO2¯ and NO3¯. 
Decreased antioxidant capacity has also been measured in smokers compared 
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to non-smokers, i.e. a decrease in serum superoxide dismutase, catalase and 
glutathione peroxidase (Waseem et al, 2012).  
Histone deacetylase 2 (HDAC2) was found to be significantly nitrated in the 
peripheral lung tissue of smokers compared to non-smokers and it was shown 
that nitration increased proteasomal degradation (Osoata et al, 2009). HDAC2 
lowers inflammatory gene expression and decreased expression in peripheral 
lung tissue has been observed in chronic obstructive pulmonary disease 
(COPD), a disease where a strong inflammatory response is seen in the 
airways (Barnes, 2009). Smoking is widely linked to COPD, a leading cause of 
morbidity and mortality worldwide (Mannino and Buist). It has also been 
suggested that COPD has an autoimmune component (Agustí et al, 2003). 
Kirkham et al (2011) found that cigarette smoke forms carbonyl adducts on 
proteins and that COPD patients had both an increase in carbonyl modified 
proteins, in the lung and circulation, and the presence of autoantibodies against 
carbonyl modified proteins. As has already been mentioned, a link between 
proteins with oxidative modifications and autoimmunity has been established 
(Griffiths, 2008; Ryan et al, 2014) and as such, smoking-induced protein 
modifications (in addition to carbonyl adducts) could be an important factor in 
COPD pathology.  
1.5.4. Oxidative/nitrative stress in sepsis, as an example of an infective 
inflammatory disease 
Sepsis is an example of an acute infective inflammatory disease. In essence, 
sepsis is a systemic host response to infection that is maladaptive (Vincent and 
Abraham, 2006); involving a dysfunctional level of pro-inflammatory cytokines in 
the circulation followed by a later immunosuppressive stage, caused by an 
increase in anti-inflammatory cytokines (Figure 1.9). This immunosuppressive 
stage has been described as a compensatory anti-inflammatory response 
syndrome and leaves patients vulnerable to a secondary infection (Adib-Conquy 
and Cavaillon, 2008). 
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Figure 1.9: Sepsis disease progression 
Sepsis is maladaptive systemic response to infection, some of the stages and mediators are described above. (1) Innate immune 
cells (macrophages and neutrophils shown) respond to an infection (a bacterial infection is shown but it can be viral or fungal). (2) 
Release of cytokines, chemokines and ROS into the circulation. (3) ROS mediated damage. (4) Tissue damage, organ dysfunction 
and hypotension. (5) Compensatory anti-inflammatory response. 
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A 2006 database review (Harrison et al, 2006) of sepsis in England, Wales, and 
Northern Ireland revealed that ‘the number of admissions to UK critical care 
units with severe sepsis within the first 24 hours of admission is increasing’ 
going from 23.5 % in 1996 to 28.7 % in 2004. Despite a decrease in mortality 
over this time there was an increase in the total number of deaths (~9,000 to 
~14,000) (Harrison et al, 2006). The pathology of sepsis is highly complex and 
heterogeneous and there has been much debate over the definition and 
diagnosis criteria of sepsis, with only 17% of physicians agreeing on any single 
definition in a 2004 survey (Vincent et al, 2009).  
Diagnosing sepsis clinically is far from simple. To begin with, the inflammatory 
response is comparable to a sterile inflammatory response initiated by trauma, 
burns, pancreatitis, etc., in which no infection is involved (and thus 
antimicrobials are ineffective as a treatment). Sepsis is not confined to one type 
of organism (i.e. the pathogen may be viral, bacterial or fungal) or to one 
origination point (i.e. infection may occur anywhere in the body) (Vincent and 
Beumier, 2013). The progression, and outcome, of the response will vary 
depending on the microorganism present and individual characteristics of the 
patient (e.g. age, co-morbidity, etc.) (Vincent et al, 2009). All these factors make 
finding one defining marker of disease next to impossible. Instead, diagnosis 
depends on multiple signs and markers. 
The British Medical Journal Best Practice sets out diagnostic criteria of sepsis 
based on the consensus of a 2001 conference (Levy et al, 2003). Sepsis is 
considered if at least 2 of the following are present in conjunction with infection: 
 Hypothermia (<36°C) or hyperthermia (>38.3°C) 
 Tachycardia (>90 beats per minute) 
 Tachyponea (>20 breaths per minute) 
 PCO2 <4.3 kPa (32 mmHg) 
 Hyperglycaemia in the absence of diabetes (>6.66 mmol/L) 
 Acutely altered mental state 
 White blood cell count <4 or >12 x 109/L 
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The “cytokine storm” produced during sepsis is both an excessive release of 
pro-inflammatory cytokines, in response to infection, and an extreme 
counteractive release of anti-inflammatory cytokines (Chaudhry et al, 2013; 
Schulte et al, 2013). Increased IL-6 has shown a correlation with disease 
severity (r = 0.63, p <0.001, Damas et al (1992)) and persistent overproduction 
of IL-10 is considered a risk factor for a fatal outcome (Chaudhry et al, 2013). A 
pilot study by (Lukaszewski et al, 2008) measured mRNA expression levels for 
a panel of cytokines (IL-1β, IL-6, IL-8, IL-10, TNFα, FasL and CCL2) prior to 
diagnosis of sepsis in intensive care unit patients (ICU - these patients have a 
higher risk of sepsis) and ICU patients without complications (i.e. no sepsis). 
With this data, they were able to produce a successful neural network model for 
predicting which ICU patients would develop sepsis. This is one of the few 
studies that measured markers prior to sepsis diagnosis and, as the 
effectiveness of antimicrobial therapy rapidly decreases following the onset of 
sepsis (Kumar et al, 2006; Weiss et al, 2014), identifying biomarkers to allow for 
earlier diagnosis is a vital area of research. 
The acute phase proteins CRP and procalcitonin have both been studied as 
potential markers of sepsis (Pierrakos and Vincent, 2010). CRP is a well-known 
inflammatory marker routinely measured in clinical settings and has been 
studied as a potential marker for differentiating sepsis from systemic 
inflammatory response syndrome with an area under the curve of 0.94 (Sierra 
et al, 2004). However, some have reported that its ability to distinguish between 
patients with infection and patients with a sterile inflammatory response is not 
discriminatory (Lavrentieva et al, 2007). Increased procalcitonin concentrations 
have been associated with bacterial infections (Delévaux et al, 2003) and some 
studies suggest that procalcitonin is superior to CRP at indicating infection 
during systemic inflammatory response syndrome (Luzzani et al, 2003; Uzzan 
et al, 2006; Kibe et al, 2011). However, some meta-analysis studies have 
suggested that procalcitonin still has a low-to-moderate diagnostic performance 
for the identification of sepsis (Jones et al, 2007; Tang et al, 2007). As a 
prognostic marker, procalcitonin is superior to CRP due to the fact that levels 
decrease far quicker (Standage and Wong, 2011). 
As previously discussed, the inflammatory response leads to the recruitment of 
immune cells and the generation and release of ROS/RNS. Sepsis is no 
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exception to this and extensive evidence of oxidative stress has been observed 
in sepsis (Martins et al, 2003; Santos et al, 2012). This oxidative stress has 
been linked to endothelial dysfunction, aiding progression to septic shock 
(Azevedo et al, 2006; Huet et al, 2011) and damage to mitochondria, leading to 
dysfunction and multiple organ failure – severe sepsis (Figure 1.9) (Victor et al, 
2004; Castellheim et al, 2009). This suggests that oxidative stress is not only a 
result of sepsis but also a pathological feature, which can cause a serious 
deterioration in the patient’s condition. 
High amounts of free radical generation (e.g. ˙NO and O2˙¯) and MPO release 
would increase Tyr-NO2 formation and free Tyr-NO2 has indeed been found to 
be greatly elevated during sepsis (Fukuyama et al, 1997; Ohya et al, 2002). 
Nitration can affect protein function (Radi, 2012) and this too may contribute to 
disease progression. For example, nitration of manganese superoxide 
dismutase (a mitochondrial enzyme) results in a loss of function and thus an 
accumulation of O2˙¯ and further oxidative damage (MacMillan-Crow et al, 
1998; Moreno et al, 2011). 
The presence of Tyr-NO2 in sepsis means it could potentially be used as a 
biomarker for this disease. Indeed, some have suggested that free Tyr-NO2 in 
plasma is associated with sepsis prognosis (Ohya et al, 2002). This is 
discussed further in Chapter 5. 
1.5.5. Oxidative/nitrative stress in Alzheimer’s disease; a chronic disease 
with an inflammatory component 
As life expectancy improves, many countries now have to deal with the health 
consequences of an ageing population, one of which is an increasing 
prevalence of dementia (Sosa-Ortiz et al, 2012). In 2010 it was estimated that 
35 million people worldwide had dementia (Sosa-Ortiz et al, 2012), with 
Alzheimer’s disease (AD) making up approximately 70% of this group (Zhu and 
Sano, 2006). The second largest sub-group is vascular dementia (VaD). 
However, it is thought that a ‘mixed’ dementia (AD with cerebrovascular 
disease) sub-group is underestimated in the population (Kalaria, 2002). 
AD is characterised by three pathological changes in the brain – intracellular 
neurofibrillary tangles (containing the microtubule-associated protein tau), 
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extracellular amyloid-β plaques and loss of synapses (Sultana et al, 2006; 
Reynolds et al, 2007; Reyes et al, 2011), changes that can only be observed 
post-mortem. Neuronal loss and widespread atrophy are also observed (Fox et 
al, 2001). A transition step between healthy ageing and AD is mild cognitive 
impairment and this condition is often studied to observe early physical changes 
in AD (Cenini et al, 2008).  
Neuroinflammation is known to occur in AD and is now being viewed as an 
important pathological factor in disease progression (Heneka et al, 2015). The 
central nervous system has resident innate immune cells (microglia and 
astrocytes) that are activated by DAMPs such as amyloid plaques (Heppner et 
al, 2015) (Figure 1.10). The neurofibrillary tangles and plaques can also 
activate complement pathways and dementia is associated with increased 
levels of cytokines and chemokines that may be released by neurons, as well 
as the resident immune cells (Akiyama et al, 2000). 
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 Figure 1.10: The inflammatory response in dementia 
Amyloid-β acts as a DAMP that activates the brain immune cells; microglia and astrocytes. Once activated these cells release 
cytokines, chemokines and ROS. Neurofibrillary tangles (containing tau) and amyloid plaques can both activate complement 
pathways. Neurons can also release cytokines, chemokines and ROS.  
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An altered antioxidant status has been implicated in dementia. Decreased 
circulating levels of antioxidants have been associated with poor memory 
(Perkins et al, 1999), while increased dietary intake of antioxidants is linked with 
an improved cognitive performance (Masaki et al, 2000). However, prospective 
studies looking at dietary intake of antioxidants and AD risk have had mixed 
results, such as a decreased risk regardless of genotype (Engelhart et al, 
2002), decreased risk only in those that are not a carrier of apolipoprotein E4 
gene (Morris et al, 2002) and no decreased risk at all (Luchsinger et al, 2003). A 
two year controlled clinical study (double-blind, placebo-controlled, randomised 
and multicentre), treating ‘moderate’ AD patients with high dose vitamin E (2000 
IU/day) was performed (Sano  et al, 1997). Although the treatment group saw a 
significant delay in time to the primary outcomes (progression to severe AD and 
death), there was no impact on the rate of cognitive decline. Praticò (2008) 
carried out a review, of clinical studies using antioxidant treatments, and made 
the important point that many studies failed to measure markers of oxidative 
burden in the patients and as such, it is unknown whether the antioxidant drugs 
were decreasing oxidative stress in the central nervous system.  
The species involved in Tyr-NO2 formation are present in the AD brain, e.g. ˙NO 
is produced by neuronal (nNOS), endothelial (eNOS) and inducible (iNOS) nitric 
oxide synthase (Law et al, 2001). Superoxide dismutase (SOD) activity was 
found to be reduced in the AD brain (Marcus et al, 1998). As mentioned earlier 
(see section 1.1 ), SOD is responsible for dismutating O2• ¯ to H2O2 and 
therefore a loss of activity will lead to an increase in available O2• ¯ which, in the 
presence of •NO, will lead to ONOO¯ formation leading to nitration of proteins 
within the brain (Good et al, 1996; Castegna et al, 2003; Butterfield et al, 
2007b). An increased expression of MPO has also been observed in the AD 
brain (Green et al, 2004), where MPO appeared to be localised to amyloid 
plaques. Active MPO catalyses the nitration of tyrosine residues in the presence 
of NO2¯ and H2O2 (section 1.5, pathway 1.2). 
An increase in Tyr-NO2 has been observed in AD brains when compared to 
control subjects (Good et al, 1996; Castegna et al, 2003; Sultana et al, 2006; 
Butterfield et al, 2007b; Sultana et al, 2007; Reed et al, 2009). Nitrated tau was 
observed in tangles, with evidence that this could occur early in the disease 
(Butterfield et al, 2007b). However, it has been suggested that tau nitration may 
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have a physiological role, possibly in neuron differentiation (Cappelletti et al, 
2004). 
Nitration of other proteins may affect neuronal survival. For example, nitration of 
the pro-apoptotic protein p53 is suggested to play a part in neuronal cell death 
(Cenini et al, 2008). This protein showed significantly more nitration in specific 
cerebral regions of Alzheimer’s brains compared to age-matched controls 
without a history of dementia, an observation not made in samples from patients 
with mild cognitive impairment (Cenini et al, 2008). Nitration of certain enzymes 
in neurons could also affect the enzymatic function, altering important cellular 
processes such as glucose metabolism and cell survival (Sultana et al, 2006). 
Dildar et al (2010) reported that serum Tyr-NO2 concentrations were no different 
in AD patients when compared to control subjects and that this modification 
might only be observable in the brain. However, the accurate measurement of 
Tyr-NO2 in plasma/serum is currently a matter of debate, as there are widely 
varying levels being reported between research groups (discussed in section 
1.5.1). The method used by Dildar et al (2010) was a commercial sandwich 
ELISA kit with a limit of detection of 2 nM. Even if we assume that plasma Tyr-
NO2 is indeed increased in this pathology, during preparation the samples were 
diluted and, given that Tyr-NO2 is suspected to be present in very low 
concentrations in plasma, this method may have been too insensitive to detect 
Tyr-NO2. Tyr-NO2 in dementia is discussed further in Chapter 6. 
Animal models play a key role in biomedical research, aiding in target discovery 
and validation of therapeutic approaches. Transgenic animal models express 
foreign DNA, e.g. human genes. This technique has been used to produce mice 
with pathological hallmarks of AD pathology, allowing researchers to 
understand some of the mechanisms and the disease progression (Houdebine, 
2007).  There are several mouse models for AD that exhibit some, though not 
all, AD pathology (Morrissette et al, 2009; Elder et al, 2010). Mouse models of 
AD are discussed further in Chapter 6, section 6.1. 
Oxidative stress is observed in the brain of AD mouse models, with some 
studies suggesting that this is an important factor in disease pathology rather 
than a consequence of plaque and tangle formation (Matsuoka et al, 2001; 
Praticò et al, 2001; Kanamaru et al, 2015). Models of AD have the benefit of 
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allowing the time course of the disease to be studied, not just the final hallmarks 
of pathology. For instance, Praticò et al (2001) measured urinary, plasma and 
brain lipid peroxidation levels over several time points in a transgenic mouse 
model (Tg2576) and found that isoprostane levels increased prior to the 
amyloid-β plaque deposition (8 and 12 months respectively). They concluded 
that this indicates oxidative stress helps drive AD pathology rather than being a 
result of the amyloid-β plaque formation. Supporting this hypothesis is the study 
by Kanamaru et al (2015), in which an AD mouse model was crossed with a 
mouse model that exhibits increased oxidative stress. It was found that the 
double transgenic had plaque pathology earlier than the AD single transgenic 
model, implying that oxidative stress accelerates the AD-like pathology. Based 
on the idea that oxidative stress is important in driving AD pathology, Lim et al 
(2001) tested the effect of the antioxidant curcumin on a mouse model of AD. 
They found that both low and high doses reduced the levels of oxidised proteins 
and plaque burden, in brain tissue, compared to untreated mice.  
Although these studies suggest that oxidative stress is central in AD 
progression the results cannot be extrapolated to humans, due to both species 
differences and the fact that mice do not exhibit the full range of AD pathology. 
However, oxidative stress remains an interesting area for therapeutic targeting 
and biomarkers of oxidative stress could help determine the efficiency of 
interventions.  
1.5.6. Further inflammatory conditions where 3-nitrotyrosine may have 
clinical utility  
Various studies have reported the production of Tyr-NO2 in diseases involving 
an inflammatory response and below are a selection of studies that have 
focused on whether Tyr-NO2 is (or has the potential to be) a clinically relevant 
biomarker.  
Gastrointestinal inflammatory conditions 
Intestinal inflammation is observed in inflammatory bowel diseases, i.e. Crohn’s 
disease (CD) and ulcerative colitis (UC). In CD and UC, Tyr-NO2 has been 
detected using semi-quantitative immunohistochemical studies, with little or no 
staining observed in non-inflamed or control tissue (Dijkstra et al, 1998; Perner 
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et al, 2001). Plasma Tyr-NO2 in CD and UC has not been reported, but has 
been reported in coeliac disease, another inflammatory intestinal disorder (Ter 
Steege et al, 1998). In the latter study, Tyr-NO2 was measured using an ELISA 
method, where a decrease in protein-associated Tyr-NO2 was observed 
following a gluten-free diet.  
For clinical purposes, quantitatively assessing a biomarker in an accessible 
human tissue such as plasma is preferable to using gut biopsies for qualitative 
immunohistochemical studies. Therefore, before Tyr-NO2 can be considered as 
a biomarker in gastrointestinal inflammatory disorders it first needs to be 
determined that the plasma concentrations of Tyr-NO2 are: (a) elevated during 
episodes of inflammation and (b) decreased following clinically successful 
therapeutic intervention. The study on coeliac disease (Ter Steege et al, 1998) 
demonstrates, in principle, that plasma protein-associated Tyr-NO2  
concentrations may fall in response to treatment and thereby reflect disease 
activity, but follow-up studies are needed.  
Systemic lupus erythematosus  
Systemic lupus erythematosus (SLE) is an autoimmune disease and involves 
chronic systemic inflammation. The fluxes of ROS/RNS, such as O2˙¯, ˙NO and 
hydroxyl radical are known to increase in SLE (Khan et al, 2006; Wang et al, 
2010). Interestingly, in addition to an increase in protein nitration, anti-Tyr-NO2 
antibodies have been reported in the serum of SLE patients (Khan and Siddiqui, 
2006) and such antibodies are also being investigated as a possible biomarker 
in this disease. Wang et al (2010) used an ELISA to compare serum Tyr-NO2 
concentrations to disease activity score (“SLE Disease Activity Index”, n=72) 
and found levels were significantly higher in patients with a disease activity 
score greater than six (n=44). Avalos et al (2007) suggested that oxidative 
stress is more likely to be associated with renal dysfunction than disease 
activity score. Stein (2010) also suggested that renal function should be taken 
into account, along with smoking status and obesity, when examining potential 
oxidative stress measures in SLE. 
If the correlation between serumTyr-NO2 concentration and disease activity can 
be replicated in further large clinical studies, then Tyr-NO2 could potentially be 
used as a tool for monitoring disease activity in response to therapy. Moreover, 
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if an available ELISA method can be shown to be sensitive enough to detect 
these changes, this would allow high-throughput analysis of patient samples. 
However, it is still unclear whether the measurement of plasma Tyr-NO2 
concentrations provides clinical insight into therapeutic efficacy that is more 
informative than the existing clinical criteria. 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) involves an autoimmune inflammatory reaction within 
synovial joints, which leads to the chronic destruction of the cartilage and bone 
which underlies the synovium (Stamp et al, 2012). Tyr-NO2 staining was 
observed in immunohistochemical staining of the synovium from RA patients 
(Mapp et al, 2001; Sandhu et al, 2003) as well as within RA plasma/serum 
(Kaur and Halliwell, 1994; Misko et al, 2013). Quantification of Tyr-NO2 in 
aspirated samples of knee-joint synovial fluid has demonstrated the importance 
of selecting the correct methodology when measuring Tyr-NO2, as the 
concentrations reported in RA (Kaur and Halliwell, 1994), using HPLC-UV, 
could not be confirmed by LC-MS/MS (Yi et al, 2000). The latter study reported 
Tyr-NO2 to be undetectable in RA synovial fluid. HPLC using electrochemical 
detection has been confounded by an artefact that co-eluted with Tyr-NO2 in 
human brain tissue (Kaur et al, 1998) and this may also be an issue with other 
tissue samples when not using MS to provide an unequivocal structural 
identification of the Tyr-NO2 analyte. 
As well as an increased plasma concentration of Tyr-NO2 in RA patients, 
compared to healthy control participants, studies have demonstrated a fall in 
plasma Tyr-NO2 concentration following treatment with various drugs 
(Nemirovskiy et al, 2009; Misko et al, 2013). Nemirovskiy et al (2009) have 
shown a fall in plasma Tyr-NO2 concentrations in animal models of arthritis 
following administration of experimental iNOS inhibitors. Within human subjects, 
Misko et al (2013) reported a lowering of plasma Tyr-NO2 concentrations after 6 
months of anti-TNF treatment (3774 pg/ml to 2955 pg/ml, n=18), as well as a 
correlation with other RA markers (e.g. the acute phase protein CRP and matrix 
metalloproteinase-3). The method employed was LC-MS/MS and total Tyr-NO2 
was measured (i.e. both protein-associated and free Tyr-NO2). The drop in 
plasma Tyr-NO2 concentration was also associated with a change in the RA 
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disease activity score (DAS28-3 CRP). However, this does not provide any 
more clinically useful information than measuring CRP and future work should 
focus on what new information Tyr-NO2 can provide, if any.  
Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary disease (COPD) involves an abnormal 
inflammatory response in the lungs that becomes chronic and has been shown 
to be coupled with systemic inflammation (Chung and Adcock, 2008). White 
blood cells accumulate in the small airways and alveolar destruction is, in part, 
caused by neutrophils and macrophages. This damage causes the release of 
DAMPs and further inflammation (Barnes, 2004; O'Donnell et al, 2006; Chung 
and Adcock, 2008). The associated oxidative stress is also thought to cause 
activation of pro-inflammatory transcription factors, such as NF-κB (Rahman 
and Adcock, 2006). Increased oxidative stress in COPD may be the result of 
increased MPO levels. Zhu et al (2014) performed a meta-analysis and found 
sputum MPO levels were higher in COPD patients, compared to controls, and 
increased further during exacerbations. MPO is measured as a marker of 
neutrophil activity and could be a potential novel therapeutic target (Zhu et al, 
2014). Increases in MPO could cause an increase Tyr-NO2 levels, which could 
then potentially be measured as a marker of MPO activity. However, 
consideration must also be given to the observed in vitro decrease in Tyr-NO2 
levels in the presence of HOCl, another product of MPO activity (Section 1.5) 
(Whiteman and Halliwell, 1999). 
The majority of research into Tyr-NO2 in COPD has been done by 
immunostaining techniques (Ichinose et al, 2000; Sugiura et al, 2003; 
Ricciardolo et al, 2005; Rytila et al, 2006) with Tyr-NO2 staining determined to 
be greater in the later stages compared to early stages and controls (smokers). 
Of those studies that have used semi-quantitative methods (i.e. ELISA) 
Ricciardolo et al (2005) found free Tyr-NO2 to be higher in bronchoalveolar 
lavage fluid in severe COPD, compared with mild/moderate COPD and patients 
with normal lung function and Footitt et al (2016) found sputum Tyr-NO2 to be 
higher in COPD compared to non-smoking control participants. This suggests 
Tyr-NO2 has potential as a marker of oxidative stress in COPD but further work 
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with quantitative methods is needed before firm conclusions can be drawn from 
Tyr-NO2 measurements in this disorder. 
Cardiovascular Disease 
Atherosclerosis has an inflammatory component, with immune cells such as 
macrophages being active at the site of the atherosclerotic plaque (Chinetti-
Gbaguidi et al, 2011). Many studies have found nitrated proteins within the 
plaque tissue (Beckman et al, 1994b), e.g. LDL (Leeuwenburgh et al, 1997) and 
high MPO levels are associated with cardiovascular disease (Loria et al, 2008; 
Roman et al, 2010). 
Some studies have investigated whether plasma/serum concentrations of Tyr-
NO2 change in response to statin therapy for cardiovascular disease. 
Shishehbor et al (2003) reported an association (from a study using LC-MS/MS) 
between the concentration of plasma protein-associated Tyr-NO2 and coronary 
artery disease (defined as documented myocardial infarction, coronary artery 
bypass graft surgery, percutaneous coronary intervention or a stenosis of 50% 
or greater in a major coronary vessel), as well as a reduction in plasma Tyr-NO2 
following statin treatment. This lowering effect was concluded to be independent 
of the fall in lipid parameters and CRP. Pirro et al (2007) also reported a fall in 
plasma protein-associated Tyr-NO2 (using an ELISA) following rosuvastatin 
treatment in hypercholesterolemia. A drop in plasma protein-associated Tyr-
NO2 concentrations, following statin treatment, being observed by two different 
studies and methods (LC-MS/MS and ELISA) suggests that Tyr-NO2 has 
potential as a biomarker for disease monitoring following therapeutic 
intervention in cardiovascular disease. The former method offers high assay 
specificity and replication but the latter method suggests that a semi-
quantitative high-throughput assay is also applicable in these circumstances. 
However, as with many of the other diseases mentioned, further clinical studies 
are needed to confirm that Tyr-NO2 meets the requirements of a clinical 
biomarker (i.e. high sensitivity and specificity, section 1.4).  
Tyr-NO2 has also been associated with coronary artery disease in pre-diabetes. 
A prospective study by Chu et al (2012) reported an increase in plasma Tyr-
NO2 concentration (measured via ELISA), two hours after an oral glucose 
tolerance test. In those with an abnormal glucose tolerance plasma Tyr-NO2 
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levels were significantly higher in those with coronary artery disease compared 
to those without. Many studies have also been conducted to assess whether 
there is an association between circulating Tyr-NO2 concentration and 
endothelial dysfunction (an important part of cardiovascular disease pathology) 
in diabetes (Mihm et al, 2000; Ceriello et al, 2007; Ceriello et al, 2008).  
In conclusion, the issue of which method to employ for the determination of Tyr-
NO2 in the high-throughput analysis of clinical samples needs be addressed, as 
mass spectrometry is not yet feasible for high-throughput analysis and other 
methods in the literature suffer from methodological flaws or cannot be properly 
assessed due to a lack of detailed methodological information (Duncan, 2003).  
When measuring protein-associated Tyr-NO2, another factor that needs to be 
investigated is the effect of protein turn-over rate on protein-associated Tyr-NO2 
concentration. A fall in protein-associated Tyr-NO2 concentration will only be 
measurable if the nitrated protein is degraded in parallel with a decrease in 
disease activity. As mentioned in section 1.5 there is evidence that nitration of 
certain proteins can enhance proteolytic degradation (Grune et al, 1998; Souza 
et al, 2000a) or inhibit it (Davies, 2001; Dunlop et al, 2009). 
Validation of oxidative stress modifications as useful biomarkers in disease has 
been hindered by methodological flaws.Tyr-NO2 is no exception to this and this 
topic has been reviewed (Griffiths et al, 2002; Tsikas and Caidahl, 2005; Tsikas 
and Duncan, 2014; Frijhoff et al, 2015). There is still much work to be done in 
assessing Tyr-NO2 as a clinically useful biomarker, with more clinical studies 
(e.g. randomised drug trials and prospective cohort studies) assessing 
sensitivity and specificity needed in particular. However, findings so far – at 
least in relation to some inflammatory diseases – have been encouraging, with 
some studies showing that plasma Tyr-NO2 levels correlate with disease activity 
(e.g. high Tyr-NO2 levels were seen in patients with a high SLE disease activity 
index (Wang et al, 2010)) and are decreased following successful therapeutic 
interventions (e.g. as seen with statin treatment in cardiovascular disease 
(Shishehbor et al, 2003)). The question of whether Tyr-NO2 is any more 
informative, in clinical terms, than other markers that are already available, e.g. 
CRP, is still to be addressed. 
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Other post-translational modifications of proteins have been used clinically to 
aid diagnosis, prognosis or disease monitoring. For example, the presence of 
antibodies, in serum, to citrullinated proteins can aid diagnosis of rheumatoid 
arthritis (Schellekens et al, 2000; Luban and Li, 2010). Citrullination is a post-
translational modification caused by peptidylarginine deiminase enzymes, that 
converts arginine residues to citrulline residues (Vossenaar and van Venrooij, 
2004). In diabetes, glycated haemoglobin can be used to assess/monitor a 
person’s glycaemia levels over the preceeding 120 days, an erythrocyte’s 
average lifespan (Bunn, 1981; Goldstein et al, 2004; Nathan et al, 2007). 
Glycation of haemoglobin is an effectively irreversible non-enzymatic 
modification and the glycation is directly proportional to the glucose 
concentration in the surrounding area (Goldstein et al, 2004).  
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1.6. Hypothesis and Aims 
The main hypothesis, which forms the basis of the following research project, is 
that Tyr-NO2 is a clinically relevant biomarker of inflammation. 
Within this project the aims have been to: 
1. Develop and validate a new sensitive ELISA method for the high-
throughput analysis of protein-associated Tyr-NO2 in human samples 
(Chapter 3). 
2. Measure ˙NO metabolites and protein-associated Tyr-NO2 in serum to 
assess nitrative stress following an acute inflammatory response, i.e. 
after surgery (Chapter 3). 
3. To determine whether high dietary NO3¯ ingestion by smokers leads to 
an increase in nitrative stress-induced post-translational modifications of 
proteins (Chapter 4). 
4. Compare protein-associated Tyr-NO2 to CRP as a marker of 
inflammation in patients post-surgery and assess its clinical utility in the 
diagnosis of patients that developed post-surgery sepsis (Chapter 5). 
5. Measure ˙NO metabolites and protein-associated Tyr-NO2 in brain tissue 
to assess nitrative stress in dementia (Chapter 6). 
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Chapter 2  
General Methods 
 
Materials and methods used throughout this project are detailed within the 
following sections and will be referred to throughout this thesis.  
2.1. Materials 
Phosphate buffered saline (PBS; 10mM) (P5368), RIPA buffer, protease 
inhibitor cocktail, bovine serum albumin (BSA) fraction V, bromophenol blue 
sodium salt, sodium dodecyl sulfate (SDS), Ponceau S, N,N,N′,N′-
tetramethylethylenediamine (TEMED), β- mercaptoethanol, methanol, hydrogen 
peroxide (H2O2), manganese (IV) oxide (MnO2), dithiothreitol (DTT), vanadium 
chloride and hydrochloric acid (HCl) were purchased from Sigma-Aldrich 
(Gillingham, UK). 
Glycine, Tris base, zinc sulfate (ZnSO4), glacial acetic acid, Tween-20 and 
ammonium persulfate (APS) were from Fisher Scientific (Loughborough, UK).  
The protein-free blocking buffer, bicinchoninic acid (BCA) assay reagents, pH 
indicator paper and “PageRuler” pre-stained protein ladder were from Thermo-
Fisher Scientific (Cramlington, UK).  
The TGX FastCast acrylamide kit (12%) and nitrocellulose membrane (0.45 µm) 
were from Bio-Rad (Hemel Hempstead, UK). 
The protein carbonyl enzyme immunoassay (EIA) kits were from Biocell 
Corporation Ltd (Auckland, NZ). 
Coomassie Brilliant Blue was from LKB Produkter (Stockholm, Sweden). 
All buffers and reagents were made up in deionised, ultrapure H2O (ddH2O, 
18.2 MΩ/cm) unless otherwise stated.  
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2.1.1. Antibodies  
Table 2.1: Details of the antibodies used in the ECL ELISA and western blotting 
Antigen Host Conjugation Type 
Supplier 
(product 
number) 
Lot number 
ELISA 
dilution 
Western 
Blot 
dilution 
Nitrotyrosine Mouse - 
Monoclonal Cambridge 
Biosciences 
189542 
0426640-1 1 µg/ml  
Monoclonal 0460908-1  1:1,000 
Nitrotyrosine Mouse Biotin Monoclonal 
Cambridge 
Biosciences 
10006966 
0448074-1 2 µg/ml  
Actin Rabbit - Polyclonal 
Cambridge 
Biosciences 
A300-485A 
A300485A-2  1:5,000 
Mouse IgG Goat IRDye680RD Polyclonal 
LiCor 
926-68070 
C40312-02  1:15,000 
Rabbit IgG Goat IRDye800CW Polyclonal 
LiCor 
926-32211 
C40325-02  1:15,000 
Mouse IgG Goat IRDye800CW Polyclonal 
LiCor  
925-32210 
C40826-04  1:15,000 
Rabbit IgG Goat IRDye680RD Polyclonal 
LiCor 
925-68071 
C41022-02  1:15,000 
Biotin n/a IRDye800CW Streptavidin  
LiCor 
925-32230 
C50226-03  1:5,000 
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2.2. Samples 
Serum: 4ml clotted blood sample was collected at each time point. These were 
centrifuged and the serum stored frozen as a single aliquot (2.0-2.5 ml) at DSTL 
(further details in sections 3.2.1 and 5.1). 
Plasma: Blood was collected in 5ml EDTA vacutainers and spun at 350 g for 20 
minutes, the plasma supernatant was then collected and frozen. 
Human brain tissue homogenates were collected and lysed by the South West 
Dementia Brain Bank (further details in section 6.1). 
Forebrain and cerebellum tissue samples from the brain of transgenic (n=24) and 
wild-type mice (n=14) were collected and snap frozen, then stored at -80°C until 
lysis (further details in section 6.1). 
Plasma, serum and brain samples were stored at -80°C until use. Further 
preparation was method dependent. 
 
2.3. Determination of protein concentration 
The bicinchoninic acid (BCA) assay (Thermo Fisher, Cramlington, UK) was 
used to determine the protein concentration of samples (range 0.06 – 2 mg/ml). 
The BCA assay uses the Biuret reaction (reduction of copper (II) to copper oxide 
(I), in alkali conditions, by the peptide bond), which is then followed by the 
formation of a complex between copper oxide (I) and BCA. This produces a 
deeper purple colour than the Biuret reaction alone and has an absorbance 
maximum at 562 nm (Smith et al, 1985). Bovine serum albumin (BSA) in H2O 
was used for a 6 point standard curve with a range of 0.06 – 2.00 mg/ml. The 
sample was diluted in H2O as necessary to fit within this range (e.g. 
plasma/serum was diluted 1 in 100).  
Clear, flat bottom, 96-well microtiter plates (Sterilin, Fisher Scientific, 
Loughborough UK) were used and 25 µl of the sample/standard was mixed with 
the 200 µl BCA reagent - if the sample volume was limited 10 µl sample was 
used (altering the assay working range to 0.125 – 2 mg/ml). The plate was then 
covered and incubated at 37°C for 30 minutes before measuring the 
absorbance on a Fluostar Optima plate reader (BMG Labtech, Ortenberg, 
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Germany), with a 550-10 excitation filter. Calculated concentrations were then 
multiplied by the samples dilution factor. A typical standard curve from this 
assay is shown in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4. SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) 
Denaturing and reducing conditions were used during SDS-PAGE to separate 
sample proteins by mass. Samples were denatured by addition of Laemmli 
buffer and heating. Laemmli buffer contains SDS and a reducing agent. SDS is 
both denaturing and an ionic detergent that binds evenly to proteins, giving 
them all an equivalent negative charge and allowing separation by mass only in 
the gel. β-mercaptoethanol or DTT were used as a reducing agent; breaking the 
Figure 2.1: BCA assay standard curve 
Bovine serum albumin was used as the protein standard at a range of 
0.06 – 2.00 mg/ml 
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disulphide bonds so that proteins are no longer in their tertiary or quaternary 
structures.  
Samples then underwent electrophoresis; this process uses a positive charge to 
draw the proteins through the pores in the polyacrylamide gel. A 12% 
acrylamide gel was used as this has a small pore size, allowing low molecular 
weight proteins to be resolved. The gel was then either stained with Coomassie 
stain or used for a western blot.  
2.4.1. Preparation of gels 
Bio-Rad (Hemel Hempstead, UK) FastCast acrylamide kits and mini-protean 
plates were used according to the manufacturers instructions to make 1.5 mm 
thick gels with 10 wells. Resolving gel was 12% acrylamide and stacking gel 4% 
acrylamide. Kit instructions were followed using the listed reagents (n = number 
of gels):  Stacking gel – 1.5 ml x n Stacker A, 1.5 ml x n Stacker B, 3 µl x n 
TEMED and15 µl x n 10% fresh ammonium persulfate (APS). Resolving gel – 4 
ml x n Resolver A, 4 ml x n Resolver B, 4 µl x n TEMED, 40 x n 10% fresh APS. 
 2.4.2. Sample preparation 
Sample protein concentration was determined by the BCA assay (see section 
2.1) and the required volume (for 60 µg protein per well) was calculated and 
mixed with 8 µl of 5x Laemmli buffer (Laemmli, 1970), the volume was made up 
to 40 µl with H2O. Samples were then boiled at 99°C for 5 minutes and all 40 µl 
were applied to the track. 
Composition of 5x Laemmli buffer: 200 mM Tris (pH 6.8), 10% SDS, 50% 
Glycerol, pinch of bromophenol blue (to colour) and H2O to required volume. 
And one of the following reducing agent (added immediately prior to use): 100 
mM dithiothreitol or 1% β-mercaptoethanol.  
2.4.3. Electrophoresis 
Gels were placed in a Mini Trans-Blot cell (Bio-Rad Hemel Hempstead, UK) and 
the middle reservoir filled with 1x SDS running buffer. Once it was confirmed 
that there was no leaking, the tank was then half filled with SDS-running buffer 
and samples were loaded into the wells. The first well was loaded with 4 µl pre-
stained protein marker. This marker contained proteins of known molecular 
weights (10 – 170 kDa) that had been stained so that their progress down the 
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gel could be observed (Figure 2.2). This marker was used to estimate the 
molecular weight of protein bands obtained from the samples.  
The PowerPac HC (Bio-Rad Hemel Hempstead, UK) voltage was set to a 
constant 70V for the first 20 minutes as proteins passed through the stacking 
gel. This voltage was then increased to a constant 100V until the loading dye 
reached the end of the gel (approximately 90 minutes). The electrophoresis was 
then stopped and the gel removed from the tank. 
Composition of 10x SDS running buffer: 0.25 M Tris base, 1.92 M glycine, 1% 
SDS and H2O to required volume. 
2.5. Coomassie staining 
To visualise protein bands the SDS-PAGE gel was dyed with Coomassie 
Brilliant Blue dye (G25). The staining solution contains methanol, to fix proteins 
by stopping diffusion through the gel, and acetic acid. Within this acidic buffer 
Coomassie can bind to residues within proteins.  
Composition of 1L Coomassie Brilliant Blue staining solution: 500 ml Methanol, 
100 ml Glacial acetic acid, 400 ml H2O and 2.5 g Coomassie Brilliant Blue. 
The gel was incubated in the dye for 2 hours. A de-staining solution (the same 
as the staining solution but without Coomassie Brilliant Blue) was then used to 
remove any of the non-bound dye, after an hours incubation, the destain 
solution was refreshed and then incubated overnight.  All incubations were at 
room temperature with gentle rocking.  
The gel was imaged on a LiCor Odyssey CLx (LI-COR Biosciences UK Ltd 
Cambridge, UK). By comparing band position to the pre-stained protein marker 
a rough estimate of molecular weight for each protein band was achieved.  
This gel image can then be compared to blot images obtained from western 
blots or bands of interest can be excised from stained gels for mass 
spectrometry analysis. An example gel is seen in Figure 2.2, this gel contained 
a molecular weight marker, human brain tissue samples and nitrated bovine 
serum albumin (this acted as a positive control in tandem western blots). 
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2.6. Western blotting 
Western blotting uses antibodies to probe for a certain target antigen within a 
sample, following the transfer of proteins from the SDS-PAGE gel to a 
membrane. This technique was described and named by Burnette (1981) and 
the main principles of the procedure have not changed since. 
2.6.1. Transfer 
Transfer from the SDS-PAGE gel to the membrane (nitrocellulose 0.45 µm) was 
performed using the ‘wet’ tank electrotransfer method. With this method, a 
transfer ‘sandwich’ was created in which the gel and nitrocellulose membrane 
were placed between two sheets of filter paper and transfer pads (all pre-
soaked in cold transfer buffer). It is important to remove air bubbles between the 
gel and membrane before transfer as they will interfere with the process; a roller 
Figure 2.2: A Coomassie stain of brain samples run on an SDS-PAGE gel 
Track 1: molecular weight marker. Tracks 2-7 contain 60 µg human brain tissue 
homogenate. Track 8: nitrated bovine serum albumin (blue arrow, purchased from 
Sigma Aldrich, Gillingham UK). 
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was used for this. The sandwich was then placed in a Mini Trans-Blot cell (Bio-
Rad Hemel Hempstead, UK), with the membrane closest to the anode, along 
with an ice block and magnetic stirrer. A lot of heat is generated during the 
transfer process and this can melt the gel. Therefore, the tank was kept cold 
throughout. The tank was filled with cold transfer buffer and the PowerPac HC 
(Bio-Rad Hemel Hempstead, UK) constant current set to 0.35 A, the gel was set 
to transfer for 60 minutes. Transfer of the pre-stained protein marker from the 
gel to the membrane was used as a marker of a successful transfer. 
Gels were stained with Coomassie (section 2.4) after transfer to confirm that 
proteins had effectively migrated out of the gel. 
Composition of transfer buffer: 50 mM Tris base, 40 mM glycine, 20% methanol, 
0.1% SDS and H2O up to required volume. 
2.6.2. Blocking the membrane 
The nitrocellulose membrane has a high affinity for protein and therefore would 
bind the antibodies if not ‘blocked’ first. Protein-free blocking buffer was used, 
rather than the common BSA blocking solution, as nitrated tyrosine could be 
expected to be present in albumin. The blocking component of this protein-free 
buffer is proprietary but it was able to efficiently block the membrane.  This step 
was performed overnight at 4°C with gentle rocking.  
2.6.3. Antibody incubation 
The antibodies listed previously (Table 2.1) were used, with actin (a 
cytoskeletal protein present in all cells) as a loading control marker. The anti-
actin antibody binds to the γ-actin isoform (Uniprot P63261, MW 41,793 Da), 
with some cross-reactivity for β-actin (Uniprot P60709, MW 41,737).  
The secondary antibodies are conjugated to fluorophores that emit in near-
infrared (NIR) wavelengths (700 and 800 nm). These fluorophores produce a 
signal directly proportional to the antigen and are stable over time. 
The primary and secondary antibodies were both incubated at room 
temperature for one hour with gentle agitation.  
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2.6.3.1. Western blot controls 
Nitrated BSA was used as a positive control, to verify antibody binding. This 
was either commercial or nitrated in-house using peroxynitrite (see section 2.8). 
2.6.4. Imaging 
For imaging the LiCor Odyssey CLx system was used (LI-COR Biosciences UK 
Ltd Cambridge, UK), this platform has an infrared laser for excitation of the NIR 
fluorophores. The Image Studio Lite (LI-COR Biosciences UK Ltd Cambridge, 
UK) software was then used to analyse the images. This software allows for the 
image to be edited (e.g. cropped, flipped, brightened) without changing the 
actual signal intensities (numerical data) collected so that comparisons between 
bands are valid. 
Nitrotyrosine bands were quantified by expression as a ratio of the actin signal. 
An example of a typical blot and quantification can be seen in Figure 2.3.  
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 2.7. Mass Spectrometry 
Details of the applicable sample digestion protocols can be found in the relevant 
chapters. The following HPLC-MS/MS protocol was used for all mass 
spectrometry. 
Digested peptide mixtures were separated by liquid chromatography on an 
Ultimate 3000 system (Dionex, UK). A C18RP pre-column (C18 PepMapTM, 5 
µm, 5 mm x 0.3 mm i.d.  Dionex, UK) was used for capturing and desalting 
peptides, by washing for 4 min with 2% aqueous acetonitrile (0.1% formic acid) 
at 30 µL/min. A C18 nano-HPLC column (C18 PepMapTM, 5 µm, 75 µm i.d. x 
150 mm, Dionex, UK) was then used for separation with a gradient elution 
running from 2%  to 45% aqueous acetonitrile (0.1% formic acid) over an hour. 
The final wash step then ran from 45 % to 90 % aqueous acetonitrile (0.1% 
formic acid) in 1 min.  The system was then washed with 90% aqueous 
Figure 2.3: An example of a NIR western blot 
Red bands are actin positive and green bands nitrotyrosine positive. Signal intensity 
quantification is shown for the two circled bands. Track 1 molecular weight marker. Tracks 2-7 
contain 60 µg human brain tissue homogenate. Track 8 nitrated bovine serum albumin 
monomer (blue arrow) and nitrated aggregate (red arrow) (Enzo Life Sciences, New York 
USA). 
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acetonitrile (0.1% formic acid) for 5 min and then equilibrated with 2% aqueous 
acetonitrile (0.1% formic acid).  
A 5600 Triple TOF mass spectrometer was used for mass spectrometry 
analysis (Sciex, Warrington UK). Peptide ionization was achieved with a spray 
voltage set at 2.4 KV, a source temperature of 150ºC; declustering potential 
was set at 50 V with a curtain set at 15 V. Scans were collected using survey 
high resolution TOF MS mode in positive mode 400 to 1200 da for 200 ms.  
Information-dependent acquisition was used to collect MS/MS data, with the 
following criteria: the 10 most intense ions with +2 to +5 charge states and a 
minimum intensity of 500 counts-per-second were chosen, using dynamic 
exclusion for 20 s, 250 ms acquisition time and rolling collision energy. 
The data analysis is detailed for each project in individual chapters. 
2.8. Protein carbonyl enzyme immunoassay  
Protein carbonyls were measured with an enzyme immunoassay (EIA) kit 
(Biocell PC test, NZ) which utilises derivatization by dinitrophenylhydrazine 
(DNP) and an anti-DNP antibody.  
Kit instructions were followed for high protein concentration samples (i.e. 
serum) and room temperature incubations were performed at 21°C. 
The serum was incubated with a DNP solution for 45 min before dilution in an 
EIA buffer; the samples were then used to coat the plate overnight. The plate 
was then blocked before incubation with a biotinylated anti-DNP antibody. 
Streptavidin-HRP and chromatin reagent were then used for colour 
development. Absorbance was measured at 450 nm, using the Fluostar Optima 
plate reader (BMG Labtech, Ortenberg, Germany). A typical standard curve can 
be seen in Figure 2.4. 
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2.9. Peroxynitrite synthesis 
Peroxynitrite was synthesised as a nitrating agent for in vitro experiments, 
according to the method described by Beckman et al (1994a). Solutions were 
cold and all steps were performed using glass beakers on ice. Three solutions 
(each 50 ml) were made: (1) 0.6 M NaNO2, (2) 0.7 M acidified H2O2 (0.6 M HCl) 
and (3) 1.2 M NaOH. Stock H2O2 concentration was measured (Spectra Max 
M2e, Molecular Devices, USA) prior to use; 3 ml of 100x diluted solution was 
placed into a quartz cuvette and the absorbance was read at 240 nm (extinction 
coefficient 43.6 M-1 cm-1 (Hildebrandt and Roots, 1975)). 
The acidified H2O2 was quickly poured into the NaNO2, immediately followed by 
the NaOH. This results in a yellow solution of diluted peroxynitrite. MnO2 (~15 
mg) was added to deplete excess H2O2 and the solution was then filtered and 
frozen at -20°C. The top layer of this frozen solution was concentrated 
peroxynitrite that thaws rapidly, this layer was collected and aliquoted for later 
use. Concentrations of 200 – 210 mM were routinely achieved when measuring 
Figure 2.4: Protein carbonyls standard curve 
Oxidised protein standards in the range 0.10 – 0.95 nmol/mg protein 
were used in the protein carbonyl assay. 
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the absorbance at 302 nm (extinction coefficient 1670 M-1 cm-1 (Hughes and 
Nicklin, 1968). The aliquots were kept at -20°C for up to 3 months (-80°C for 
longer storage) and the concentration was checked upon defrosting (Equation 
2.1). Aliquots were used within 30 minutes of defrosting. 
Equation 2.1:  
𝑀𝑜𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  
2.9.1. Nitration of protein 
A BSA solution of 2 mg/ml was generated in a bicarbonate based nitration 
buffer. The solution was exposed to 3 mM peroxynitrite (stock diluted to 30 mM 
with H2O), whilst being gently vortexed. The pH of the solution was then 
checked using pH indicator paper (pH 0-14, Fisher Scientific, Loughborough 
UK), to ensure that a neutral pH had been retained. Successful nitration could 
be observed by a change in colour of the solution from clear to a faint yellow. 
Nitration was measured, at pH 10, on a Cary 300 UV-Vis spectrophotometer 
(Agilent Technologies LDA UK Limited, Cheshire UK), using the extinction 
coefficient 428nm = 4200 M-1cm-1 (van der Zee et al, 1977). An example 
spectrum can be seen in Figure 2.5. 
Composition of nitration buffer: 100 mM Potassium phosphate (KH2PO4) and 25 
mM Sodium bicarbonate (NaHCO3). 
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2.10. Ozone-based chemiluminescence (NO2¯ and NO3¯ measurement) 
Nitrite (NO2¯) and nitrate (NO3¯) were measured using a Sievers •NO analyser 
(Sievers NOA 280; Analytix, UK). This method involves the reduction of NO2¯ 
and NO3¯ to •NO which then reacts with ozone to produce luminescence, this 
light was then measured by a photomultiplier tube. An example of the time trace 
is shown in Figure 2.6. 
Five known concentrations of sodium nitrite (0.2 – 10 µM) and sodium nitrate 
(0.5 – 20 µM) were used as standards for NO2¯ and NO3¯ respectively. 
Samples were deproteinized prior to measurement using 0.5 M NaOH and 10% 
zinc sulfate (ZnSO4). The ratio was always 1:2:2 (sample: NaOH: ZnSO4), a 
sample dilution factor of 5, with at least 100 µl sample being used. After addition 
of NaOH and ZnSO4, samples underwent a brief vortex before incubation at 
room temperature for at least 15 minutes. Samples were then centrifuged at 
17,500 g for 5 minutes and the supernatant analysed.  
 
Figure 2.5: UV-visible spectrophotometry spectra of native and nitrated BSA 
The spectra of native BSA (purple) and nitrated BSA (red) were recorded at wavelengths 
between 200 and 500 nm (pH 10). Polypeptides show a peak at 280 nm and nitrotyrosine a 
peak at 428 nm. 
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Aliquots (100 µl) of the deproteinised samples were refluxed in a reaction 
chamber with 1 ml 0.3 M sodium iodide and 4 ml glacial acetic acid (at 35°C) for 
NO2¯ measurement, or with 4ml 0.1 M vanadium III chloride /1M HCl (at 95°C) 
for NO3¯ measurement.  
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Figure 2.6: Time trace for ozone based chemiluminescence, measuring nitrate in 
serum samples. 
Each peak represents an injection of a sample and the area of this peak was calculated 
for comparison to a standard curve. Injection 1 was the blank, injections 2 and 23 were a 
10 µM NO3¯ standard, injections 3-22 were serum samples in duplicate (i.e. 10 samples). 
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Chapter 3  
Validation of a new electrochemiluminescence ELISA for the 
measurement of protein-associated 3-nitrotyrosine 
 
3.1. Introduction 
As discussed in Chapter 1 (section 1.5) the formation of Tyr-NO2 in human 
tissues/bio-fluids is associated with several pathologies which involve a strong 
inflammatory component. For example, plasma protein-associated Tyr-NO2 
concentrations have been shown to be increased in patients with systemic 
lupus erythematosus (Khan et al, 2006), celiac disease (Ter Steege et al, 1998) 
and cardiovascular disease (Shishehbor et al, 2003; Eleuteri et al, 2009), when 
compared to controls (in the aforementioned papers, ‘controls’ being individuals 
with no clinical signs of disease). This is perhaps unsurprising given that the two 
most cited initiators of nitration - peroxynitrite (Skatchkov et al, 1997; Kuhn et al, 
2004) and myeloperoxidase (Gaut et al, 2002b; Sun et al, 2007) - are both 
increased in inflammatory conditions. 
This has led to the suggestion that Tyr-NO2 could be measured as a marker of 
oxidative stress in clinical studies. Some studies have shown that Tyr-NO2 
correlates with disease activity (Ohya et al, 2002; Wang et al, 2010) and 
decreases following treatment (e.g. with the cholesterol reducing drugs statin 
and rosuvastatin in cardiovascular conditions, Shishehbor et al (2003); Pirro et 
al (2007)). 
Evidence supporting oxidative stress modifications as useful biomarkers in 
disease has been hindered by a fragmented literature and Tyr-NO2 is no 
exception to this (Frijhoff et al, 2015). There have been two main approaches to 
quantifying Tyr-NO2 levels in vivo, high-throughput ELISA’s and highly sensitive 
GC/LC-MS/MS. Both of these methods have advantages and disadvantages: 
ELISA methods are high throughput, less costly and do not involve extensive 
sample preparation but have low sensitivity and are semi-quantitative. GC/LC-
MS/MS is quantitative, highly sensitive and accurate but is low-throughput, time-
consuming and expensive - limiting this method’s usefulness in a clinical 
setting.  
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When measuring Tyr-NO2 there are two major methodological issues to 
consider: (1) low concentrations of the analyte and (2) artefactual formation of 
Tyr-NO2 during sample processing (Yi et al, 2000). Mass spectrometry 
measurement of Tyr-NO2 is considered to be the ‘gold standard’, and offers the 
greatest sensitivity, but also has the biggest risk of Tyr-NO2 formation during 
sample preparation.  
For the measurement of a large number of clinical samples an ELISA is a more 
practical method, but for a Tyr-NO2 ELISA to be successful the drawbacks of 
this method need to be addressed. Despite a wealth of studies utilising ELISAs 
for Tyr-NO2 measurement in clinical samples, the literature contains 
inconsistent methodologies and results (as discussed in Chapter 1, section 
1.5.1). For example, along with differences in ELISA design (indirect, 
competitive and sandwich) the standard has also varied; Ter Steege et al 
(1998) used nitrated plasma, where others have used nitrated BSA (BSA-NO2) 
(Khan et al, 1998; Bo et al, 2005; Weber et al, 2012). These ELISA methods 
have reported drastically different values of Tyr-NO2, in the plasma of healthy 
controls, from undetectable, with a LOD of 0.2 nM (Ter Steege et al, 1998), to 
>4000 nM (Bo et al, 2005). Additionally, there is an ambiguity in reported 
results, as many results are reported as absolute concentrations when they are 
in fact standard equivalents. For the authors to report an absolute concentration 
the exact amount of nitrated Tyr residues in the protein standard must be 
known. However, often all that is known/reported is the concentration of the 
nitrated protein standard. Therefore, the presented results are equivalent to the 
protein concentration, not the Tyr-NO2 content. Earlier studies have reported 
the development of ELISA’s for Tyr-NO2 (Ter Steege et al, 1998; Sun et al, 
2007; Weber et al, 2012) and commercial Tyr-NO2 assays are widely available. 
However, an obstacle still to be addressed is poor sensitivity, in that these 
ELISAs are often unable to detect Tyr-NO2 in a high proportion of human serum 
samples. 
Therefore, a high-throughput assay based on a highly sensitive 
electrochemiluminescence (ECL) platform has been developed for Tyr-NO2 
measurement. The base of an ECL ELISA plate contains carbon electrodes 
which transmit the electrical current to the antibody/antigen complex. The 
streptavidin tag is conjugated to a ruthenium complex which undergoes redox 
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cycling, following electrical stimulation, resulting in the production of light 
(Figure 3.1).  
In the present study, our developed ELISA, for protein-associated Tyr-NO2, was 
applied to serum samples from patients undergoing major elective surgery, with 
serum being collected prior to and one day after the surgery as an exemplar of 
the acute inflammatory response in humans.  
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Figure 3.1: Electrochemiluminescence ELISA schematic 
A sandwich ELISA was utilised for the measurement of protein-associated Tyr-NO2. The tag is 
a ruthenium complex that produces light upon electrical stimulation. Tripropylamine (TPA) is 
within the Read buffer and is a co-reactant for light generation. 
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3.2. Materials and methods 
3.2.1. Patient serum samples 
The serum samples were collected in a study approved by the NRES 
Committee South Central (REC ref 06/Q1702/152) and prior informed consent 
to take part in the study was obtained from each individual.  
A clotted blood sample was collected at each time point, these were centrifuged 
and the serum was frozen. 
Serum was collected from 35 individuals (18 male, 17 female; 59 ± 13 years 
old) prior to major elective surgery and again 24 hours after surgery.  
3.2.2. Additional samples 
The assay was also applied to lysed blood cells. These additional samples 
were: 
 Erythrocytes and monocytic cells isolated from healthy human blood (all 
volunteers gave informed consent, and this study was approved by the 
Institutional Research Ethics Committee - approval number 2014/781). 
 U937 cells, a histiocytic lymphoma cell line (Sigma-Aldrich, Gillingham 
UK. ECACC supplied, Lot 11D008). 
3.2.3. Materials 
Ultra-pure water was used for buffer preparations throughout. The following 
reagents were used in addition to those listed in Chapter 2, section 2.1: 
acetonitrile, iodoacetamide, trypsin (proteomics grade), RIPA buffer, protease 
inhibitor cocktail and Percoll (lot 10226958) (Sigma Aldrich, Gillingham UK). 
Dextran (batch DB4311) was from Pharmacosmos, Holbæk, Denmark. 
Methanol (analytical reagent grade), ammonium bicarbonate (analytical reagent 
grade), Formic acid 99% , foetal bovine serum (FBS, lot 41F6547K) and 
HyClone™ antibiotic-antimycotic solution (Lot J140011) were purchased from 
Fisher Scientific, Loughborough, UK. Dulbecco's modified Eagle's medium 
(DMEM), high glucose DMEM, and L-glutamine were obtained from Lonza, 
Wolverhampton UK.  
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The details of the two anti-nitrotyrosine (biotinylated and non-biotinylated) 
antibodies can be found in Table 2.1 (Chapter 2, section 2.1.1). Blocking buffer 
A (BSA), SULFO-TAG-labelled streptavidin and Read Buffer T 4x was 
purchased from Meso Scale Discovery (MSD), Maryland, USA. Nitrated bovine 
serum albumin (BSA-NO2) (Enzo Life Sciences, New York, USA).  
We used standard bind single spot 96 well plates (MSD, Maryland USA) and an 
electrochemiluminescence Sector Imager 2400 (MSD, Maryland USA).  
3.2.4. Validation of the assay 
LLOQ and CV: 
The lower limit of quantification (LLOQ) was defined as the lowest standard with 
a mean accuracy of 80 – 120% and a duplicate variation of <20%. 
The coefficient of variation (CV) was determined by preparing and measuring 
the same sample multiple times within and across plates (n=8). CV% = 
(standard deviation/mean) x 100. 
The inter-assay CV for room temperature incubations compared to a constant 
25°C (Jeio Tech Lab Companion SI-300R shaking incubator, Seoul Korea) was 
also assessed.  
The variation between sample duplicates, at low concentrations of Tyr-NO2, was 
also determined. 
Recovery and linearity: 
A plasma sample was spiked with 1 nM nitrated BSA (BSA-NO2) and diluted to 
four different concentrations (1 in 2, 1 in 5, 1 in 10 and 1 in 20) to determine the 
linearity and recovery of the assay. 
Antibody specificity: 
Pre-incubation of the detection antibody and spiking of the sample, with free 
Tyr-NO2, was performed to assess the antibodies binding affinities.  
Comparison of mass spectrometry and ELISA: 
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BSA (2 mg/ml) in a bicarbonate buffer (25 mM NaHCO3 and 100 mM KH2PO4) 
was exposed to 11 mM peroxynitrite (synthesised according to the method 
described by (Beckman et al, 1994a)) to cause nitration of tyrosine residues 
(Chapter 2, section 2.8). Half of this solution was then exposed to 1 mM sodium 
dithionite to chemically reduce the nitro groups to amino groups (Nikov et al, 
2003). 
Native (unmodified), nitrated and chemically reduced BSA samples were then 
analysed by SDS-PAGE (as described in Chapter 2, section 2.3; β-
mercaptoethanol was used as the reducing agent) and the bands excised and 
trypsin digested based on a previously described protocol (Shevchenko et al, 
2006). Mass spectrometry (MS/MS) analysis involved high pressure liquid 
chromatography (Dionex, UK) coupled to a 5600 Triple TOF mass spectrometer 
(Sciex, Warrington UK) and is detailed in Chapter 2, section 2.6.  
The generated data was then analysed with Mascot Daemon statistical software 
v 2.3.2 (MatrixScience, 2014) with the following settings applied: 
Digestion enzyme: Trypsin 
Fixed modifications: 
 Carbamidomethyl (C) (formed by the iodoacetamide) 
Variable modifications: 
 Oxidation (M) Nitro (Y) Amino (Y) 
Instrument type: ESI QUAD TOF 
Taxonomy: Mammalian  
Charge: 2+, 3+ and 4+ 
Fragment mass tolerance: 0.5 Da 
Peptides were then further examined using Peak View (Version 1.0 
(ABSCIEX)); this was to examine their extracted ion chromatograms (XIC). For 
this, the m/z of the peptides containing either unmodified tyrosine, nitrotyrosine 
or aminotyrosine were entered, along with an XIC range width of 0.1. 
Analysis of this data was based on the assumption that modified peptides would 
be measured with the same sensitivity as the unmodified forms, and therefore 
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the results are an approximation of the nitration occurring. To manually confirm 
the analysis by Mascot, the following criteria were applied: peaks with 
intensities below 1.0 x 104 were excluded and peaks without the mono-isotopic 
peak were excluded as an artefact. The peptide sequence was then confirmed 
by de novo sequencing. For the remaining peaks, the intensities were recorded 
allowing calculation of the total peptide intensity (unmodified + modified) and 
the percentage contribution for each modification calculated.   
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3.2.5. ELISA method 
Buffers 
Blocking buffer (3% blocker A in PBS), dilution buffer (1% blocker A in PBS), 
washing buffer (0.05% Tween-20 in PBS) and 2x Read buffer (50% Read buffer 
T4x, 50% H2O). The primary antibody was diluted in PBS (1 µg/ml). The BSA-
NO2 standard (10 nM), secondary antibody (2 µg/ml) and streptavidin (1:500)  
were prepared in dilution buffer.  
Standard preparation 
Commercial BSA-NO2 was aliquoted into 1000 nM stock solutions 
(reconstituted with distilled water) prior to use. A 1000 nM stock was then 
diluted with dilution buffer to 10 nM to form the top point of the standard curve. 
Dilutions (2.5-fold) were used for the next six standards and dilution buffer was 
used as a blank (standard range 0.04 nM – 10 nM).  
Serum preparation 
Serum samples were defrosted (stored at -80°C) and centrifuged at 14,000 g for 
15 minutes at 4°C, to pellet any debris. The serum was kept cool and diluted 1 
in 5 with dilution buffer immediately prior to use.  
ELISA protocol 
Primary antibody (non-biotinylated) was placed into each well of the plate and 
then incubated at 4°C overnight. The plate was then blocked with 150 µl 
blocking buffer at 25°C for one hour with gentle agitation (these were the 
conditions for all further incubations). Each standard/sample (25 µl) was added 
to the relevant well, with quadruplicate repeats of each, and incubated. A 
biotinylated secondary antibody was used alongside a streptavidin tag coupled 
to a ruthenium complex. Read buffer (150 µl, 2x concentration) was placed into 
each well and the plate immediately read on the MSD Sector Imager 2400.  
The standard curve was plotted and the sample concentrations calculated from 
these known values. Results were expressed as BSA-NO2 equivalents.  
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3.2.6. Additional methods 
Protein concentration was determined by the BCA assay (Chapter 2, section 
2.2). Protein carbonyl content was measured using a commercial enzyme 
immunoassay kit (Chapter 2, section 2.7). C-reactive protein (CRP) was 
measured by myself at the Clinical Chemistry department at the Royal Devon 
and Exeter (RD&E) Hospital, using a standard clinical assay - an 
immunoturbidimetric assay on a Roche Cobas automated analyser (Roche 
Diagnostics, West Sussex UK), with a range of 0.3 – 350 mg/L. In order to 
perform this assay, serum was placed in a reaction cuvette with latex particles 
coated with a monoclonal anti-CRP antibody. Any aggregates formed by the 
binding of CRP to these particles were determined turbidimetrically. Due to the 
low volume of serum available, the CRP test was carried out on a smaller 
volume than usually applied (when doing routine clinical analyses) but 
preliminary tests run by Emily Brewer (RD&E Hospital) confirmed that the 
volume (50 µl) was suitable for testing.  
NO2¯ is oxidised to NO3¯ in the presence of oxyhaemoglobin (Kim-Shapiro et 
al, 2005). As serum was collected rather than plasma, this meant that NO2¯ and 
haemoglobin had a longer amount of time to react. Therefore, only NO3¯ 
concentrations were evaluated. NO3¯ concentration was measured by ozone-
based chemiluminescence (Chapter 2, section 2.9). 
During collection clinical information was recorded for some of these samples 
(e.g. white blood cell count). 
3.2.7. Cell culture and isolation 
U937 cells were cultured in DMEM supplemented with 10% FBS, 4 mM L-
glutamine, and an antibiotic/antimycotic solution (100 units penicillin, 100 µg 
streptomycin and 0.25 µg amphotericin B).  
For the separation of cells from blood, the following protocol was used (Shaw et 
al, 2011): whole blood (5ml) was collected into EDTA tubes and centrifuged (20 
minutes, 350g), and the plasma removed. Red blood cell sedimentation was 
achieved by incubating the cells with dextran (6% w/v), for 30 minutes, room 
temperature. Further separation of cells into mononuclear and 
polymorphonuclear cell types was then accomplished using a discontinuous 
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Percoll gradient (81: 68: 55%). Centrifugation through the gradient (20 minutes, 
720g, 4°C) resulted in mononuclear cells being retained at the upper boundary 
(between the 68 and 55% Percoll) and polymorphonuclear cells at the lower 
boundary (between the 68 and 81% Percoll).  
All cells were lysed in order to measure cellular protein nitration. For this, RIPA 
buffer with a protease inhibitor cocktail was used according to the 
manufacturer’s instructions. Lysate protein content was measured by BCA 
assay (Chapter 2, section 2.2). 
3.2.8 Statistical analysis 
Data sets were tested for a normal distribution using the Shapiro-Wilk’s test and 
the appropriate parametric (two-way ANOVA) or non-parametric test (Wilcoxon 
matched pairs and Kruskal-Wallis) selected accordingly. 
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3.3. Results  
Optimisation and validation of the assay 
The combination, and concentration, of antibodies for the assay had already 
been determined (see Section 2.1.1, Table 2.1).   
The results from assays run at 25°C were more consistent than assays run at 
room temperature (Table 3.1). 
Table 3.1: Temperature dependent variation in the ECL ELISA 
The standard deviation (SD) at room temperature was far higher than when the assay 
was run at a consistent 25°C. 
 Tyr-NO2 (BSA-NO2 equivalents; nM)  
 #1 #2 #3 #4 Mean SD 
Room 
temperature 
1.899 2.578 1.810 0.155 1.610 1.03 
25°C 1.778 1.885 1.745 1.247 1.664 0.28 
 
The CV was determined, at 25°C, for within the assay (intra-assay CV 6.5%) 
and between days (inter-assay CV 11.3%) (Table 3.2). The LLOQ was 0.04 nM 
BSA-NO2, the highest standard used was 10 nM BSA-NO2. 
Table 3.2: Determination of ECL ELISA intra- and inter-assay CV 
The mean and SD of 8 replicates was determined to calculate the CV ((SD/mean) 
x100). 
 Tyr-NO2 (BSA-NO2 equivalents; nM)   
 #1 #2 #3 #4 #5 #6 #7 #8 Mean SD CV% 
Intra-
assay 
1.87 1.80 1.83 1.58 1.82 1.65 1.66 1.88 1.8 0.1 6.5 
Inter-
assay 
2.5 2.67 2.77 2.18 2.45 2.19 2.02 2.67 2.4 0.3 11.3 
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Control plasma samples, spiked with BSA-NO2, revealed that low 
concentrations of Tyr-NO2 (i.e. near the LLOQ) had higher replicate variation 
than samples with higher concentrations (i.e. midway on the standard curve), 
percentage variation 13.8 and 6.1% respectively. As plasma levels of Tyr-NO2 
are known to be low, in healthy individuals, the variation of duplicate and 
quadruplicate measurements, of healthy human plasma (average concentration 
0.09 ± 0.06 nM Tyr-NO2 (BSA-NO2 equivalents; nM)), were compared (Table 
3.3). Variation of <20% was achieved more often with quadruplicate 
measurement than duplicate variation. Therefore, quadruplicate measurement 
was selected for analysis of plasma/serum samples in the ECL ELISA. 
 
Table 3.3: Table comparing duplicate and quadruplicate measurement variation 
in the ECL ELISA 
Plasma samples from healthy volunteers were analysed in the ECL ELISA (average 
concentration 0.09 ± 0.06 nM Tyr-NO2 (BSA-NO2 equivalents; nM)). Quadruplicate 
measurement produced variation of less than 20% more often than did duplicate 
measurement.  
Plasma sample 
Duplicate variation  
(%) 
Quadruplicate variation (%) 
1 20.6 11.1 
2 21.8 37.8 
3 7.6 14.6 
4 18.2 15.5 
5 32.3 42.5 
6 19.2 12.7 
7 39.7 17.1 
8 120.4 12.5 
 
The average linearity and recovery were 0.998 ± 0.001 (n=3) and 106 ± 3% 
(n=4), respectively (Table 3.4). A 1 in 5 dilution was selected for sample 
analysis of serum as a balance between maximising the signal in low 
concentration samples whilst only needing a low volume of sample. 
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Table 3.4: Linearity and recovery for a spiked plasma sample in the ECL ELISA 
Plasma was spiked with 1 nM BSA-NO2 and diluted to 4 different concentrations for 
determination of linearity and recovery. 
 #1 #2 #3 #4 Mean 
Linearity 
(R2) 
0.9987 0.9996 0.9969 
 
0.9984 
Recovery (%) 107 103 108 109 106 
 
Pre-incubation of the secondary antibody with free Tyr-NO2 inhibited the ELISA 
(p = 0.03, Kruskal-Wallis test, n=3). However, when Tyr-NO2 and BSA-NO2 
were competing within the assay, inhibition of the signal did not reach 
significance, despite the concentration of free Tyr-NO2 being in excess of the 
protein associated Tyr-NO2 (free Tyr-NO2 would inhibit the assay signal due to 
the ‘sandwich’ design needing two epitopes), suggesting that the antibody has a 
higher affinity for the protein associated Tyr-NO2. Unmodified BSA was not 
inhibitory (the antibody dilution buffer contains unmodified BSA). 
This method offers far more sensitivity than a colorimetric ELISA (Figure 3.2), 
due to a lower background. 
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Figure 3.2: ECL ELISA vs. Colorimetric ELISA 
The limit of detection of the ECL ELISA was lower than that of the colorimetric ELISA; a 
more relevant physiological range was also covered. R.L.U. relative light units. BSA-NO2, 
nitrated BSA. 
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Comparison to mass spectrometry 
In a preliminary experiment, three BSA samples (native, nitrated and chemically 
reduced) were analysed by mass spectrometry and ECL ELISA (Figure 3.3).  
The percentage modification for 3 peptide sequences (residues confirmed to be 
nitrated by de novo sequencing) was determined by mass spectrometry for 
comparison to the ECL ELISA data. The data (n=1) shows an increase in Tyr-
NO2 in the peroxynitrite exposed sample compared to the native sample in both 
methods. A decrease in signal was then seen for the dithionite treated 
(reduced) sample (Figure 3.3), although the mass spectrometry still shows a 
higher level of nitration than seen in the native BSA sample. The BSA standard 
was also analysed and the three confirmed Tyr-NO2 residues are highlighted in 
Figure 3.4. 
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Figure 3.3: A comparison of mass spectrometry with the ECL ELISA 
The same three BSA samples (see section 3.2.4) were analysed by mass spectrometry 
and ECL ELISA to see if there was agreement in relative nitration levels (n=1). 
P
e
rc
e
n
ta
g
e
 m
o
d
if
ic
a
ti
o
n
d
e
te
c
te
d
 b
y
 m
a
s
s
 s
p
e
c
tr
o
m
e
tr
y
T
y
r-N
O
2
(B
S
A
-N
O
2  e
q
u
iv
a
le
n
ts
; n
M
) b
y
 E
L
IS
A
Native Nitrated Dithionite treated
0
10
20
30
40
50
0
1
2
3
4
5
Mass spec
ELISA
 82 
 
 
 
Application of the ECL ELISA to pre- and post-surgery serum samples 
Due to natural variations in protein concentration, and a statistically significant 
(p<0.01, Wilcoxon matched pairs) fall in protein concentration post-surgery, 
results were normalised to protein content and expressed as fmol BSA-NO2 
equivalents/mg protein. 
A statistically significant (p<0.05, Wilcoxon matched pairs) increase in serum 
Tyr-NO2 was seen post-surgery (Figure 3.5), median (IQR): 0.59 (0 – 1.3) and 
0.97 (0 – 1.7) Tyr-NO2 fmol BSA-NO2 equivalents/mg protein for pre- and post-
surgery respectively. 
Figure 3.4: Tertiary positions of nitrated residues in the BSA standard 
The figure represents a 3D model of BSA. Tyrosine residues confirmed to be 
nitrated by mass spectrometry (see section 3.2.4) are highlighted in red, blue coils 
represent alpha helices and pink strands are random coils. BSA contains 21 Tyr 
residues, approximately 70% of these residues are buried and 30% exposed. Of the 
Tyr residues highlighted above Tyr 355 and Tyr 364 are both buried and Tyr 424 is 
exposed.  
424 
355 364 
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Median serum CRP levels increased significantly following surgery (p<0.0001, 
Wilcoxon matched pairs). 
Median serum protein carbonyls increased significantly following surgery 
(p<0.05, Wilcoxon matched pairs).  
Some of the samples had data on the white blood cell populations in the blood 
(n = 40, both days combined). A significant increase was seen in total neutrophil 
population number (p<0.001, two-way ANOVA). 
Median (IQR) serum NO3¯ concentrations before surgery were 41.3 (29.1 – 
62.2) µM and a statistically significant (Wilcoxon matched pairs, p=0.0002) 
decrease in the median was observed post-surgery; median (IQR) post-surgery 
28.8 (17.7 – 49.7) µM.  
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Figure 3.5: Median serum nitration levels before and after surgery 
The Tyr-NO2 was measured as per the protocol described in section 3.2.5. The median 
and inter-quartile range are shown (n=35). Serum nitration levels increased following 
major elective surgery (*p= 0.02, Wilcoxon matched pairs). 
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Tyr-NO2 levels in additional samples 
Cellular levels of Tyr-NO2 were investigated to determine whether this fraction 
of blood is more susceptible to nitration than the plasma/serum. Levels of Tyr-
NO2 were far higher in cellular samples compared to the serum, with the highest 
levels being observed in the cell line U937 (Figure 3.6). There was poor 
separation of polymorphonuclear cells during cell isolation, so Tyr-NO2 was not 
measured for this cell population. 
 
 
 
Figure 3.6: A comparison of 3-nitrotyrosine levels in serum and blood cells 
Levels of nitration were far lower in the serum compared to cellular samples. Tyr-NO2 was 
measured as per the protocol in section 3.2.5. Cells collected as per protocol in section 3.2.7. 
RBC (red blood cells), MC (mononuclear cells) and U937 cells (histiocytic lymphoma cell line) 
at a normal glucose (NG - 5.6 mM) and high glucose (HG – 24 mM) concentration. A log 
scale has been used for the y-axis, samples that had undetectable Tyr-NO2 were plotted at 
the LLOQ so as to appear on this log scale. 
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3.4. Discussion 
A sensitive ECL ELISA was developed for the measurement of Tyr-NO2 in bio-
fluids, this assay has an improved LLOQ compared to existing colorimetric 
ELISAs (LLOQ 0.04 nM BSA-NO2, Figure 3.2) as well as good linearity, 
recovery, and specificity. The importance of performing incubations at 25°C was 
shown by comparing the assay variation at room temperature and at 25°C 
(Table 3.1). Agreement on measurement of nitration between methods was 
seen between the ECL ELISA and mass spectrometry for the native and 
nitrated BSA. However, this experiment was only done once and needs to be 
repeated to confirm the level of agreement between the methods. The two 
methods showed disagreement for the relative nitration of the chemically 
reduced BSA, this may have been due to the mass spectrometry being more 
sensitive but could also have been the result of residual dithionite affecting the 
ECL ELISA performance.  
The ECL ELISA was applied to the measurement of Tyr-NO2 in serum from 
patients undergoing major elective surgery, with samples collected before and 
after surgery. This gave us paired samples for before and after an inflammatory 
insult (as confirmed by CRP levels and neutrophil count). NO3¯ concentration 
was measured as another marker of ˙NO production and, despite the initiation 
of an inflammatory response and an increase in Tyr-NO2, the median 
concentration of NO3¯ significantly decreased following the surgery. However, 
this NO3¯ concentration decrease may be accounted for by dilution of the blood, 
such as by intravenous fluids, following surgery. A change in oxidative stress 
status was confirmed by measuring serum protein carbonyl levels. As has 
already been discussed, in Chapter 1 (section 1.5.2), a rise in oxidative stress 
post-surgery has been linked with tissue damage and recovery time (Kaminski 
et al, 2002; Rosenfeldt et al, 2013). As the ROS required for Tyr-NO2 formation 
have been implicated in ischaemia-reperfusion injury (Zweier and Talukder, 
2006), protein nitration may be an ideal marker of ROS production following 
surgery. 
Multiple sample types were also measured by this new ECL ELISA, showing the 
versatility of the assay. These results also show that Tyr-NO2 levels are far 
higher in cellular samples compared to circulating serum levels. The highest 
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results by far were in unstimulated U937 cells, this is a cell line grown at 
atmospheric oxygen concentrations, and could, therefore, be considered to be 
in a constant state of oxidative stress (Halliwell, 2003).  
Tandem mass spectrometry (MS/MS) is considered to be the ‘gold-standard’ 
method for measuring Tyr-NO2 as the method is highly accurate and can 
quantify absolute Tyr-NO2 concentration (Tsikas and Caidahl, 2005; Ryberg and 
Caidahl, 2007; Tsikas and Duncan, 2014). However, this method is not suitable 
for the analysis of a lot of samples (such as in a clinical setting) as it is time-
consuming (low-throughput) and expensive. ELISA methods address these 
issues but are only semi-quantitative and not as accurate. 
Commercial ELISA assays for measuring Tyr-NO2 are available but are unlikely 
to be sensitive enough to detect the low levels of Tyr-NO2 present in serum. 
Some studies using this kind of assay do report Tyr-NO2 levels to be 
undetectable in healthy human plasma (Ter Steege et al, 1998; Ceriello et al, 
2001). However, other studies have reported levels far higher than those 
observed here, even in health (i.e. the absence of inflammation), see Chapter 1, 
section 1.5.1, Table 1.3 (Bo et al, 2005; Rossner Jr et al, 2007). This 
discrepancy cannot be explained with any certainty, but a few possibilities for 
these contradictory results are differences in methodology, antibody binding, the 
standards used and/or the reporting style (e.g. absolute Tyr-NO2 concentration 
or standard equivalents). 
The wide variation in the baseline (i.e. before surgery) serum nitration levels 
(median (IQR): 0.048 (0 – 0.102) nM BSA-NO2 equivalents) was thought to be 
due to the range of medical conditions and general heterogeneity of the sample 
group. There was also a significant (Wilcoxon matched pairs, p = 0.007) drop in 
serum protein concentration following surgery; this was most likely due to the 
use of intravenous fluids during recovery. To account for this change in protein 
concentration Tyr-NO2 levels were adjusted for protein concentration. When this 
was done, a statistically significant difference (Figure 3.5) was observed 
between pre- and post-surgery samples, which was not seen prior to the protein 
adjustment.  
Increased oxidative stress (and nitration) may also lead to an enhanced 
degradation of modified proteins. When the degradation of proteins modified by 
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oxidative stress has been investigated, the 20S proteasome has been found to 
be largely responsible (Davies, 2001; Jung et al, 2014) and peroxynitrite 
modified proteins are degraded faster than unmodified protein (Gow et al, 1996; 
Souza et al, 2000b). When Souza et al (2000b) exposed Cu-Zn superoxide 
dismutase to ONOO¯ nitration of a single Tyr residue was determined to be the 
only structural modification, and degradation by the proteasome was enhanced. 
This suggests that nitrated proteins are marked for degradation and therefore 
more likely to be removed than non-nitrated proteins. Based on this, it seems 
reasonable to speculate that the measured protein-associated Tyr-NO2 
underrepresents the actual level of nitration. However, it should be noted that 
when oxidative stress becomes excessive proteins may cross-link and 
aggregate, preventing them from being degraded and may even bind to and 
inhibit the proteasome (Davies, 2001; Shringarpure and Davies, 2002).  
Radák et al (2003) measured Tyr-NO2 daily in people doing a super-marathon, 
an extreme exercise that induces an inflammatory reaction. The authors noted 
an increase in serum Tyr-NO2 from baseline to day one of the race but then 
levels reached a plateau, despite the increasing intensity of the race. They 
theorised that this was due to nitration and degradation reaching equilibrium. 
However, they did not mention measuring the protein concentration of the 
serum over the course of the race (intense exercise can cause proteinuria), or 
correction of their results for protein content. If a drop in protein concentration 
was seen with each day then adjustment for protein would have shown nitration 
levels increasing rather than remaining constant. However, few studies in the 
literature do this and it may account for some of the discrepancies in results 
between studies. Weber et al (2012) suggested that all samples should be 
diluted to the same protein concentration prior to measurement. This was 
highlighted as a methodological issue (as protein concentration may affect 
assay performance) but would also act as a way of normalising the samples to 
a single protein concentration.  
This study was limited by the large variety of pathologies and surgeries 
encountered within the sample population. Additionally, the patient numbers for 
any one type of surgery were too small to allow analysis of whether a particular 
surgery type is associated with significantly higher levels of Tyr-NO2. The blood 
cell populations were only harvested from healthy volunteers. It is therefore 
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unknown what happens to the levels of Tyr-NO2 in blood cells following 
surgery/inflammation. A further study with fewer patient groups, but with large 
sample numbers for each pathology/surgery, and collection of both serum and 
blood cells, would address these issues. 
3.5. Conclusion 
The ECL ELISA described was able to detect Tyr-NO2 in many of the samples, 
although even with its improved sensitivity some samples were below the 
LLOQ. The assay was also able to measure a statistically significant increase in 
serum Tyr-NO2 following activation of an inflammatory response (i.e. by 
surgery).  
The assay has attempted to not only improve sensitivity but to produce and 
report a valid and robust way to measure Tyr-NO2. However, there is room for 
further improvement of the assay, such as the reporting of results as BSA-NO2 
equivalents rather than as an absolute Tyr-NO2 concentration. This is a flaw 
found in many reported ELISA results and needs to be addressed for published 
research to be accurately compared. 
 
  
 90 
 
3.6. Acknowledgements 
Pre- and post-surgery serum samples were provided by Dr R Lukaszewski 
(Defence Science and Technology Laboratory). 
Human blood was collected from healthy volunteers by Dr Stephen Bailey, 
Sport and Health Science University of Exeter.  
Mass spectrometry was performed with the aid of Professor A Pitt, Dr C 
Spickett and Dr K Tveen-Jensen (Aston University).   
Nitrated BSA residues, in the ECL ELISA standard, were mapped on to a 3D 
model with the aid of Dr Michail Isupov and Professor Jennifer Littlechild 
(University of Exeter, College of Life and Environmental Sciences). 
CRP measurement was performed with the aid of Emily Brewer and Dr Tim 
McDonald (Royal Devon and Exeter NHS Foundation Trust). 
 
 
 
 
 
 
 
 
 
 
 91 
 
Chapter 4  
3-Nitrotyrosine levels in plasma and saliva from healthy human 
volunteers following nitrate supplementation 
4.1. Introduction 
Nitrite (NO2¯) and nitrate (NO3¯) are often used as biomarkers of ˙NO 
production (Chapter 1, section 1.4.1) (Kleinbongard et al, 2003; Tsikas, 2004). 
However, NO2¯ and NO3¯ in the diet affect the concentrations of NO2¯ and 
NO3¯ in the blood (Kelly et al, 2014). It is also now thought that the reactions 
shown in Figure 4.1 can proceed in the reverse direction, meaning the 
traditional nitric oxide synthase (NOS) pathway for ˙NO production is not the 
only means of producing ˙NO, e.g. dietary NO3¯ could lead to ˙NO production 
(Duncan et al, 1995). 
Ingestion of NO3¯ has previously been viewed as harmful, leading to strict 
regulations on the NO3¯ content of water supplies (Johnson and Kross, 1990; 
McKnight et al, 1999). However, there is now evidence to suggest that ingesting 
high levels of NO3¯ may also have beneficial effects (e.g. lowering of blood 
pressure (Lundberg et al, 2006)) and it is thought these effects rely on the 
reduction of NO3¯ to ˙NO (Gilchrist et al, 2010).  
Figure 4.1: Nitric oxide metabolism 
˙NO can be formed by NOS enzymes and oxidised to NO2¯ and NO3¯. 
Alternatively NO3¯ ingested in the diet can be reduced to NO2¯ and ˙NO by 
NO3¯ and NO2¯ reductases respectively (Duncan et al, 1995; Zhang et al, 1998; 
Cosby et al, 2003; Doel et al, 2005; Shiva et al, 2007). 
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Several studies have shown that NO3¯-rich dietary supplementation can 
enhance sports performance in healthy participants by reducing the oxygen cost 
of submaximal exercise and improving exercise tolerance (reviewed by Jones 
(2014) and Affourtit et al (2015)). The NO3¯ itself is thought to be inert but 
ingestion leads to an increase in plasma NO2¯ concentration, for example 
through the NO3¯ reductase activity of bacteria in the mouth (Duncan et al, 
1995; van der Vliet et al, 1997; Doel et al, 2005). The NO2¯ generated by NO3¯ 
reductase activity is then depleted during exercise (Larsen et al, 2007; Kelly et 
al, 2014). Several mechanisms by which NO2¯can affect exercise performance 
have been suggested, such as augmented vasodilation in contracting muscles 
through the generation of ˙NO from NO2¯ by deoxyhaemoglobin (Cosby et al, 
2003), deoxymyoglobin (Shiva et al, 2007) or xanthine oxidase (Zhang et al, 
1998). In the hypoxic conditions of exercising muscles, this will be enhanced, 
whereas the classical ˙NO production pathway (i.e. NOS) will be impaired, as 
oxygen is required for this pathway. However, supplementation in individuals 
with diseases such as diabetes and COPD has not shown a significant effect on 
the oxygen cost of mild exercise (Shepherd et al, 2015a; Shepherd et al, 
2015b).  
Oldreive et al (2001) found that a NO3¯-rich meal did not increase plasma Tyr-
NO2 levels in healthy non-smoking participants. However, neutrophil count and 
serum MPO levels have been found to be higher in smokers compared to non-
smokers (Andelid et al, 2007; Martins et al, 2013). As has been previously 
described (in Chapter 1, section 1.5) MPO can utilise NO2¯ as a substrate, 
leading to the formation Tyr-NO2 (detailed in Pathway 4.1). It could, therefore, 
be hypothesised that smokers ingesting high amounts of NO3¯ may have 
increased serum Tyr-NO2 formation.  
Pathway 4.1: Tyrosine nitration in the presence of NO2¯ and MPO 
i. H2O2 + MPO     MPO-I + H2O  1.8 x 107 M-1 s-1 (Marquez et al, 1994) 
ii. MPO-I + NO2¯        MPO-II + ˙NO2 2 x 106  M-1 s-1 (Burner et al, 2000) 
iii. MPO-I + Tyr     MPO-II + Tyr˙  7.7 x 105 M-1 s-1 (Marquez and Dunford, 1995) 
iv. Tyr˙ + ˙NO2     Tyr-NO2  3 x 104 M-1 s-1 (Lepoivre et al, 2005) 
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Studies have shown that post-translational modifications (PTMs) can lead to the 
formation of neo-epitopes (Karsdal et al, 2010). These epitopes may not be 
recognised as ‘self’ by the immune system and thus, can elicit an immune 
response and auto-antibodies (reviewed by Ryan et al (2014)). An example of 
PTMs creating neo-epitopes is citrullination via the catalysed conversion of 
arginine to citrulline in RA. Arginine is converted to citrulline by removal of the 
imine group and this is catalysed by peptidylarginine deiminases (György et al, 
2006). Within RA patient tissues, citrullinated proteins are a target for 
autoantibodies and this has become an important factor in the diagnosis of the 
disease (Luban and Li, 2010). Autoantibodies that bind nitrated proteins have 
been observed in the autoimmune conditions RA and SLE (Khan and Ali, 2006; 
Khan and Siddiqui, 2006). Therefore, conditions that increase nitration of 
proteins could potentially also increase a person’s risk of auto-antibody 
production. As NO3¯-rich supplements are becoming increasingly popular, it is 
important to determine whether NO3¯ ingestion increases PTMs.  
NO2¯ concentrations in the saliva of healthy humans have been measured at 
30-210 µM (van der Vliet et al, 1997), and these levels rise significantly 
following NO3¯ ingestion; as mentioned above, this is due to NO3¯ reduction by 
the oral microflora (Duncan et al, 1995; van der Vliet et al, 1997; Doel et al, 
2005). One possible fate for this NO2¯ is a reaction catalysed by peroxidases, 
such as MPO, in the saliva (Takahama et al, 2003). Takahama et al (2003) 
observed H2O2/ NO2¯-dependent nitration of salivary proteins in vitro and 
suggested that this reaction could happen in vivo during an immune response. 
Klebanoff (1993) also suggested that the reaction of MPO/H2O2 and NO2¯ 
(Pathway 4.1) may increase bactericidal activity, although he notes that under 
certain conditions (in vitro) NO2¯ inhibits the antibacterial activity of MPO (e.g. 
high [MPO] with low pH). Although nitration of bacterial proteins could aid host 
defences (Takahama et al, 2003), the nitration of host proteins could potentially 
alter protein function (Radi, 2012). Additionally, the NO2¯ that is swallowed will 
become acidified in the stomach and increase the bactericidal activity of gastric 
acid through the generation of reactive nitrogen intermediates that have 
cytotoxic properties  (Dykhuizen et al, 1996; McKnight et al, 1999). 
There has been little research into salivary nitration in vivo, although Ueshima 
et al (2007) measured protein-associated levels of Tyr-NO2, and concluded that 
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the levels of protein-associated Tyr-NO2 in saliva do not interfere with the 
measurement of Tyr-NO2 in sputum from COPD and asthmatic patients; they 
found 0.02 ± 0.01 pmol/ml protein-associated Tyr-NO2 in saliva from COPD 
patients. 
In light of the above mentioned concerns that NO3¯-rich supplements may 
increase nitration, particularly in smokers, and that this can create neo-epitopes 
that are not recognised by the immune system, the plasma and salivary Tyr-
NO2 levels in smokers/non-smokers, who had been administered a NO3¯-rich 
supplementation (beetroot juice), were measured.  
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4.2. Methods 
4.2.1. Study design 
The study used a cross-over design (Figure 4.2) so that each participant 
ingested both the supplement (NO3¯-rich beetroot juice, 70 ml containing 4.2 
mmol NO3¯) and the placebo (NO3¯-depleted beetroot juice, 70 ml containing 
0.04 mmol NO3¯). The depletion of NO3¯ from beetroot juice was done using 
Purolite resin (Gilchrist et al, 2014)). Physiological measures, such as blood 
pressure and exercise performance, were taken along with blood and saliva 
being collected for analysis. Blood was collected in a 5 ml EDTA vacutainer and 
spun at 350 g for 20 minutes. The plasma supernatant was then collected and 
frozen. Saliva was collected by direct void into a container for 5 minutes. 
Subjects were asked to keep a consistent diet throughout the study and 
samples were collected at the start to establish baseline levels. Subjects were 
then randomly assigned a condition (placebo or supplement) for 6 days. The 
juice was taken twice a day (morning and evening) for 5 days and then 140 ml 
(i.e. two doses) was consumed 2 hours before collection of samples on the sixth 
day. A 7-10 day washout period separated the two conditions. The smokers 
were determined to have normal blood pressure, normal respiratory function, 
healthy body mass index and a similar aerobic fitness to the non-smokers. 
There were 17 volunteers (non-smokers n=8, smokers n=9) with 8 females (4 
non-smokers) and 9 males (4 non-smokers). The mean age of all participants 
was 24 (range 18-37) years overall, the mean age within each group was also 
24 years (non-smokers 18-32 years, smokers 18-37 years). All volunteers gave 
informed consent, and this study was approved by the Institutional Research 
Ethics Committee (approval number 2013/539 (rev2)). 
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4.2.2. Electrochemiluminescence-based ELISA for 3-nitrotyrosine 
The protocol described in Chapter 3 (section 3.2.5) was used to measure Tyr-
NO2. Plasma was diluted 1 in 5, with dilution buffer, and measured in 
quadruplicate. Saliva was diluted 1 in 2, with dilution buffer, and measured in 
duplicate. Both were corrected for protein content as determined by the BCA 
assay (Chapter 2, section 2.2). 
Figure 4.2: Nitrate supplementation cross-over study design 
All participants provided samples prior to the study and were then either given the 
placebo (NO3¯-depleted beetroot juice) or supplement (NO3¯-rich beetroot juice) and 
samples were taken again. The participants were then switched to the opposite treatment 
and samples collected again. 
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4.2.3. Assays of nitrite, nitrate, thiocyanate and asymmetric dimethylarginine 
Dr Stephen Bailey (University of Exeter Sport and Health Science) also 
collected data on plasma and saliva concentrations of: NO2¯ and NO3¯ (using 
ozone-based chemiluminescence (see Chapter 2, section 2.9)), thiocyanate 
(using the König reaction (Tsuge et al, 2000)) and plasma asymmetric 
dimethylarginine (using a competitive enzyme immunoassay (Immundiagnostik, 
2009)).  
4.2.4. Statistical analysis 
Nonparametric tests were applied for the statistical analysis of the data 
(Wilcoxon matched pairs, Freidman test and Mann-Whitney test) unless the 
Shapiro-Wilk test indicated that the data were normally distributed (parametric 
test – paired and unpaired t test).   
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4.3. Results 
4.3.1. Plasma 
There was no statistically significant difference in the median plasma nitration 
levels between the non-smokers and smokers prior to supplementation: median 
(IQR) 0.92 (0.67-1.34) and 1.28 (0.77-2.35) Tyr-NO2 fmol BSA equiv./mg 
protein in the non-smokers and smokers respectively (Mann-Whitney p=0.44, 
Figure 4.3A). There was also no statistically significant difference in plasma 
Tyr-NO2 levels between non-smokers and smokers after NO3¯-rich 
supplementation: median (IQR) 0.97 (0.57-1.92) and 1.13 (0.69-2.23) Tyr-NO2 
fmol BSA equiv./mg protein in the non-smokers and smokers respectively 
(Mann-Whitney p=0.37, Figure 4.3B).  
There was no statistically significant change in median plasma Tyr-NO2 levels 
when comparing pre-experiment and post NO3¯-rich supplementation for either 
non-smokers or smokers (Figure 4.4). There was also no statistically significant 
difference between the median levels prior to supplementation and after 
placebo (NO3¯-depleted) supplementation for either subject group. 
Although both groups showed a statistically significant increase in mean plasma 
NO2¯ and NO3¯ concentration following NO3¯-rich supplementation (p=0.007 
and 0.0009 for non-smokers and smokers respectively, paired t-test) (Figure 
4.5) the post-supplementation concentrations were lower in the smokers 
compared to the non-smokers (unpaired t-test: NO3¯ p = 0.005, and NO2¯ p= 
0.04).
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Figure 4.3: 3-Nitrotyrosine levels in the plasma from healthy non-smokers and smokers before and after nitrate-rich beetroot 
supplementation 
The NO3¯-rich supplementation protocol was as described in section 4.2.1. The plasma Tyr-NO2 levels were measured as described in Chapter 3, 
section 3.2.5. The median and IQR values are shown. Non-smokers n=8 and smokers n=9. (A) Non-smokers and smokers before beetroot 
supplementation (Mann-Whitney, p=0.44) and (B) Non-smokers and smokers after NO3¯-rich beetroot supplementation (Mann-Whitney, p=0.37). 
There was no statistically significant difference between the median levels of Tyr-NO2 in the two subject groups either prior to supplementation or 
after NO3¯-rich beetroot supplementation. 
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Figure 4.4: Non-smoker’s and smoker’s plasma 3-nitrotyrosine levels before and after each supplementation condition 
The supplementation protocol was as described in section 4.2.1. The plasma Tyr-NO2 was measured as described in Chapter 3, section 
3.2.5. Non-smokers n=8 and smokers n=8, median and IQR shown. (A) Non-smokers (Freidman test p= 0.53) and (B) Smokers (Freidman 
test p= 0.05). Neither of the subject groups showed a statistically significant change in median plasma Tyr-NO2 levels with NO3¯-depleted or 
NO3¯-rich supplementation.  
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Figure 4.5: Plasma nitrite and nitrate concentrations, in non-smoker’s and smoker’s, before and after nitrate-rich beetroot 
supplementation 
The NO3¯-rich supplementation protocol was as described in 4.2.1, and the salivary NO2¯ and NO3¯ was measured as described in Chapter 
2, section 2.9. The mean and SD are shown.  Open bars represent the non-smokers (n=8), filled (grey) bars represent the smokers (n=9). (A) 
Plasma NO2¯ concentration increased significantly in both groups following supplementation but not with placebo (**p<0.01, ***p<0.001, 
repeated measures ANOVA). After supplementation the smokers had lower concentrations than non-smokers (*p<0.05, unpaired t test). (B) 
Plasma NO3¯ also increased with supplementation in both groups but not with placebo (**p<0.01, ***p<0.001 – repeated measures ANOVA). 
After supplementation the smokers had lower concentrations than non-smokers (**p<0.01, unpaired t test). The data shown was collected by 
Dr S Bailey. 
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4.3.2. Saliva 
There was no statistically significant difference in the median saliva nitration 
levels between the non-smokers and smokers prior to NO3¯-rich 
supplementation (Mann-Whitney p=0.71, Figure 4.6A) or after the NO3¯-rich 
supplementation (Mann-Whitney p=0.23, Figure 4.6B). 
With non-smokers there was a decrease in salivary Tyr-NO2 when comparing 
baseline with post-supplementation (Friedman test p=0.03): median and (IQR) 
0.57 (0.09 – 1.07) and 0.21 (0.03 – 0.52) Tyr-NO2 pmol BSA equiv./mg protein 
for baseline and post-supplementation respectively (Figure 4.7A). The smokers 
had no significant change with NO3¯-rich supplementation (Friedman test 
p=0.08) (Figure 4.7B). However, a statistical difference was seen with post-
testing when comparing the placebo supplementation and the real 
supplementation in the smokers (Dunn’s multiple comparison test p<0.05): 
median (IQR) 0.86 (0.33 – 1.57), 0.995 (0.80 – 1.87) and 0.49 (0.33 – 0.64) Tyr-
NO2 pmol BSA equiv./mg protein for baseline, placebo and real supplement 
respectively. There was no difference between the placebo and baseline Tyr-
NO2 levels in either group.  
There was an increase in mean salivary NO2¯ concentration for both groups 
following supplementation (p=0.004 and 0.0002 for non-smokers and smokers 
respectively, ANOVA repeated measures) (Figure 4.8A). The levels of NO3¯ 
also increased following supplementation in both groups (p<0.0001 for non-
smokers and smokers, ANOVA repeated measures). However, the mean 
concentration was lower in smokers compared to non-smokers (p=0.046, Mann-
Whitney test) (Figure 4.8B).    
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Figure 4.6: 3-Nitrotyrosine levels in the saliva from healthy non-smokers and smokers before and after nitrate-rich beetroot 
supplementation 
The NO3¯-rich supplementation protocol was as described in section 4.2.1, and the salivary Tyr-NO2 was measured as described in 
Chapter 3, section 3.2.5. The median and IQR values are shown: (A) before supplementation - n=8 for each group (Mann-Whitney 
p=0.71), and (B) after supplementation - non-smokers n=8, smokers n=9 (Mann-Whitney p=0.23). There was no difference between 
the two subject groups in either condition. 
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Figure 4.7: Non-smoker’s and smoker’s saliva 3-nitrotyrosine levels before and after each supplementation condition 
The NO3¯-rich supplementation protocol was as described in section 4.2.1, and the salivary Tyr-NO2 was measured as described in Chapter 3, 
section 3.2.5. The median and IQR shown values are shown. (A) In non-smokers there was a significant decrease in Tyr-NO2 levels following 
supplementation, n=8 (Friedman test *p=0.03). (B)  Smokers showed a trend towards a decrease in saliva Tyr-NO2 levels, but this was not 
statistically significant, n=8 (Friedman test p=0.08). However, the post-test showed a statistically significant difference between the placebo group 
and the supplement (Dunn’s multiple comparison test p<0.05). 
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Figure 4.8: Salivary nitrite and nitrate concentrations, in non-smoker’s and smoker’s, before and after nitrate-rich beetroot 
supplementation  
The NO3¯-rich supplementation protocol was as described in section 4.2.1, and the salivary NO2¯ and NO3¯ was measured as described in 
Chapter 2, section 2.9. The median and IQR values are shown.  Open bars represent the non-smokers (n=8), filled (grey) bars represent smokers 
(n=9). (A) Salivary NO2¯ concentrations showed a statistically significant increase following supplementation in both groups but not with the 
placebo (**p<0.01, ***p<0.001, ANOVA repeated measures). (B) Salivary NO3¯ concentrations also showed a statistically significant increase in 
both groups but not with placebo (***p<0.001, ANOVA repeated measures). However, smokers had a lower salivary NO3¯ concentration than non-
smokers (*p<0.05, Mann-Whitney test). The data was collected by Dr S Bailey. 
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4.3.3. Correlations 
There were no statistically significant correlations between plasma nitration and 
plasma NO2¯ or NO3¯ or salivary NO2¯ or NO3¯ levels.  
Plasma thiocyanate negatively correlated with plasma NO3¯ concentration 
(Spearman’s rank correlation r = -0.50, p= 0.04, Figure 4.9A) as did salivary 
thiocyanate and salivary NO3¯ concentration (Spearman’s rank correlation r = -
0.52, p= 0.03, Figure 4.9B). 
Salivary Tyr-NO2 negatively correlated with salivary NO2¯ (Spearman’s rank 
correlation r -0.37, p= 0.008) and this significance was maintained following the 
Bonferroni correction (p= 0.04) (Figure 4.10A). A statistically significant 
negative correlation between salivary nitration and plasma NO2¯ was also 
maintained after the Bonferroni correction (Spearman’s rank correlation r -0.34, p 
= 0.01 after Bonferroni correction) (Figure 4.10B). 
There were no statistically significant correlations between salivary Tyr-NO2 and 
NO3¯ levels in either plasma or saliva.  
Plasma and salivary Tyr-NO2 levels did not show a statistically significant 
correlation with each other. 
Salivary thiocyanate showed a statistically significant correlation with salivary 
Tyr-NO2 (Spearman’s rank correlation r = 0.4, p = 0.005) (Figure 4.11). There 
was no correlation between plasma thiocyanate and plasma Tyr-NO2. 
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Figure 4.9: Inverse correlation of thiocyanate concentrations with nitrate concentrations in plasma and saliva 
NO3¯-rich supplementation and thiocyanate measurement was performed as described in section 4.2.1. (A) Correlation between plasma thiocyanate 
and plasma NO3¯ showed a statistically significant negative correlation (Spearman’s rank correlation r = -0.50, p= 0.04), and (B) correlation between 
salivary thiocyanate and salivary NO3¯ showed a statistically significant negative correlation (Spearman’s rank correlation r = -0.52, p= 0.03). The 
data shown was collected by Dr S Bailey. 
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Figure 4.10: Inverse correlation of salivary 3-nitrotyrosine levels with salivary and plasma nitrite concentrations 
The NO3¯-rich supplementation protocol was as described in section 4.2.1. Tyr-NO2 was measured as described in Chapter 3, section 3.5.2. 
(A) Correlation between salivary Tyr-NO2 levels and salivary NO2¯ concentrations showed a statistically significant negative correlation 
(Spearman’s rank correlation r = -0.37, p= 0.04), and (B) correlation between salivary Tyr-NO2 levels and plasma NO2¯ concentrations 
showed a statistically significant negative correlation (Spearman’s rank correlation r= -0.34, p= 0.01). Nitrite and nitrate data were collected 
by Dr S Bailey. 
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Figure 4.11: Correlation between salivary thiocyanate concentrations and salivary 3-
nitrotyrosine levels 
Thiocyanate was measured as described in section 4.2.1. There was a statistically 
significant positive correlation between salivary thiocyanate concentrations and Tyr-NO2 
levels (Spearman’s rank correlation r = 0.4, p= 0.005). Thiocyanate data were collected by 
Dr S Bailey. 
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4.4. Discussion 
NO3¯ is reduced to NO2¯ in the mouth by microflora-associated NO3¯ 
reductases (Doel et al, 2005) and NO2¯ can be further reduced to ˙NO (Zhang 
et al, 1998; Cosby et al, 2003; Shiva et al, 2007; Ferguson et al, 2013). As both 
˙NO and NO2¯ are involved in Tyr-NO2 formation it is possible that high NO3¯ 
ingestion could lead to increased protein nitration. Oxidative PTMs of proteins 
can create neo-epitopes that are not recognised as ‘self’ and lead to the 
production of auto-antibodies (Griffiths, 2008; Ryan et al, 2014), and anti-Tyr-
NO2 antibodies have been linked with the auto-immune conditions rheumatoid 
arthritis and systemic lupus erythematosus (Khan and Siddiqui, 2006). Smoking 
has been linked to increased carbonylation of proteins, which in turn has been 
suggested to be a contributing factor in a possible auto-immune response in 
COPD (Kirkham et al, 2011). 
This study sought to determine whether ingesting high amounts of NO3¯ 
affected the Tyr-NO2 levels in plasma and saliva, particular with regards to 
smokers. Smokers could potentially have higher levels of Tyr-NO2 formation 
following ingestion of NO3¯ due to increased inflammatory activity, including 
higher levels of serum MPO (Andelid et al, 2007; Martins et al, 2013). 
Within this study, the median plasma Tyr-NO2 levels were comparable in the 
two groups (non-smokers and smokers) prior to NO3¯-rich supplementation, as 
were the plasma NO2¯ and NO3¯ concentrations. Once baseline samples were 
collected, a cross-over study design was used so that participants went through 
both experimental conditions (Figure 4.2). These conditions involved the 
ingestion of either NO3¯-rich beetroot juice or NO3¯-depleted beetroot juice. 
This study was carried out under double-blind conditions to avoid bias.  
The plasma Tyr-NO2 data collected here (Figure 4.3) is in agreement with 
Oldreive et al (2001) and Pannala et al (2003) in that high dietary NO3¯ intake 
does not increase plasma Tyr-NO2 in non-smokers. Plasma NO2¯ 
concentrations increase with NO3¯ ingestion and, as both MPO levels (Martins 
et al, 2013) and H2O2 production are thought to be increased in the blood of 
smokers (Tanni et al, 2012), the substrates and catalysts for Tyr-NO2 formation 
are present.  However, the data collected here have shown that smokers do not 
have a statistically significant increase in median plasma Tyr-NO2 following 
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NO3¯ rich supplementation. It is possible that other reactions involving NO2¯ or 
H2O2 are more likely, or that the increased levels of MPO do not translate to 
increased activity of the enzyme. Although, there was an increase in plasma 
NO2¯ and NO3¯ concentration following NO3¯-rich supplementation the 
smokers did not have the same level of increase in NO2¯ and NO3¯ as non-
smokers (Figure 4.5), this may be due to increased levels of thiocyanate in 
smokers.  
Thiocyanate is an anion produced during detoxification of hydrogen cyanide, 
found in cigarettes, and salivary concentrations of thiocyanate have been used 
as a marker for smoking frequency/duration (Galanti, 1997; Aggarwal et al, 
2013). Thiocyanate and NO3¯ have been shown to have an antagonistic 
relationship for secretion in saliva (Edwards et al, 1954) that is suspected to be 
due to both anions competing for the same receptor. This competition would 
mean higher thiocyanate levels would result in less NO3¯ uptake and a negative 
correlation for both plasma and salivary thiocyanate with NO3¯ confirm this 
(Figure 4.9). 
The values for plasma NO2¯ concentration, in healthy individuals without 
supplementation, obtained by different studies have varied substantially, e.g.  
322 nM (Lauer et al, 2001) and 43 nM (Wylie et al, 2016b). Although there is 
wide variation, several studies have measured concentrations close to 100 nM 
(Larsen et al, 2007; Thompson et al, 2015; Wylie et al, 2016a), and the mean 
concentration within this study, for all participants, was 82 nM. Recorded 
concentrations of plasma NO3¯ have not varied as greatly, with many in the 
range of 25-40 µM (Lauer et al, 2001; Larsen et al, 2007; Thompson et al, 2015; 
Wylie et al, 2016b) and the mean concentration in this study was 30 µM. The 
variation in NO2¯ concentration but not NO3¯ may be due to the rapid reduction 
of NO2¯ to NO3¯ by haemoglobin in whole blood (Moshage et al, 1995), 
meaning that different collection methods may have led to different lengths of 
exposure of NO2¯ to haemoglobin. Differences in detection method may also 
influence the results obtained. 
Like the plasma, the salivary NO3¯ concentrations were significantly higher in 
the non-smokers, compared to the smokers (Figure 4.8B). However, the 
salivary NO2¯ concentrations following supplementation did not differ between 
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participant groups, though both displayed a vast increase from baseline (Figure 
4.8A). Bojić et al (2004) found that the rate of reduction in the NO2¯/ NO3¯ ratio, 
by oral bacteria, decreased with increasing NO3¯ concentration and concluded 
this could be attributed to enzyme saturation by NO3¯. Therefore, the extra 
NO3¯ in the saliva of the non-smokers, compared to the smokers, may make no 
difference to the NO2¯ levels as the enzyme is already saturated. As there is no 
statistically significant difference in the salivary NO2¯ concentrations between 
the groups it would be expected that plasma NO2¯ concentrations would also 
be comparable, between the two groups. However, as already mentioned, the 
median plasma NO2¯ concentration was lower in the smokers than the non-
smokers (Figure 4.5A).  This may be due to the large variation observed, for 
salivary concentrations, as the median, though not significantly lower, is lower 
for the smokers and a higher participant number may have led to a significant 
difference in salivary NO2¯ levels between non-smokers and smokers. 
Alternatively, thiocyanate is a potent catalyst of nitrosation under acidic 
conditions (Boyland and Walker, 1974; Moriya et al, 2002), therefore, in the 
smokers, more of the swallowed NO2¯ may be utilised in this reaction 
decreasing the amount absorbed into the blood. Nitrosation of secondary 
amines in the diet is considered carcinogenic (Hill et al, 1973; Mirvish, 1995). 
Therefore, if the increased thiocyanate in smoker’s saliva leads to increased 
nitrosamine formation following NO3¯ rich supplementation, this would have 
serious health consequences. As mentioned, NO2¯ is rapidly reduced to NO3¯ 
in whole blood (Moshage et al, 1995) but it is unlikely that this has only been a 
factor affecting samples from smokers.  
There have not been as many studies reporting salivary NO2¯ and NO3¯ 
concentrations but as with the plasma, there is variation seen. Pannala et al 
(2003) report salivary NO2¯ levels of 249-483 µM and NO3¯ levels of 204-392 
µM in the hours after a low NO3¯ meal. Doel et al (2004) measured children’s 
salivary NO2¯ and NO3¯ levels and found them to be approx. 100 µM and 1,500 
µM respectively. Sukuroglu et al (2015) looked at patients with periodontal 
disease on different treatments and reported salivary NO2¯ and NO3¯ levels of 
2.9-7.1 µM and 372-478 µM respectively. The average results of this study were 
93 µM NO2¯ and 183 µM NO3¯. Obvious variances in these studies are 
participant age and the absence of periodontal disease, and this could account 
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for some of the discrepancy. Another factor is saliva collection, Doel et al (2004) 
used swabs, Sukuroglu et al (2015) used Lashley cups (parotid gland saliva) 
and Pannala et al (2003) and this study collected saliva by direct void into a 
container over 5 minutes. However, the results here show lower levels of 
salivary NO2¯ than Pannala et al (2003) (93 µM and 249-483 µM respectively) 
but the NO3¯ levels are comparable to the lower end of the Pannala et al (2003) 
studies range (183 µM for this study and 204-392 µM for (Pannala et al, 2003)).  
Salivary Tyr-NO2 levels were also far higher (pmol range) than the levels 
measured in the plasma (fmol range) despite the lower protein concentration. 
This may be due to the higher NO2¯ levels in saliva compared to plasma 
(approx. 1000-fold) as well as peroxidase activity within the saliva. The oral 
cavity contains MPO, released from leukocytes, and salivary peroxidase, 
released from the saliva glands (Ihalin et al, 2006). Additionally, any 
inflammation in the gums (e.g. periodontal disease) will increase MPO activity 
(Cao and Smith, 1989). Ueshima et al (2007) reported 0.02 ± 0.01 pmol/ml 
protein-associated Tyr-NO2 in saliva. This level is roughly a hundred times 
lower than the average level found here (mean 1.69 pmol/ml for both smokers 
and non-smokers at baseline).  However, there were several methodological 
differences that make a direct comparison dubious. For instance Ueshima et al 
(2007) looked solely in COPD patients, who had recently had sputum collected, 
the samples then underwent extensive sample preparation for measurement by 
HPLC-electrochemical detection.  
There was no difference in salivary nitration between the non-smokers and 
smokers (Mann-Whitney p>0.05, Figure 4.6) before or after supplementation. 
However, following ingestion of NO3¯-rich beetroot juice, both subject groups 
had decreased salivary Tyr-NO2 levels; this was only statistically significant in 
the non-smokers (Freidman test p<0.05, Figure 4.7A). However, when the 
placebo group was compared to the supplement group a significant difference 
was seen in the smokers as well (Dunn’s multiple comparison test p<0.05, 
Figure 4.7B). A significant change in salivary Tyr-NO2 between the post-
placebo levels and post-supplement levels but not between baseline levels and 
post-supplement levels is likely due to the placebo samples being less varied 
than the baseline samples.  
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The fact that the Tyr-NO2 levels in the placebo condition (NO3¯-depleted 
beetroot juice) did not differ from baseline levels of Tyr-NO2, suggests that it is 
not  components/antioxidants, other than NO3¯, found in the beetroot juice that 
are responsible for the Tyr-NO2 decrease. The reason for the decreased 
nitration following NO3¯ ingestion is hard to explain; an increase (or no change) 
was expected. Logically a decrease must be the result of either anti-oxidant 
activity or decreased inflammation; although increased turn-over of modified 
proteins is also an option, this seems unlikely.  
Ingestion of NO3¯ has been shown to cause an increase in exhaled ˙NO due to 
the salivary production of ˙NO (Zetterquist et al, 1999). It has been 
hypothesised that salivary production of ˙NO, following ingestion of dietary 
NO3¯, protects the oral cavity and gut from infection (Duncan et al, 1995) and 
Doel et al (2004) have shown that significantly fewer dental caries are observed 
in those with high salivary NO3¯. It could, therefore, be hypothesised that the 
NO3¯-rich supplementation increased salivary ˙NO production, which has then 
decreased the number of pathogenic bacteria in the mouth and thus diminished 
any inflammation and ROS formation e.g. O2 • ¯ and H2O2. This, in turn, would 
mean less Tyr-NO2 formation as these species are needed alongside the NO2¯ 
and ˙NO for nitration to occur. 
A correlation of Tyr-NO2 levels with thiocyanate concentrations (Spearman 
p<0.01) was seen when all groups/conditions were combined (Figure 4.11). 
Thiocyanate has been shown to decrease the antimicrobial activity of MPO 
(Ihalin et al, 1998). This lends support to the suggestion that Tyr-NO2 levels are 
connected to oral pathogenic bacteria levels and the associated inflammation. 
Further studies are needed, investigating MPO levels/activity in the saliva, along 
with other inflammatory markers, to see if they are indeed affected by a week of 
high NO3¯ ingestion. 
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4.5. Conclusion 
Ingestion of a NO3¯-rich supplementation resulted in a significant increase in 
plasma and saliva NO2¯ and NO3¯ concentration for both groups. However, 
after supplementation, there was a difference between non-smokers and 
smokers for plasma NO2¯ and NO3¯ and saliva NO3¯, where the smokers were 
found to have significantly lower concentrations of each. This is thought to be 
due to the higher levels of thiocyanate in the smokers, which can compete with 
the NO3¯ anion for secretion in the saliva.  
The levels of Tyr-NO2 in healthy plasma were near the limit of quantification and 
appear to be unaffected by high NO3¯ ingestion, regardless of whether the 
participant was a smoker or non-smoker. Salivary Tyr-NO2 levels are far higher 
than plasma levels and were unexpectedly seen to decrease with NO3¯ 
ingestion in smokers. The reason for this is unknown but may be due to 
increased ˙NO production protecting the oral cavity from pathogens and 
reducing inflammation. The fact that there is no increase in plasma Tyr-NO2 and 
a decrease in saliva Tyr-NO2 suggests that NO3¯-rich supplementation, in 
smokers, does not risk an increase in potentially auto-immune PTMs of self-
proteins. 
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Chapter 5  
A time-course study of serum 3-nitrotyrosine levels before and 
after surgery, comparing patients who developed sepsis with 
those who did not 
5.1. Introduction 
Oxidative stress has been implicated in sepsis; examples of ROS/RNS-induced 
processes in sepsis are lipid peroxidation, mitochondrial damage and 
cytotoxicity (Victor et al, 2004). It has been hypothesised that this damage is a 
contributing factor in the organ dysfunction seen in severe sepsis (see Chapter 
1, section 1.5.4 for definition) (Victor et al, 2004; Castellheim et al, 2009). ˙NO is 
thought to play a role in the hypotension observed in septic shock and 
preclinical studies have been performed using non-specific NOS inhibitors (i.e. 
they don’t target a specific isoform). For example, a randomised, double blind, 
placebo controlled study examining the effects of NG monomethyl-L-arginine (L-
NMMA) in humans with septic shock found that L-NMMA improved the blood 
pressure of the patients (Petros et al, 1994). However, they also noted a fall in 
cardiac output that needed to be investigated in larger studies. A randomized, 
double-blind, placebo-controlled multicentre study using the inhibitor NG-
methyl-L-arginine hydrochloride also found blood pressure was improved by 
non-selective NOS inhibition (Watson et al, 2004). However, large clinical trials 
were abandoned due to an increase in mortality in those receiving the drug, 
possibly as a result of decreased cardiac output (López et al, 2004). Although 
lower concentrations of the inhibitor did show an improvement in mortality rates 
the study of NOS inhibitors in sepsis has decreased since the large clinical trials 
were abandoned. Inhibitors that selectively target iNOS have shown 
encouraging results in animal models of sepsis/septic shock (Kadoi and Goto, 
2004; Stahl et al, 2010; Su et al, 2010) but, as far as we are aware, this has not 
yet been investigated in humans with septic shock. 
As previously described (see Chapter 1, section 1.5.), ˙NO undergoes a radical-
radical reaction with O2 ˙¯ to form the ROS, peroxynitrite (ONOO¯). ONOO¯ can 
modify several molecules (e.g. DNA, lipids, enzymes, etc.). An example is  
manganese SOD: nitration of this mitochondrial enzyme causes a loss of 
function, leading to accumulation of O2 ˙¯ in mitochondria (Salvemini and 
Cuzzocrea, 2002). As O2 ˙¯ is not effectively removed this nitration leads to 
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increased formation of ONOO¯ and further oxidative modifications (Salvemini 
and Cuzzocrea, 2002). Since mitochondrial dysfunction may be a significant 
contributor to organ dysfunction (Castellheim et al, 2009), we suggest that 
reactive oxygen species, like ONOO¯, are a factor in sepsis.   We also 
postulated that – whilst therapies directed towards the prevention of nitrative 
stress might be difficult to implement in clinical practice – there could be scope 
for using measures of nitrative stress, such as Tyr-NO2, in the diagnosis and/or 
monitoring of sepsis. For example, some researchers have suggested that the 
concentration of free Tyr-NO2 in plasma is associated with sepsis prognosis 
(Ohya et al, 2002). As nitration is a rapid chemical reaction which modifies 
proteins that are already present, nitrated Tyr may also represent a marker that 
is measurable in the plasma long before other currently-used inflammatory 
markers, such as CRP, which must be synthesised by hepatocytes in response 
to inflammatory signals.  As discussed in Chapter 1 (section 1.5.4), sepsis is 
associated with a high mortality rate and improved/quicker diagnosis is needed 
in order to improve therapeutic efficiency.  
Surgery is a risk factor for septicaemia. In the USA, post-surgery sepsis made 
up 30% of all sepsis patients (Vogel et al, 2009). As part of a collaborative 
project with the Defence Science and Technology Laboratory (DSTL), serum 
samples from a cohort of 51 patients, 26 of whom developed post-surgery 
sepsis, were analysed using the new ECL ELISA (as described in Chapter 3). 
The aim of this study was (a) to determine if protein-associated Tyr-NO2 was 
increased in patients with post-surgery sepsis, compared with patients without 
post-surgery sepsis and (b) to determine whether measurement of Tyr-NO2 is a 
useful addition to the existing set of diagnostic tests and clinical measurements 
currently used to establish the diagnosis of sepsis. 
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5.2. Materials and Methods 
5.2.1. Sample details 
Serum samples were provided by DSTL as 100 µl aliquots. The samples were 
collected as part of a study approved by the NRES Committee South Central 
(REC ref 06/Q1702/152) and informed consent to take part in the study was 
obtained from each individual. 
Serum was collected prior to major elective surgery and then each day 
subsequently until whichever of the following occurred first: 
i. Hospital discharge  
ii. Seven days post-surgery 
iii. Sepsis diagnosis  
Where available, patient blood test results (e.g. white blood cell count) were 
also provided by DSTL. Information on patient group, age and gender are 
detailed in Table 5.1.  
Table 5.1: Patient information 
 No post-surgery sepsis Post-surgery sepsis 
Age in years 
(mean ± SD) 
65 ± 8.6 64 ± 10.1 
Gender 12 female, 13 male 10 female, 16 male 
 
Samples from 51 patients (each with one pre-surgery and at least one post-
surgery sample) were analysed. The patients were split into two groups: those 
with no post-surgery sepsis, i.e. controls, and those with post-surgery sepsis.  
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Those patients who developed sepsis were diagnosed at different time-points 
post-surgery, e.g. some were diagnosed two days after surgery, and others 
were diagnosed five days after surgery (Table 5.2). Therefore, during statistical 
analysis samples were either grouped in terms of ‘days post-surgery’ or ‘days 
prior to diagnosis’. For analysis 2 (Figure 5.1), samples were matched with 
control samples which were at the same time point in terms of the number of 
days since surgery. 
Table 5.2: Post-surgery sepsis patient’s diagnosis time points. 
The delay between surgery and sepsis diagnosis was variable and is summarised in 
the table. 
Days post-surgery that 
sepsis diagnosis 
occurred 
2 3 4 5 6 7 8 
Number of patients 
diagnosed on this day 
7 5 4 3 2 4 1 
 
Figure 5.1: Serum samples, grouping and analysis 
Pre-surgery 
serum 
samples 
(n=51) 
Did not 
develop 
sepsis  
(n=25) 
Developed 
sepsis  
(n=26) 
Analysis 1: data 
grouped by 
number of days 
post-surgery 
Analysis 2: data 
grouped by 
number of days 
before diagnosis 
Surgery: 
Daily 
samples 
taken 
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5.2.2. Electrochemiluminescence-based ELISA for 3-nitrotyrosine 
The Tyr-NO2 content was determined by the ECL ELISA (described in Chapter 
3, section 3.2.5). Samples were diluted 1 in 5 and measured in quadruplicate. 
The protein content was measured using the BCA assay (Chapter 2, section 
2.2) and the Tyr-NO2 levels adjusted to give values expressed as fmol BSA-NO2 
equivalents/mg protein. 
5.2.3. Mass spectrometry  
A subgroup of 10 samples was analysed by mass spectrometry (ESI-QUAD-
TOF-MS/MS). Mass spectrometry is the gold standard measurement for Tyr-
NO2. Therefore, we wished to compare the ECL ELISA with mass spectrometry 
to assess whether the two results were in agreement. The samples selected 
were from both sepsis and control patients with pre-surgery and post-surgery 
time points.  
In-solution digestion was performed (detailed in the following sections) to 
prepare these samples for mass spectrometry analysis. All incubations were at 
room temperature unless otherwise stated. 
5.2.3.1. Materials 
Along with the reagents detailed in Chapter 2 (section 2.1), the following were 
used for preparation of the samples for mass spectrometry. 
Acetonitrile and iodoacetamide were from Sigma Aldrich (Gillingham, UK). 
Methanol (analytical reagent grade), acetic acid (1M lab solution), acetone 
(99+%, extra pure) and formic acid 99% were from Fisher Scientific 
(Loughborough, UK). Rapigest was purchased from Waters (Hertfordshire, UK). 
Trypsin Gold was from Promega (Southampton, UK). 
5.2.3.2. Protein precipitation 
Serum (10 µl) was mixed with ice cold acetone (40 µl), briefly vortexed and then 
incubated for an hour (-20°C). The solution was then spun at 14,000 g (10 
minutes) to pellet the precipitated protein. The supernatant was discarded and 
remaining acetone was left to evaporate from the uncapped tube.  
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5.2.3.3. Preparation for digestion 
The protein pellet was then suspended in 50 mM Tris, 0.1% Rapigest, pH 8.4 
(100 µl). The pellet was fully re-suspended and the pH checked (via pH paper). 
Tris (5 µl, 50 mM), containing 194 mM DTT, (pH 8.4) was then added before 
vortexing the samples and incubating (1 hour). After this, 20 µl of 50 mM Tris, 
containing 184 mM iodoacetamide (pH 8.4), was added and the samples were 
mixed gently before incubation for 1 hour in the dark. Tris (20µl, 50 mM), 
containing 194 mM DTT, pH 8.4 was then added and the samples were again 
incubated for 1 hour. 
Samples were then diluted to approx. 50 µg in 100 µl of 50 mM Tris pH 8.4, 
followed by the addition of 2.5 µl of trypsin (reconstituted in 50 mM acetic acid) 
to achieve a ratio of 1:20 (trypsin: protein). This mixture was then incubated at 
37°C (24 hours) to digest. 
After digestion samples underwent centrifugal evaporation (Jouan RC 10.22) 
until dried. The dry samples were then stored at -20°C until analysis. 
Prior to mass spectrometry analysis samples were suspended in 25µl of eluent 
A (98% acetonitrile and 0.1% formic acid). 
Mass spectrometry was carried out according to the protocol in Chapter 2, 
section 2.6. Analysis of the data was performed using Progenesis QI (Nonlinear 
Dynamics, Newcastle upon Tyne, UK), Mascot Daemon statistical software 
v2.3.2 (Matrix Science, London, UK) and Peak View v1.0 (AB SCIEX, Cheshire, 
UK).  
Progenesis QI was used to compare samples by aligning the total ion 
chromatograms, to compensate for the between-run variation, and quantified 
relative abundance of the peptides (including sequences suspected to be 
nitrated). The software also accessed online databases (i.e. Swiss-Prot 
(Consortium, 2015)) to identify the proteins in the sample. A report was then 
produced detailing the relative abundance of each protein with a statistical 
analysis comparing the different time points for each sample. 
Mascot Daemon (MatrixScience, 2014) was also used to search Swiss-Prot for 
protein identifications. However, this software can only be used to analyse one 
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sample in isolation, rather than comparing peptides across samples. This 
software provided data on the ion score (score of how reliable the data is), 
nitrated peptides and retention time. This data was then used to look at 
extracted ion chromatograms and spectra, for de novo sequencing, using the 
Peak View (ABSCIEX) software. 
5.2.4. Serum CRP measurement 
CRP was measured by an immunoturbidimetric assay, as described in Chapter 
3, section 3.2.6. 
5.2.5. Statistical analysis 
Normality of the data was tested using the Shapiro-Wilk test and determined to 
be non-parametric (p<0.01). Therefore, the Mann-Whitney test, Wilcoxon 
matched pairs and Spearman rank correlation tests were chosen for 
comparison of the data sets. 
A Receiver Operating Characteristic (ROC) analysis allowed calculations of the 
area under the curve (AUC). Sensitivity/specificity of the data sets was also 
determined. 
  
 123 
 
5.3. Results 
5.3.1. Increased serum Tyr-NO2 post-surgery 
Figure 5.2 shows that the median levels of serum Tyr-NO2 were increased 
following major elective surgery, compared to pre-surgery levels (median (IQR): 
pre-surgery 1.74 (0.59 – 4.79) and post-surgery 3.00 (1.01 – 7.15) fmol BSA-
NO2 equiv./mg protein. Wilcoxon matched pairs p=0.007). This supports results 
previously reported (Chapter 3, section 3.3). The sepsis and non-sepsis groups 
were combined for the analysis shown in Figure 5.2. 
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Figure 5.2: Pre- and one day post-surgery serum levels of 3-nitrotyrosine 
Tyr-NO2 was measured as described in Chapter 3, section 3.2.5.The figure represents the 
combined data from both sepsis patients and control patients (n=34). The median and 
inter-quartile range (IQR) values are shown. A significant increase in median Tyr-NO2 
levels was observed 24 hours post-surgery (Wilcoxon matched pairs, **p=0.005).  
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5.3.2. Changes in serum Tyr-NO2 over time 
When comparing all time points (Figure 5.3) there were no statistically 
significant differences in the median levels of serum Tyr-NO2 over the time 
course for either group (Kruskal-Wallis p>0.05). The median serum Tyr-NO2 
levels were generally higher in those patients who went on to develop sepsis, 
than in those patients who did not develop sepsis, but this did not reach 
significance (Mann-Whitney, p>0.05). Sepsis patients peaked at day 5 post-
surgery (5.46 fmol BSA-NO2 equiv./mg protein) compared to the non-sepsis 
control group which peaked at day 1 post-surgery (2.37 fmol BSA-NO2 
equiv./mg protein). 
The time course was also plotted in terms of days prior to diagnosis (Figure 
5.4), with controls matched according to the number of days post-surgery that 
the sepsis patients had reached when diagnosis occurred. The post-surgery 
sepsis group had an increase in median serum Tyr-NO2 prior to diagnosis, 
compared to pre-surgery levels, with the peak occurring one day prior to 
diagnosis (Figure 5.4B). However, there was no statistically significant 
difference between the time points (Kruskal-Wallis p=0.29). The matched 
controls also had an increase in median serum Tyr-NO2 levels but this peaked 
in those matched for 3 days before diagnosis, i.e. closer to the surgery (Figure 
5.4A). The levels of serum Tyr-NO2 were significantly higher in the sepsis group 
one day before diagnosis; median values of 4.5 and 1.2 fmol BSA-NO2 
equiv./mg protein for sepsis and controls respectively (Mann-Whitney, p=0.04). 
Individual Tyr-NO2 level time courses, for each patient, can be seen in appendix 
1. 
Serum Tyr-NO2 levels pre-surgery and pre-diagnosis were analysed further in 
the following sections, with a comparison to CRP concentrations. 
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Figure 5.3: Post-surgery time course of serum of 3-nitrotyrosine in patients with and without post-surgery sepsis 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. The median and IQR values are shown for each day in 
the two groups. (A) In the case of patients who did not develop post-surgery sepsis (n=25), there was no statistically significant 
difference between the median values of each time point (Kruskal Wallis p=0.77). Tyr-NO2 levels peaked at one day post-surgery. (B) 
In the case of patients who developed post-surgery sepsis (n=26), there was no statistically significant difference between the median 
values of each time point (Kruskal Wallis p=0.50). Tyr-NO2 levels peaked at day five post-surgery. 
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Figure 5.4:  Pre-diagnosis time course for serum 3-nitrotyrosine in those patients with post-surgery sepsis and their matched controls 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. The median and IQR values are shown for each day in the two groups.  
The patients who did not develop sepsis (controls) were matched according to the number of days post-surgery the sepsis patients had reached 
when diagnosis occurred. (A) No post-surgery sepsis (Kruskal Wallis p=0.67) and (B) Post-surgery sepsis (Kruskal Wallis p=0.29).   
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To compensate for the variation in total levels and individual differences the 
absolute change and percentage change were also analysed. The absolute 
change in serum Tyr-NO2 from pre-surgery to the day before diagnosis was 
determined to be non-significant (Figure 5.5A). Absolute change median (IQR): 
control patients without post-surgery sepsis 0.66 (-0.01 – 1.45) and post -
surgery sepsis patients 1.91 (0.02 – 3.55) fmol BSA-NO2 equiv./mg protein 
(Mann-Whitney p=0.06). Percentage change was also non-significant, control 
patients without post-surgery sepsis 24.3% (-5.5 – 39.1) and post -surgery 
sepsis patients 49.7% (0 – 200) increase (Mann-Whitney p=0.17, Figure 5.5B). 
As all groups were expected to have an increase in Tyr-NO2 following surgery, 
due to the ensuing tissue damage, the serum Tyr-NO2 from day one post-
surgery to the day before diagnosis was also determined (Figure 5.6). When 
assessing absolute change the control patients (no post-surgery sepsis) 
showed a decrease in median Tyr-NO2 levels and the post-surgery sepsis 
patients an increase in median, but this did not reach significance: median 
change (IQR) -0.6 (-2.4 – -0.1) and 0.1 (-0.2 – 6.1) fmol BSA-NO2 equiv./mg 
protein change in Tyr-NO2, for control and sepsis patients respectively (Mann-
Whitney, p=0.052).However, percentage change in Tyr-NO2 levels, over this 
time period, was statistically significant: median (IQR) -27.2% (-59.5 - -9.0) and 
1.4% (-7.8 – 210) for control patients and post-surgery sepsis patients 
respectively (Mann-Whitney, p= 0.02). 
The highest serum Tyr-NO2 levels, for all post-surgery time points, for control 
patients (no post-surgery sepsis) and post-surgery sepsis patients were 21.59 
and 64.60 fmol BSA-NO2 equiv./mg protein respectively. The median peak 
levels were 2.2 (1.1 – 7.2) and 6.1 (2.4 – 11.2) fmol BSA-NO2 equiv./mg protein 
for control and sepsis patients respectively, these medians were not 
significantly different (Mann-Whitney, p = 0.086). 
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Figure 5.5: Absolute and percentage change in serum 3-nitrotyrosine from pre-surgery levels to one day before diagnosis 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. The patients who did not develop sepsis (control group) 
were matched to sepsis patients by the number of days post-surgery the sepsis patients were when diagnosed. The median and IQR 
values are shown. (A) Those that developed sepsis (n=26) did show a higher absolute median increase compared to those that did not 
(n=26), however this was not statistically significant (Mann Whitney, p=0.06). (B) The percentage increase from pre-surgery levels was 
not statistically higher in the post-surgery sepsis (n=23) group compared to the control group (n=19) group (Mann Whitney, p=0.17). 
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Figure 5.6: Absolute and percentage change in serum 3-nitrotyrosine from day one post-surgery levels to one day before diagnosis 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. The patients who did not develop sepsis (control group) were matched 
to sepsis patients by the number of days post-surgery the sepsis patients were when diagnosed. The median and IQR values are shown. (A) The 
post-surgery sepsis group (n=11) show a median increase in serum Tyr-NO2 levels and the control group (n=9) a median decrease, but this was not 
statistically significant (Mann Whitney, p=0.052). (B) The percentage change over this time was statistically significant (Mann Whitney, *p=0.02). 
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5.3.3. Serum 3-nitrotyrosine levels and CRP concentrations pre-surgery  
There was no statistically significant difference in the pre-surgery serum Tyr-
NO2 levels when comparing patients who went on to develop sepsis with those 
who did not (Figure 5.7, Mann-Whitney p=0.53). The median (IQR) values were 
1.66 (0.3-4.3) and 2.33 (0.9-5.1) fmol BSA-NO2 equiv./mg protein for the control 
and sepsis group respectively. Two patients in the sepsis group had very high 
levels of pre-surgery serum Tyr-NO2 (64.6 and 23.6 fmol BSA-NO2 equiv./mg 
protein); both these patients had a gastrectomy, one patient died from sepsis, 
whilst the outcome of the second is unknown. 
In the present study, serum CRP (mg/L) levels were above the reported normal 
value of 0.8 mg/L (0.3-1.7) (median and IQR) (Povoa, 2002) prior to surgery. In 
our study, the serum CRP concentration measured in patients was: 5.00 (1.00-
14.00) mg/L. Additionally, the median levels of CRP pre-surgery in the sepsis 
group were significantly higher than in the non-sepsis (control) group: 8.5 and 2 
mg/L respectively (Figure 5.8A, Mann-Whitney p = 0.013). 
A ROC analysis of pre-surgery serum CRP (mg/L) gave an AUC of 0.7 (Figure 
5.8B). The individuals mentioned above (in Figure 5.7), with high serum Tyr-
NO2 levels, were not amongst those with exceptionally high serum CRP 
concentrations (12 and 3 mg/L) and at the optimal cut-off (>6.5mg/L, 57.7% 
sensitivity and 60.8 % specificity) CRP levels would only have detected one of 
these patients. When serum CRP was adjusted for serum protein (i.e. mg 
CRP/mg protein x 105) values were still significantly different but the p value 
was increased and the AUC was decreased (Mann-Whitney p=0.047, AUC = 
0.66, Figure 5.9).  
Pre-surgery Tyr-NO2 levels did not correlate with age or differ between genders. 
There was a positive correlation between Tyr-NO2 and CRP (mg/mg protein x 
105) (r=0.22, p=0.003) when all data points were pooled into one group. When 
data were separated into patients who developed sepsis and patients who did 
not, there was no correlation between pre-surgery Tyr-NO2 and pre-surgery 
CRP, in either group.  
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Figure 5.7: Pre-surgery 3-nitrotyrosine levels in patients with and without a 
diagnosis of post-surgery sepsis 
Tyr-NO2 was measured as described in Chapter 3, section 3.2.5.The median and IQR 
values are shown. There was no statistically significant difference between the median 
serum Tyr-NO2 levels in patients without a post-surgery sepsis diagnosis (n=25) and the 
median serum Tyr-NO2 levels of patients with a post-surgery sepsis diagnosis (n=26) 
(Mann-Whitney, p=0.53).  
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 Figure 5.8: Pre-surgery CRP (mg/L) concentration in patients without, and patients with, a post-surgery sepsis diagnosis and 
ROC analysis 
CRP was measured by the protocol described in Chapter 3, section 3.2.6. (A) The median and IQR values are shown. The median 
pre-surgery level of CRP was significantly higher in patients who developed post-surgery sepsis (n=26) compared to the median pre-
surgery level of CRP in those who did not (n=25) (Mann-Whitney, *p=0.01). (B) ROC analysis of pre-surgery CRP levels (AUC=0.7). 
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Figure 5.9: Protein corrected pre-surgery CRP (mg/mg protein x105) levels in patients without, and patients with, a post-
surgery sepsis diagnosis and ROC analysis 
CRP was measured by the protocol described in Chapter 3, section 3.2.6 and adjusted for total serum protein concentration. (A) The 
median and IQR values are shown. The median pre-surgery levels of CRP was significantly higher in patients who developed post-
surgery sepsis (n=26) compared to the median pre-surgery level of CRP in those who did not (n=25) (Mann-Whitney, *p=0.047). (B) 
ROC analysis of pre-surgery CRP levels (AUC=0.66). 
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5.3.4. Serum Tyr-NO2 levels and CRP concentrations prior to diagnosis 
One day prior to diagnosis: 
Median serum Tyr-NO2 levels showed a statistically significant increase in the 
post-surgery sepsis group, one day prior to diagnosis, compared to the non-
sepsis control group (matched by the number of days post-surgery sepsis 
patients were when diagnosed), with median values of 4.5 and 1.2 fmol BSA-
NO2 equiv./mg protein, respectively (Figure 5.10A, Mann-Whitney p=0.02). 
ROC analysis of Tyr-NO2 levels one day prior to diagnosis produced an AUC of 
0.69 and a p-value of 0.027 (Figure 5.10B). A cut-off value of ≥1.935 fmol BSA-
NO2 equiv./mg protein gave a sensitivity of 79.2% and a specificity of 58.3%. 
When this cut-off was used the assay was able to predict 19/25 sepsis cases 
that were later diagnosed clinically. When assessing both false negative and 
false positive results, Tyr-NO2 had an accuracy of 70%.  
Serum CRP (mg/L) was also significantly higher in the sepsis group one day 
prior to diagnosis (Figure 5.11A, Mann-Whitney, p<0.0001) and gave an AUC 
of 0.89 and p-value <0.0001 (Figure 5.11B). At the optimal cut-off (>109.5 
mg/L) only three sepsis patients would fail to be diagnosed (87.5% sensitivity 
and 88.5% specificity). The overall predictive accuracy (i.e. the percentage that 
were neither false negative or false positive) was 88%. 
When adjusted for serum protein concentration (CRP mg/mg protein x 105) the 
AUC was increased to 0.9 (a cut-off >168.4 CRP mg/mg protein x 105 gave 
95.8% sensitivity and 62.6% specificity), and 1/25 sepsis patients would have 
been a false negative (overall accuracy 92%). 
Two days prior to diagnosis: 
Two days prior to diagnosis Tyr-NO2 serum levels did not show a statistically 
significant increase in the sepsis group compared to the non-septic control 
patient group: the median (IQR) values in the two groups were 3.12 (1.22–7.64) 
and 2.17 (0.85 – 3.58) fmol BSA-NO2 equiv./mg protein respectively (Mann-
Whitney, p=0.21) (Figure 5.12A). However, median CRP concentrations were 
still significantly higher in the sepsis group compared to the non-sepsis control 
patient group: median (IQR) 347.2 (202.9 – 411.9) and 90.9 (53.8 – 215.4) mg 
CRP/mg protein x105 respectively (Mann-Whitney, p=0.0007) (Figure 5.12B).
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Figure 5.10: Predictive ability of serum 3-nitrotyrosine levels to detect sepsis, one day prior to sepsis diagnosis 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. Patients who did not develop sepsis (control group) were 
matched to sepsis patients by the number of days post-surgery the sepsis patients were when diagnosed. (A) The median and IQR values 
are shown. Median nitration levels were significantly higher in the patients who developed post-surgery sepsis (n= 24) compared to those 
who did not (n=24) (Mann-Whitney, *p=0.02). (B) ROC analysis of Tyr-NO2 levels one day prior to diagnosis (AUC=0.69). 
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Figure 5.11: Predictive ability of serum CRP concentrations to detect sepsis, one day prior to diagnosis 
CRP was measured by the protocol described in Chapter 3, section 3.2.6. The patients who did not develop sepsis (control group) 
were matched to the sepsis patients by the number of post-surgery the sepsis patients were when diagnosed. (A) The median and 
IQR values are shown. Serum CRP concentrations were significantly higher in the sepsis group (n=24) compared to the control 
group (n=25) (Mann-Whitney, ****p<0.0001). (B) ROC analysis of CRP concentrations one day prior to diagnosis (AUC=0.89). 
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Figure 5.12: Serum 3-nitrotyrosine levels and CRP concentrations in sepsis patients, two days prior to diagnosis, compared with matched 
patients who did not develop sepsis 
Tyr-NO2 was measured by the protocol described in Chapter 3, section 3.2.5. CRP was measured by the protocol described in Chapter 3, section 
3.2.6. The patients who did not develop sepsis (control group, n=17) were matched to sepsis patients (n=17) by the number of days post-surgery the 
sepsis patients were when diagnosed. Median and IQR values are shown. (A) There was no statistically significant difference in median serum Tyr-
NO2 levels, between the two groups, two days prior to diagnosis (Mann-Whitney, p=0.21). (B) Serum CRP concentrations were significantly higher in 
the sepsis group compared to the control group (Mann-Whitney, ***p=0.0007).  
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5.3.5. White blood cell counts 
Serum Tyr-NO2 levels did not show a statistically significant correlation with 
total white blood cell count (WBC), neutrophil count or monocyte count in either 
the sepsis group or in the non-sepsis group, or when the groups were 
combined.  
One of the clinical signs of sepsis is a WBC <4 or >12 (x 109/L). To assess the 
sensitivity and specificity of this parameter the data was converted into a score 
of one for any value <4 or >12, with WBC values 4-12 being assigned a score of 
zero. This produced an AUC of 0.7 (p=0.034) for WBC one day prior to 
diagnosis. 
5.3.6. Combining parameters  
The scoring system above was then extended to incorporate the Tyr-NO2 and 
CRP (mg/mg protein x 105) values so that the parameters could be combined 
for ROC analysis. The cut-off points discussed for each individual assay were 
used for scoring, with levels above the relevant cut-off scoring a value of one 
and below the cut-off scoring a value of zero. Therefore, a patient could have 
any score from 0 – 3 (Table 5.3). 
Table 5.3: Parameter scoring system 
Patients were scored depending on their levels of three parameters (Tyr-NO2 levels, 
CRP levels and WBC count) one day prior to diagnosis. 
Parameter Score 
≥1.94 Tyr-NO2 (fmol BSA-NO2 equiv./mg protein) 1 
≥168 mg CRP/mg protein x 105 1 
<4 or >12 x109/L WBC count 1 
Range of possible scores 0 - 3 
 
This combining of parameters gave an AUC of 0.86 (p<0.001), improving the 
sensitivity and specificity of the results from Tyr-NO2 alone or WBC alone but 
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detracting sensitivity and specificity obtained from the results of the CRP 
(mg/mg protein alone x 105) test alone, which (as mentioned above) gave an 
AUC of 0.9. 
When this scoring system was applied to just WBC and Tyr-NO2 levels an AUC 
of 0.73 (p=0.02) was achieved, meaning that these two parameters provided 
better sensitivity and specificity when combined than when either was used 
alone. When the only parameters scored were Tyr-NO2 levels and CRP 
concentration the AUC of 0.82 was produced (p=0.0001). Again this improved 
on using only Tyr-NO2 levels but decreased the sensitivity and specificity of 
CRP concentrations alone.  
5.3.5.1. Net reclassification index (NRI) 
The NRI score determines whether the addition of a marker improves a test’s 
prediction performance. Within this analysis, Tyr-NO2 was added to CRP 
(mg/mg protein alone x 105) to assess whether combining parameters improved 
the prediction of patients who would develop sepsis from samples collected one 
day prior to diagnosis.  
Equation 5.1: Net reclassification index 
𝒏 𝒐𝒇 𝒄𝒐𝒓𝒓𝒆𝒄𝒕𝒍𝒚 𝒓𝒆𝒄𝒍𝒂𝒔𝒔𝒊𝒇𝒊𝒆𝒅
𝒕𝒐𝒕𝒂𝒍 𝒏
−
 𝒏 𝒐𝒇 𝒊𝒏𝒄𝒐𝒓𝒓𝒆𝒄𝒕𝒍𝒚 𝒓𝒆𝒄𝒍𝒂𝒔𝒔𝒊𝒇𝒊𝒆𝒅
𝒕𝒐𝒕𝒂𝒍 𝒏
= 𝑵𝑹𝑰 𝒔𝒄𝒐𝒓𝒆 
 
When combining the CRP test with the Tyr-NO2 test it was seen that the Tyr-
NO2 correctly reclassified 3 patients, one day prior to diagnosis. However, 
combining the tests also incorrectly reclassified 13 patients, resulting in an NRI 
score of -0.2 (Equation 5.1). This means that the prediction of which patients 
would develop sepsis with CRP plus Tyr-NO2 test produced results 20 % worse 
than when just the CRP test was used. 
5.3.7. Mass spectrometry analysis of 3-nitrotyrosine in sepsis 
The mass spectrometry analysis was performed using the Progenesis QI 
software. This software provides relative quantification by comparing protein 
expression and nitration over the time-points for each patient. However, the 
Progenesis QI algorithm was only able to identify a few nitrated residues from 
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data with low scores (suggesting peptide sequencing may be inaccurate). No 
statistical changes over the time-course could be seen for either patient group 
(i.e. sepsis or control), see Table 5.4.  
Table 5.4: Nitrated proteins identified by Progenesis QI 
The identified proteins each contained one sequence predicted to be nitrated. 
Patient Nitrated proteins 
Sepsis patient U1577 
Metastasis-associated in colon cancer 
protein (MACC1) 
Polycomb protein SUZ12 (SUZ12) 
Sepsis patient B1164 
Double stranded RNA binding protein, 
staufen homolog (STAU2) 
Control patient L1292 Complement C5 (CO5) 
Control patient L1287 
Complement C3 (CO3) 
Metastasis-associated in colon cancer 
protein (MACC1) 
 
It was assumed that this result was due to the low percentage of Tyr-NO2 in the 
sample. Therefore, the samples were analysed again using pseudo multiple 
reaction monitoring (MRM) and the Mascot and Peak View software. Pseudo 
MRM is a targeted approach for particular m/z values of selected peptides (m/z 
for parent and nitrated peptide). Peptide sequences from serum albumin (the 
most abundant protein in serum) were targeted. The targeted peptides are 
detailed in Table 5.5 and were selected based on previous work conducted as 
part of this project (see Chapter 3). However, when using this approach no 
nitration of these residues was detected in the serum samples.  
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Table 5.5: Peptide sequences in serum albumin targeted by pseudo MRM MS/MS 
The m/z of the unmodified (parent) and nitrated (modified) peptide were targeted during 
pseudo MRM. Nitration adds a mass of 45 Da, this is then divided by the charge state 
to determine the m/z difference for the modified peptide, compared to the parent 
peptide. 
Location in HSA 
sequence 
Amino acid sequence  
m/z (charge) 
106-117 ETY(NO2)GEMADCCAK 
Parent 717.8994 (+2) 
Modified 740.3494  
161-168 YLY(NO2)EIAR 
Parent 464.2955 (+2) 
Modified 486.7955 
287-298 Y(NO2)ICENQDSISSK 
Parent 722.4044 (+2) 
Modified 744.9044 
348-360 DVFLGMFLY(NO2)EYAR 
Parent 812.4903 (+2) 
Modified 834.9903 
469-490 RMPCAEDY(NO2)LSVVLNQLCVLHEK 
Parent 840.1748 (+3) 
Modified 855.1748 
508-524 RPCFSALEVDETY(NO2)VPK 
Parent 637.7175 (+3) 
Modified 652.7175 
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5.4. Discussion 
The British Medical Journal Best Practice sets out the diagnostic criteria for 
systemic inflammatory response syndrome (SIRS) based on the consensus of a 
2001 conference (Levy et al, 2003). Two of these criteria need to be met for a 
SIRS diagnosis, and infection must be present for a sepsis diagnosis.  
Diagnosis criteria:  
 Hypothermia (<36°C) or hyperthermia (>38.3°C) 
 Tachycardia (>90 beats per minute) 
 Tachyponea (>20 breaths per minute) 
 PCO2 <4.3 kPa (32 mmHg) 
 Hyperglycaemia in the absence of diabetes (>6.66 mmol/L) 
 Acutely altered mental state 
 White blood cell count <4 or >12 x 109/L 
As the criteria for SIRS are non-specific (and will be met by many within the 
intensive care unit), and as infection cannot always be confirmed, other 
biomarkers are needed to determine which treatment is necessary (Vincent et 
al, 2009). CRP and procalcitonin are both used clinically but both have 
questionable specificity (Pierrakos and Vincent, 2010), and differing baselines 
between individuals. This makes changes in time more relevant than a single 
value (Vincent et al, 2011). In a 2010 review of studies looking at sepsis 
biomarkers, 3370 studies were found, in which researchers examined 178 
different markers (Pierrakos and Vincent, 2010); this is a far larger pool of 
potential markers than found in many other diseases, emphasising the complex 
nature of this disease.  
The primary aim of this study was to determine whether serum Tyr-NO2 levels 
were higher in those with post-surgery sepsis, compared to those without. 
Samples were collected from patients prior to, and for several days after, major 
elective surgery and split into two groups; those without post-surgery sepsis 
(n=25) and those with post-surgery sepsis (n=26). Previous studies, showing 
that free Tyr-NO2 is elevated in sepsis, obtained the samples at one time point 
from patients already diagnosed with septic shock, i.e. sepsis plus hypotension 
and did not measure the protein-associated form of Tyr-NO2 (Fukuyama et al, 
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1997; Ohya et al, 2002). Therefore, these results did not show whether protein-
associated Tyr-NO2 was elevated, or if any nitration could be observed prior to 
sepsis diagnosis as reported here. As can be seen in Figure 5.3 the median 
levels of serum Tyr-NO2 were higher in the post-surgery sepsis group for all 
post-surgery time points. Though, due to the large variation in values, there 
wasn’t a significant difference between the groups at any post-surgery time 
point. However, when the time points were changed from days post-surgery to 
days prior to diagnosis a significant difference was observed one day prior to 
diagnosis, with levels being higher in the post-surgery sepsis group compared 
to their matched controls (median and IQR 5.15 (2.38-8.32) and 1.3 (0.79-5.55) 
fmol BSA-NO2 equiv./mg protein respectively, Figure 5.10). Median levels were 
also higher at two and three days before diagnosis (Figure 5.4) but this did not 
reach significance. Absolute and percentage change was also analysed. When 
day one post-surgery was compared to one day before diagnosis a significant 
difference in the percentage change for the post-surgery sepsis and their 
matched controls was observed (Figure 5.6), as the control group was 
decreasing between these time points and the sepsis group was increasing 
between these time points. This data shows, for the first time, that sepsis 
patients have increased nitrative stress prior to sepsis diagnosis. In the case of 
post-surgery sepsis, serum Tyr-NO2 can be seen to rise in the days following 
surgery whereas matched controls subjects have a reduction in nitrative stress 
(following the peak observed immediately post-surgery). Another study that has 
looked at pre-diagnosis markers of sepsis  was Lukaszewski et al (2008) who 
measured the  daily mRNA levels of the cytokines IL-1β, IL-6, IL-8, IL-10, TNFα, 
FasL and CCL2 in intensive care unit patients following high risk procedures. 
Using a neural network they were able to achieve a predictive accuracy of 
94.55% with these 7 markers.  
A delay (even of a few hours) in anti-microbial treatment was found to affect 
sepsis survival rates (Kumar et al, 2006; Weiss et al, 2014), therefore looking at 
potential markers prior to clinical diagnosis is vitally important in developing 
ways to identify sepsis early and improve mortality rates. Therefore, this study 
also sought to determine if serum Tyr-NO2 could be a potentially useful addition 
to the clinical markers of sepsis, i.e. aid a quicker and more accurate diagnosis. 
There was no difference in the pre-surgery levels of Tyr-NO2 between the two 
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groups, suggesting no pre-surgery prognostic value. However, two of the sepsis 
patients did have very high pre-surgery levels of serum Tyr-NO2 (Figure 5.7). 
Both these patients were having a gastrectomy (removal of part or all of the 
stomach). These levels could reflect a high level of inflammation associated 
with their illnesses, or possibly the beginnings of an infection that would develop 
into sepsis; a control patient (i.e. did not develop sepsis) who had a 
gastrectomy had undetectable Tyr-NO2.  
As was also seen in Chapter 3 (section 3.3) there was a wide range in pre-
surgery Tyr-NO2 levels (0 - 64.6 fmol BSA-NO2 equiv./mg protein) and this is 
probably due to the heterogeneous nature of the medical conditions within the 
studied patient population. Ideally, this confounding factor would be removed by 
studying a population with the same medical condition, and undergoing the 
same operation. However, this would not accurately reflect the highly 
heterogeneous nature of sepsis. 
The CRP levels observed at the pre-surgery time-point were higher than would 
be seen in healthy individuals (healthy median 0.8 mg/L (Povoa, 2002)), i.e. if 
there was no acute phase response, as the patients in the present study had a 
wide variety of diseases. A small, but statistically significant (p<0.05), difference 
was seen between the two groups at this pre-surgery time point: the median 
and IQR for the sepsis group was 8.5 (3-18) mg/L and the corresponding values 
for the control (non-sepsis) group were 2.0 (0.85-11) mg/L) (Figure 5.9). This 
could potentially be an indication that these patients were in an inflammatory 
state that predisposed them to sepsis following surgery. Fransen et al (1999) 
and Boeken et al (1998) found that a high pre-operative CRP was a strong 
predictor of post-operative infection, in patients undergoing cardiac surgery. 
Fransen et al (1999) suggested that this could be due to pre-existing chronic 
inflammation dysregulating the immune system in the post-operative period, 
and thereby increasing the risk of infection. High pre-operative CRP has also 
been indicated as a marker of poor prognosis in cancer related surgeries 
(Crumley et al, 2006; Zahlten-Hinguranage et al, 2006; Steffens et al, 2012; 
Steffens et al, 2013). The CRP (mg/L) levels for the two subjects with high pre-
surgery Tyr-NO2 were 3 and 12 mg/L. Therefore, the former subject may not 
have raised any concerns about their pre-operative state, based on CRP (mg/L) 
 146 
 
alone (cut off >6.5 mg/L), but the Tyr-NO2 levels would have been indicative of 
high levels of inflammation. 
A significant increase in Tyr-NO2 was observed one day after surgery (p<0.01), 
when compared to pre-surgery levels, with the two groups combined (median 
and IQR: pre-surgery 1.7 (0.59 – 4.79) and post-surgery 3.0 (1.01-7.15) Tyr-
NO2 fmol BSA-NO2 equiv./mg protein). However, when the groups were 
separated into no post-surgery sepsis (control) and post-surgery sepsis, 
significant differences only remain for the control group (control p=0.036 and 
sepsis p=0.055). If the sepsis patients were experiencing a dysregulated 
immune response prior to surgery (as suggested by Fransen et al (1999) with 
regard to high pre-operative CRP) then a possible explanation for the smaller 
increase in the sepsis group could be that the pathways, for Tyr-NO2 formation, 
are not as quickly activated post-surgery in these patients as they are in 
controls. This would cause the control group to have a larger increase in 
nitration one day post-surgery compared to those that would go on to develop 
sepsis. 
Ohya et al (2002) suggested that free Tyr-NO2 levels in plasma had prognostic 
value in predicting survival, but this was based on a low patient number (n=12). 
In our study, the samples from one day prior to sepsis diagnosis were analysed 
with control samples matched by the number of days after surgery. As 
mentioned the median serum protein-associated Tyr-NO2 levels were 
significantly higher for the sepsis patients compared to non-sepsis controls 
(Figure 5.10). This is consistent with the fact that the sepsis patients had an 
ongoing/worsening inflammatory response as a result of infection, in addition to 
tissue damage caused by the surgery. Whilst in the non-sepsis control patients 
there is a resolution of the inflammation, purely related to surgery-associated 
tissue damage, as they recover from the surgery (although the time course for 
resolution will vary with medical condition/surgery undertaken). Patient outcome 
was only known for a subset of patients and therefore the prognostic potential of 
serum Tyr-NO2 could not be assessed. Serum CRP concentrations were also 
significantly higher one day prior to diagnosis (Figure 5.11, p<0.0001) and 14 
out 24 (58%) of patients had a WBC count <4 or >12 x 109/L. Tyr-NO2 levels 
were not correlated with WBC count but Tyr-NO2 and CRP (mg/mg protein x 
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105) showed a weak positive correlation (r =0.22, p<0.01) when all data points 
were pooled into one group.  
ROC analysis was performed for each of these indicators (i.e. Tyr-NO2, CRP 
and WBC) alone and in combination to assess the indicators potential as a 
diagnostic tool (determined by the AUC). When analysed alone, the AUC’s for 
each assay were: Tyr-NO2 = 0.69, CRP = 0.88 and WBC = 0.7. Brubaker (2008) 
defined a diagnostic test with an AUC of 0.5-0.75 as ‘fair’ and 0.75-0.92 as 
‘good’ (0.92-0.97 is ‘very good’ and >0.97 is ‘excellent’). With these categories, 
Tyr-NO2 and WBC were ‘fair’ diagnostic tools and CRP was a ‘good’ diagnostic 
tool. When the parameters were scored (see Table 5.3), and combined an AUC 
of 0.86 was produced. Therefore combining the three factors failed to improve 
upon the ‘good’ rating of CRP alone. The NRI score also indicated that 
combining Tyr-NO2 and CRP reduced the diagnostic potential of CRP by 20%. 
CRP levels have previously been measured in a prospective study to 
differentiate SIRS from sepsis, where an AUC of 0.94 was seen (Sierra et al, 
2004). The Sierra et al (2004) study also had a much lower CRP mg/L cut-off 
(80 mg/L) than seen here (109.5 mg/L), this is probably due to our control group 
having background inflammation, from the surgery, and therefore, a higher cut-
off was needed to differentiate between the groups. Other studies have 
suggested that CRP is of limited use for differentiating between those with and 
without infection when a high background inflammatory state is present, such as 
seen with burn patients (Lavrentieva et al, 2007; Barati et al, 2008). 
Due to the fact that Tyr-NO2 formation is strongly associated with 
immune/inflammatory pathways (e.g. O2 ˙¯ production and MPO activation) it 
would be expected that Tyr-NO2 levels would increase vastly in sepsis. 
However, although the median Tyr-NO2 level in sepsis is higher than the non-
sepsis controls, across all days, the only time-point at which this is significant is 
one day prior to diagnosis. This lack of a significant difference is due, in part, to 
the large variation in levels observed; indeed, some patients had non-detectable 
Tyr-NO2 prior to diagnosis. One possible explanation for this is the 
compensatory anti-inflammatory response that can occur in sepsis, where anti-
inflammatory cytokines are up-regulated, lymphocyte number is reduced and an 
immunocompromised state is created (Adib-Conquy and Cavaillon, 2008; Ward 
et al, 2008). During this state, neutrophils have a lowered rate of phagocytosis 
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and intracellular microbicidal activity (Adib-Conquy and Cavaillon, 2008) which 
would be connected with a decreased release of MPO. If free radical production 
is also limited, there would be very little possibility of Tyr-NO2 formation. 
However, low WBC count was not correlated with low serum nitration so it is 
likely other factors are involved in determining the serum Tyr-NO2 levels.  
Capillary leak is also observed as part of sepsis and this involves the loss of 
proteins from the blood into the interstitial space (Yang et al, 2014), making the 
adjustment of Tyr-NO2 for serum protein concentration an important factor. 
However, it may be that the loss of serum albumin (the most abundant serum 
protein) in this way also results in a loss of a large proportion of the nitrated 
tyrosine.  
Mass spectrometry data was unable to provide robust data on the relative 
amount of nitration, or in which proteins nitration occurred. A few low-
abundance proteins were highlighted as containing Tyr-NO2 by Progenesis QI 
(see Table 5.4) the scores from these hits were low suggesting they may not be 
true hits. The proteins identified are also doubtful, for example, all but the 
complement proteins are intracellular proteins, so would not be expected in the 
serum. Additionally, far more nitration (and within more abundant proteins) was 
expected. It is suspected that the inability of the analysis to detect nitrated 
peptides is due to the fact the number of nitrated Tyr residues compared to the 
number of non-nitrated residues in the sample is very small (around 1 in 10,000 
(Radi, 2004)). Additionally, there would have been many sequenced peptides 
that did not contain Tyr at all. This means the modified peptides are hidden by 
the greatly more abundant unmodified peptides and may not get sequenced. 
The low efficiency of mass spectrometry in detecting low abundance PTMs was 
discussed by Zhao and Jensen (2009), and enrichment of the modified peptides 
is often required. Therefore, any future work to identify Tyr-NO2 in human serum 
would require that the nitrated peptides be separated from the non-nitrated 
peptides (e.g. by affinity chromatography) prior to mass spectrometry analysis. 
Such separation procedures would, in themselves, provide additional 
challenges to obtaining quantitative data. 
A targeted pseudo MRM MS/MS approach, in which only serum albumin 
peptides were analysed, was used in an attempt to filter out a large amount of 
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the non-nitrated peptide sequences. However, nitrated sequences could still not 
be identified. This could be due to there still being too much non-modified 
peptide as albumin is the most abundant protein in the serum (approx. 55% 
(Anderson and Anderson, 2002). On the other hand, it might have been 
expected that albumin would be the most nitrated protein due to this high 
abundance and the significant content of Tyr residues within its polypeptide 
sequence.  
This study was limited by the measurement of only one oxidative stress marker. 
Consequently, it is unknown whether other markers of oxidative stress act in a 
similar manner to Tyr-NO2 prior to sepsis diagnosis, following surgery, or if they 
follow another pattern. A further study should therefore measure a panel of 
oxidative stress markers, such as carbonyls and isoprostanes, over the time 
course as well as Tyr-NO2. 
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5.5. Conclusion 
As far as we know this is the first time oxidative stress has been measured in 
sepsis patients prior to diagnosis. The results show that oxidative stress is 
measurable in the days prior to diagnosis and, that a significant difference is 
seen at the time point one day before diagnosis, with the patients who went on 
to develop sepsis having higher levels of Tyr-NO2 than patients who did not 
develop sepsis (matched by number of days post-surgery). 
The patient group analysed here was highly heterogeneous in terms of medical 
conditions and surgeries undertaken. This confounding factor likely contributes 
towards the wide variation in results and overlap between groups for all 
markers. To improve the study of sepsis it has been suggested that the patient 
groups need to be graded, in order to achieve more homogenous populations. 
For this, the PIRO model has been put forward (Vincent et al, 2006; Howell et 
al, 2011; Granja et al, 2013). The PIRO model categorises patients based on 
four factors: Predisposition (e.g. age, pre-existing conditions), Infection (e.g. site 
and whether hospital or community acquired), Response (e.g. temperature, 
heart rate, cardiac output, etc.) and Organ dysfunction (Vincent et al, 2009; 
Howell et al, 2011; Granja et al, 2013). Using this model to score patient 
populations appears to have better predictive value for mortality and intensive 
care unit stay than other scoring systems, i.e. APACHE II (acute physiology and 
chronic health evaluation) (Vincent et al, 2009). In the present study, it was 
observed that serum Tyr-NO2 was not as sensitive a marker for sepsis as CRP. 
However, separation of patients into more homogenous groups using the PIRO 
model, may lead to more informative results being achieved.  
This project had some methodological problems in that a new antibody lot 
number did not perform correctly and this greatly reduced the number of 
samples in the cohort (we were unable to obtain data for approximately 100 
collected patient samples). A larger number of samples would have allowed for 
stratification of samples into groups based on factors such as surgery being 
undertaken or patient outcome, whilst still maintaining a large enough n number 
for robust statistical analysis. 
Despite this heterogeneity the present study did, as mentioned, show that 
sepsis patients had significantly higher levels of Tyr-NO2 than controls one day 
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before diagnosis. This confirms that the aberrant inflammatory response, seen 
in sepsis, causes increased oxidative/nitrative stress. Nitration can then lead to 
dysfunction of the affected proteins and further pathology. 
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Chapter 6  
Nitration in the brain tissue of Alzheimer’s disease models and 
patients 
 
Alzheimer’s disease (AD) is characterised by histopathological features, such 
as senile amyloid plaques and neurofibrillary tangles (Sultana et al, 2006; 
Reynolds et al, 2007; Reyes et al, 2011) and neuroinflammation can be initiated 
by both the amyloid plaques and neurofibrillary tangles (Akiyama et al, 2000; 
Heppner et al, 2015) this is described in Chapter 1 (section 1.5.5). The clinical 
diagnosis of AD is mostly reliant on the exclusion of other causes for the decline 
in cognitive function/dementia and will still only result in a diagnosis of either 
possible or probable AD (McKhann et al, 2011). Neural imaging and 
cerebrospinal fluid (CSF) biomarkers are, at the moment, insufficient for a 
definitive diagnosis and post-mortem neuropathological examination is required 
(McKhann et al, 2011). Additionally, when a probable AD diagnosis is given the 
disease is at a neuropathologically advanced stage, however, it is believed that 
new drugs will be most effective in the early stages when neurodegeneration 
can be slowed, before a severe loss in cognitive function has occurred (Hampel 
et al, 2010). For this reason biomarkers are needed to improve early detection 
of the disease. 
Transgenic  mouse AD models have been developed to aid understanding of 
what causes this disease, the underlying pathology, testing of potential 
therapeutic strategies and for preclinical testing. These models tend to use 
mutations found in familial AD (Morrissette et al, 2009), such as the Swedish 
mutation, which is a double mutation found in a Swedish family that results in 
increased production of amyloid-β (Haass et al, 1995). Many models exhibit 
amyloid pathology but some transgenic lines have been crossed to produce 
mice with both amyloid-β plaques and neurofibrillary tangles. However, it has 
proved difficult to produce a model which displays the full range of AD 
pathology (Elder et al, 2010). As has already been discussed in the introduction 
(Chapter 1, section 1.5.5) oxidative stress has been observed in the brain of 
mouse AD models, and is thought to accelerate the AD pathology observed 
(Lim et al, 2001; Praticò et al, 2001; Kanamaru et al, 2015). Lim et al (2001) 
found that a ˙NO scavenger (curcumin) reduced the plaque burden seen in the 
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brain tissue. This suggests that ˙NO may be an important factor in AD 
pathology.  
All three NOS isoforms are expressed in the human brain, i.e. neuronal (nNOS), 
endothelial (eNOS) and inducible (iNOS) (Law et al, 2001). The 
expression/activity of NOS, along with the role of ˙NO, in AD has been 
extensively studied but inconsistent results have been seen. Norris et al (1996) 
found nNOS mRNA levels were not significantly different in those with AD 
compared to controls with no sign of neurological disease. Yew et al (1999) also 
measured mRNA for nNOS and found that in AD patients the number of 
neurons expressing nNOS mRNA goes down but, those neurons expressing the 
mRNA produce more than seen in non-demented control tissue. However, 
mRNA expression is not the same as protein activity. Dorheim et al (1994) 
found that NOS activity in the brain microvessels is increased with AD, they also 
observed an increase in the expression of both the constitutive (endothelial and 
neuronal) and inducible NOS compared to the brains of non-demented controls. 
To determine ˙NO production in the human brain many have measured NO2¯, 
NO3¯ or NO2¯ plus NO3¯ (NOx). Kuiper et al (1994) and Navarro et al (1996) 
both measured NO2¯ and NO3¯ in the CSF as a way of assessing the ˙NO 
production, in the central nervous system, of living AD patients. Kuiper et al 
(1994) found that levels of these metabolites were lower in the CSF compared 
to the plasma and suggested that, as they are anions, they do not freely pass 
through the blood brain barrier. NO2¯ concentrations were not found to be 
significantly different in AD but NO3¯ concentrations were significantly lower in 
the CSF of AD patients compared to controls free of neurodegenerative 
disease. However, Navarro et al (1996) measured NO3¯ in plasma and CSF 
and found no significant difference between AD and controls. DiCiero Miranda 
et al (2000) measured NOx concentration in post-mortem brain tissue and found 
that they were lower in those with AD compared to non-demented aged 
controls. Whether ˙NO production is neurotoxic or neuroprotective is a matter of 
debate as ˙NO is a neurotransmitter and can be anti-inflammatory (Law et al, 
2001). Malinski (2007) suggests that ˙NO is cytoprotective in the absence of 
O2˙¯, as mentioned (Chapter 1, section 1.5) these radicals react to form 
ONOO¯ which is far more reactive than ˙NO. SOD activity has been found to be 
reduced in the AD brain (Marcus et al, 1998). SOD is responsible for 
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dismutation of O2˙¯ to H2O2, therefore, a loss of activity will lead to an increase 
in available O2˙¯. Additionally, NOS can become uncoupled, for example due to 
decreased levels of its cofactor tetrahydrobiopterin – as seen in AD (Foxton et 
al, 2007) –  and produce O2˙¯ instead of ˙NO. Tyr-NO2 can be formed, as a 
result of ONOO¯ production, and has been shown to be associated with fibrillar 
amyloid-β in mouse models of AD (Matsuoka et al, 2001). Tyr-NO2 has also 
been observed in human AD brain tissue (Good et al, 1996; Hensley et al, 
1998; Calabrese et al, 2006; Butterfield et al, 2007b). 
Two studies were conducted assessing nitrative stress in AD brain tissue.  
(1) Brain tissue samples from transgenic mouse AD models were analysed for 
Tyr-NO2 content to test whether Tyr-NO2 could be measured in these models. 
The number of samples was limited so this project was performed to determine 
whether a further investigation with greater numbers was warranted. Two 
transgenic mouse models were used during this study, Tas-TPM and Tau35. 
Tas-TPM is a double transgenic created by cross-breeding two transgenic lines, 
TAS10 and TPM. These parent models express human amyloid precursor 
protein and Presenilin-1 respectively, each of these genes contain established 
mutations in familial AD (AlzForum, (n.d)). As a result of these mutations the 
mice develop extensive amyloid pathology but they do not develop 
neurofibrillary tangles (AlzForum, (n.d)). The Tau35 mice express low levels of 
a disease-related fragment of human tau, to mimic tauopathy in mice (Wray et 
al, 2008). Tauopathy covers several neurodegenerative diseases with 
hyperphosphorylated/aggregated tau, AD is the most common of these 
(Williams, 2006) and insoluble tau is a large part of neurofibrillary tangles 
(Hanger and Wray, 2010).  
(2) A pilot study measuring products of ˙NO production in the human AD brain 
was conducted. The aim of the study was to determine whether there was an 
increase in nitrative stress in the AD brain, if there was then this would be the 
rationale behind measuring nitration in other tissues that are accessible prior to 
death (e.g. CSF and blood). 
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6.1. Materials and Methods 
Mouse samples 
Forebrain and cerebellum tissue samples from the brain of transgenic (n=24) 
and wild-type mice (n=14) were collected and snap frozen, then stored at -80°C.  
The samples were thawed and homogenised using a 1% SDS lysis buffer (100 
mM NaCl, 10 mM Tris (hydroxymethyl) methylamine (pH 7.6), 1 mg/ml 
aprotinin, PMSF and 1% SDS) and a Retsch Mixer Mill 400. For 
homogensitation, the samples were weighed and lysis buffer added at a 5 µl/mg 
tissue ratio (300 µl buffer was used if this was the greater volume), samples 
were then incubated on ice for at least 20 minutes. Two magnetic beads were 
then used for homogenisation at 25 hertz/second, in 30-second bursts until the 
sample was determined to be homogenised by visual inspection. The sample 
was then pulse centrifuged and the supernatant transferred to a fresh 1.5 ml 
micro-centrifuge tube. Protein concentration of samples was determined by 
BCA (Chapter 2, section 2.2), with a 1 in 20 dilution, samples were then stored 
at -80°C until ready for Tyr-NO2 measurement.  
Human samples 
Human brain tissue homogenates were prepared by the South West Dementia 
Brain Bank (SWDBB). Samples were collected under Brains for Dementia 
Research (BDR) ethics with the informed consent of the individual or a close 
relative. 
Tissue was collected from the frontal lobe of frozen hemispheres of 15 
Alzheimer’s disease, 15 vascular dementia (VaD) and 15 non-dementia controls 
(45 samples in total). The tissue was kept on ice throughout the process. 1% 
SDS lysis buffer (as above) was used at an approximate ratio of 1ml per 200 
mg tissue.  
Approx. 200 mg of tissue was homogenised in a Precellys 24 Homogeniser 
(Stretton Scientific Ltd, Derbyshire UK) using 2.3 mm ceramic beads. The 
samples were homogenised at 3000 g for 15 seconds, then left for 3 minutes on 
ice before the process was repeated. The samples were stored at -80°C until 
collection. 
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After collection, from SWDBB, samples were defrosted and centrifuged at 
14,000 g for 10 minutes and the supernatant placed in 100 µl aliquots and 
stored at -80°C until analysis.  
6.1.1. Electrochemiluminescence-based ELISA for 3-nitrotyrosine 
Tyr-NO2 content of the tissue was measured by the ECL ELISA (Chapter 3, 
section 3.2.5) with a 1 in 10 dilution. As the components of the lysis buffer can 
interfere with the signal produced by the ELISA (Figure 6.1) the standard curve 
was run with an equivalent concentration of lysis buffer to the samples (i.e. 
0.1%).  
The tissue levels of Tyr-NO2 were found to be far higher than serum/plasma 
levels. As the assay showed improved reproducibility, with regards replicate 
variation, at Tyr-NO2 levels midway on the standard curve (see Chapter 3, 
section 3.3) the brain samples were run with duplicate measurements, rather 
the quadruplicate measurements used for the serum/plasma. 
The intra-assay CV for brain tissue was calculated due to all human samples 
being run on two plates, making within assay variation more relevant than 
between assay variation. The intra-assay CV was determined by preparing the 
same human brain sample 8 times and measuring these preparations within 
one plate. 
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Figure 6.1: Loss of ECL ELISA signal from BSA-NO2 in the presence of 1% SDS 
Nitrated BSA was diluted in dilution buffer containing different amounts of SDS, 1% SDS resulted 
in a complete loss of ECL signal (n=1). However, a concentration of 0.1% SDS did not result in 
any signal loss from BSA-NO2. R.L.U. Relative light units (arbitrary). 
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6.1.2. Near infra-red western blotting for nitrated proteins 
Western blotting for Tyr-NO2 was performed to determine (A) the molecular 
weight of the nitrated proteins and, (B) if there was a different pattern of nitration 
between groups. 
Western blotting for Tyr-NO2 was performed (as described in Chapter 2, section 
2.5) to determine the molecular weight of the nitrated proteins. DTT was used 
as the reducing agent and 60 µg of protein was loaded per lane. Actin was used 
as the loading control with an IRDye680RD (red fluorescence) anti-rabbit 
secondary antibody (Chapter 2, Table 2.1).  
Mouse samples 
A biotinylated anti-nitrotyrosine antibody and a streptavidin IRDye800CW 
(green fluorescence) secondary antibody were used for detection of Tyr-NO2 
(Chapter 2, Table 2.1). 
Human samples 
The mouse non-biotinylated anti-nitrotyrosine antibody and anti-mouse 
IRDye800CW (green fluorescence) secondary antibody was used for detection 
of Tyr-NO2 and the anti-actin and anti-rabbit IRDye680RD for the loading control 
(red fluorescence) (Chapter 2, Table 2.1).  
Gels for Coomassie staining (protocol described in Chapter 2, section 2.4) were 
run simultaneously so that bands could be excised for mass spectrometry 
analysis. Quantification of the band signal was done using the LiCor Studio Lite 
software analysis tool. The ratio of the Tyr-NO2 signal to the actin signal was 
then calculated. 
6.1.3. Mass spectrometry 
Human samples 
To identify proteins in the nitrated bands mass spectrometry was performed. 
For this, seven bands corresponding to Tyr-NO2 positive staining were cut from 
a Coomassie gel and digested (Figure 6.12). The actin positive band was also 
cut out to confirm that the anti-actin antibody was binding to actin. 
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6.1.3.1. Materials 
In addition to the materials listed in Chapter 2 (section 2.1) the following 
reagents were used to prepare samples for mass spectrometry analysis. 
Acetonitrile and iodoacetamide and trypsin (proteomics grade), were from 
Sigma-Aldrich (Gillingham, UK). Ammonium bicarbonate (analytical reagent 
grade) and Formic acid 99% were from Fisher Scientific (Loughborough, UK).  
6.1.3.2. In-gel digest 
Relevant bands were excised from a Coomassie-stained gel using a clean 
scalpel. Bands were cut into several pieces (approximately 1mm wide) and 
placed in a 1.5 ml microcentrifuge tube. All incubations were at room 
temperature unless otherwise stated. 
Firstly, gel bands were washed (500 µl, 100 mM ammonium bicarbonate) and 
the tubes incubated on a tube roller (30 minutes). The wash solution was 
discarded and a second wash performed (500 µl, 50% acetonitrile 100 mM 
ammonium bicarbonate), this wash was then discarded. Samples were reduced 
with 150 µl of 100 mM ammonium bicarbonate and 10 µl 45 mM DTT 
(incubated for 30 minutes at 60°C). Samples were cooled to room temperature, 
then alkylated (10 µl 100 mM iodoacetamide) and incubated in the dark (30 
minutes).  
The solvent was then removed and the samples washed (500 µl, 50% 
acetonitrile 100 mM ammonium bicarbonate). The wash was discarded and the 
gel pieces shrunk (50 µl acetonitrile, approximately 10 minutes incubation), the 
solvent was removed and the samples were dried under centrifugal evaporation 
(Jouan RC 10.22).  
A trypsin vial was re-suspended in 25 mM ammonium bicarbonate and used to 
rehydrate gel pieces (just enough to allow gel pieces to swell to the original 
size, approximately 25 µl). The gel pieces were then covered in 25 mM 
ammonium bicarbonate and incubated at 37°C overnight, while digestion took 
place. 
The tubes were then pulse centrifuged to pellet the gel pieces and the 
supernatant transferred to a fresh microtube. The gel pieces were incubated (20 
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µl, 5% formic acid) for 20 minutes at 37°C, 40 µl acetonitrile was then added for 
a further 20 minutes. The samples were pulse centrifuged again and the 
supernatant collected and combined with the previously collected supernatant. 
This combined solution was then dried down using a centrifugal evaporator 
(Jouan RC 10.22) and stored at -20°C until analysis.  
Prior to mass spectrometry analysis samples were suspended in 25 µl of eluent 
A (98% acetonitrile and 0.1% formic acid). 
6.1.3.4. Mass spectrometry analysis 
Mass spectrometry (MS/MS) analysis involved high pressure liquid 
chromatography (HPLC) coupled to a 5600 Triple TOF mass spectrometer.  
The samples were eluted over a 45 minute gradient on a C18 nano-HPLC 
column. Scans were collected for 200 ms. Information dependent acquisition 
was used to collect MS/MS data (10 most intense ions), as described in 
Chapter 2 (section 2.6).  
The generated data was then analysed with Mascot Daemon statistical software 
v 2.3.2 (Matrix Science, London, UK) with the following settings applied: 
Digestion enzyme: trypsin 
Fixed modifications: 
 Carbamidomethyl (C) (formed by the iodoacetamide) 
Variable modifications: 
 Oxidation (M) 
 Nitro (Y) 
Instrument type: ESI QUAD TOF 
Taxonomy: Human  
Charge: 2+, 3+ and 4+ 
Fragment mass tolerance: 0.5 Da 
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6.1.4. Ozone-based chemiluminescence (NO2¯ and NO3¯ measurement) 
Measurement of NO2¯ and NO3¯ in human brain samples was performed by Dr 
Miranda Smallwood (University of Exeter Medical School) as per the protocol in 
Chapter 2 (section 2.9), with the following adaptations: 200 µl of homogenate 
was deproteinised (dilution of 1 in 5). This means that there was 0.2% SDS in 
the samples and the standards were run with this concentration as well. 
Samples were analysed in duplicate. As this analysis was done over several 
days the between assay variation was determined (inter-assay CV 6.1%).  
6.1.5. Statistical analysis 
Following a test of normality (Shapiro-Wilk), non-parametric (Mann-Whitney, 
Kruskal-Wallis and Spearman’s r correlation) or parametric (one way ANOVA 
and two- way ANOVA) testing was applied. Bonferroni correction was applied to 
cases of multiple correlations against the same data set. 
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6.2. Results 
6.2.1. Mouse brain 3-nitrotyrosine levels 
When measuring the overall nitration levels by ELISA there was a statistically 
significant difference between the wild-type (WT) and transgenic (Tg) mice 
(models and brain regions combined; Mann-Whitney p=0.044), with the Tg mice 
having a higher median value: median (IQR) 1.04 (0.72 – 1.53) and 1.36 (1.07 – 
1.97) Tyr-NO2 pmol BSA equiv./mg protein for WT and Tg mice respectively 
(Figure 6.2).  
A comparison of the two models (Tas-TPM and Tau35), showed that the Tau35 
Tg mice had a higher median Tyr-NO2 value, but this did not reach statistical 
significance and animal numbers were low (Tas_TPM WT n=16, Tau35 WT 
n=3, Tas_TPM Tg n= 5 and Tau35 Tg n=12, Kruskal-Wallis p=0.066) (Figure 
6.3).  
The forebrain and cerebellum regions were compared in the WT and Tg mice 
(models combined) but no statistically significant differences were seen 
between regions or between Tg and WT mice within each brain region (Figure 
6.4).  
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Figure 6.2: Brain tissue nitration: wildtype versus transgenic mice 
The median and IQR values are shown. Tyr-NO2 was measured in duplicate by ECL 
ELISA as described in section 6.1.1. Mouse models are described in section 6.1. 
Transgenic mice (n=17) had a statistically significant increase in median nitration 
compared to wildtype mice (n=18) (Mann-Whitney, *p=0.044).  
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Figure 6.3: A comparison of brain tissue nitration in two transgenic mouse models of Alzheimer’s disease 
The median and IQR values are shown. Tyr-NO2 was measured in duplicate by ECL ELISA as described in section 6.1.1. Transgenic 
mouse models are described in section 6.1. The two models were split into Tg and WT samples, this meant the number of samples in some 
groups was small (Tas_TPM WT n=16, Tau35 WT n=3, Tas_TPM Tg n= 5 and Tau35 Tg n=12). Tau35 Tg mice showed the highest median 
levels of nitration but this was not significant (Kruskal-Wallis, p= 0.066).  
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Figure 6.4: 3-Nitrotyrosine levels in the cerebellum and forebrain of wildtype and 
transgenic mice 
The median and IQR values are shown. Tyr-NO2 was measured in duplicate by ECL ELISA as described 
in section 6.1.1. Mouse models are described in section 6.1. There were no significant differences 
between brain region median nitration levels for WT or Tg mice (two-way Anova p=0.82. Cerebellum 
wildtype n=7 and transgenic n=5. Forebrain wildtype n=12 and transgenic n=8).  
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6.2.2. Nitrated proteins in mouse brain tissue 
Western blots were performed to determine the number, and molecular weight, 
of nitrated proteins in the mouse brain tissue. However, the results were 
affected by the presence of endogenous biotin, which is possibly associated 
with carboxylases, leading to inappropriate binding of the secondary 
streptavidin antibody. Nevertheless, when comparing a blot with the primary 
anti-Tyr-NO2 to a blot run without the primary antibody (this blot showed the 
false binding of the streptavidin), it was observed that the low molecular weight 
bands were not false positives (i.e. not endogenous biotin) as they were not 
present on the second blot (Figure 6.5).  
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Figure 6.5: Western blot for nitrated proteins in mouse brain tissue 
Western blotting protocol described in section 6.1.2. green = nitrotyrosine, red = actin. A biotinylated Ab was used to 
avoid cross reactivity with mouse proteins. However, there was endogenous biotin in the brain tissue (blue arrows) 
and a blocking step is needed prior to Ab incubation. Lane 1 positive control; BSA-NO2 (red arrow), Lane 2 and 3 
transgenic mice cerebellum brain samples (A) Blot without an anti-Tyr-NO2 Ab and (B) blot with an anti-Tyr-NO2 Ab. 
The green bands present in B but not A (green arrows) are thought to be true Tyr-NO2 staining but further work is 
needed.  
A B 
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6.2.3. Human 3-nitrotyrosine levels 
Intra-assay CV (n=8) was calculated by dividing the SD, of the concentration, by 
the mean, of the concentration, and multiplying by 100 (Table 6.1). Intra-CV 
was 6.36%. 
Table 6.1: Determination of intra-assay CV for brain tissue analysis 
 
#1 #2 #3 #4 #5 #6 #7 #8 Mean SD CV 
Concentration 
(nM) 
5.19 4.80 4.75 4.62 4.42 4.33 4.37 4.42 4.61 0.29 6.36 
 
The Tyr-NO2 levels were adjusted for sample protein concentration and the 
median and IQR determined for each group (Figure 6.6). No statistically 
significant differences were observed between these median values (Kruskal-
Wallis p=0.97): median (IQR) AD 0.29 (0.19-0.57); VaD 0.36 (0.18-0.40) and 
non-demented controls 0.3 (0.22-0.55) Tyr-NO2 pmol BSA-NO2 equiv./mg 
protein.  
Brain NO3¯ was found to positively correlate with Tyr-NO2 (Spearman’s r = 
0.42, p= 0.03) (Figure 6.7). NO2¯did not correlate with Tyr-NO2 (Spearman’s r = 
0.31, p= 0.19). 
When examining the patient data no association could be found between Tyr-
NO2 levels and patient age, gender, tissue pH or post-mortem interval. 
Nitration in the mouse brain tissue was significantly higher than in the human 
brain tissue: median (IQR) 1.24 (0.98 – 1.71) and 0.32 (0.21 – 0.45) Tyr-NO2 
pmol BSA equiv./mg protein respectively (Figure 6.8). 
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Figure 6.6: 3-Nitrotyrosine levels in brain tissue from human dementia and 
dementia free control volunteers. 
Data represents median and IQR values. Tyr-NO2 was measured in duplicate by ECL ELISA as 
described in section 6.1.1.  All groups showed high variability in Tyr-NO2 levels (all n=15) and 
the median values were not statistically different (Kruskal-Wallis test p>0.05).  
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Figure 6.7: Correlation between 3-nitrotyrosine and nitrate concentration in brain tissue 
from human dementia patients and dementia free control volunteers 
NO3¯ was measured by ozone-based chemiluminescence as described in section 6.1.4. and 
Tyr-NO2 in duplicate by ECL ELISA as described in section 6.1.1. n=45. NO3¯ positively 
correlated with Tyr-NO2, p = 0.03 (with Bonferroni correction) and r = 0.42 (Spearman’s rank 
correlation).   
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Figure 6.8: A comparison of median 3-nitrotyrosine levels in human and mouse 
brain tissue 
The median and IQR values are shown. Tyr-NO2 was measured in duplicate by ECL ELISA as 
described in section 6.1.1. Human samples are as described in section 6.1. and mouse 
models in section 6.1. The mouse brain Tyr-NO2 levels (n=38) were far higher than the Tyr-
NO2 levels in the human brain samples (n=44) (Mann-Whitney ****p<0.0001).  
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6.2.4. Nitrite and nitrate levels in human brain tissue 
Mean brain NO2¯ levels were significantly different between the 3 groups (One-
way ANOVA, p= 0.03) with AD significantly higher than non-demented controls, 
but there was no difference between VaD and either of the other groups (mean 
± SD): AD 0.12 ± 0.05; VaD 0.11 ± 0.03 and non-demented 0.09 ± 0.03 
nmol/mg protein (Figure 6.9A).  
There were no statistically significant differences between groups for median 
NO3¯ levels (Kruskal-Wallis, p= 0.65): AD 2.6 (1.8-4.9); VaD 2.4 (1.9-3.3) and 
non-demented controls 2.1 (1.8-2.3) nmol/mg protein (Figure 6.9B). NO3¯ and 
NO2¯ positively correlated (Spearman’s rank correlation r = 0.53, p= 0.001) 
(Figure 6.10).  
There were no correlations between NO2¯ or NO3¯ with patient age, gender, 
tissue pH or post-mortem interval.  
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Figure 6.9: Nitrite and nitrate levels in human brain tissue from dementia patients and dementia free control volunteers 
NO2¯/ NO3¯ levels were measured by ozone-based chemiluminescence as described in section 6.1.4. and corrected for protein. Data 
represents median and IQR values, n=15 in each group. (A) NO2¯ median level showed a statistical difference, *p=0.03 (Kruskal-Wallis 
test), post-hoc testing (Dunn's Multiple Comparison test) showed the difference to be between the AD and control group. (B) No 
significant differences were found between groups for NO3¯ levels (Kruskal-Wallis, p= 0.65).  
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Figure 6.10: Correlation of nitrate with nitrite in human brain tissue samples from dementia 
patients and dementia free control volunteers 
NO2¯ and NO3¯ levels were measured by ozone-based chemiluminescence as described in section 6.1.4. 
n=45. A statistically significant positive correlation between NO2¯ and NO3¯ was observed, p = 0.001 (with 
Bonferroni correction) r = 0.53 (Spearman’s rank correlation). 
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6.2.5. Nitrated proteins in human brain tissue 
Western blotting did not reveal any qualitative differences between the three 
groups (Figure 6.11). Bands at ~15 and ~18 kDa were nearly always present 
and semi-quantitative analysis was performed for these bands by calculating 
the ratio of the Tyr-NO2 signal to actin signal for each sample. However, neither 
showed a statistically significant difference between groups (Kruskal-Wallis, 
p=0.06 and 0.4 for the 15 kDa and 18 kDa bands respectively). Suspected actin 
cleavage was observed but there was no significant difference, in the signal for 
the cleaved fragments, between the groups (Kruskal-Wallis, p=0.74).  
6.2.6. Mass spectrometry analysis of human brain tissue 
Due to the crude nature of the samples, numerous proteins were identified 
within each Tyr-NO2 positive band, these results were organised by the most 
abundant proteins (emPAI) and the reliability of the MS data assessed (Table 
6.2 A-G). The ion score produced by the Mascot software is the “calculated 
probability that the observed match between the experimental data and the 
database sequence is a random event” With scores >50 indicating identity or 
extensive homology at the p= 0.05 cut off (MatrixScience, 2014).  
The actin positive band MS/MS results reported actin as the most abundant 
protein (ion score of 14,579), confirming that the anti-actin antibody is binding 
appropriately and, that the Mascot Daemon software is able to correctly identify 
the proteins in the gel bands. Table 6.2 A-G represents the bands A-G, 
indicated in Figure 6.12. The top 10 proteins, based on emPAI score, for each 
band is listed; emPAI is a score of protein abundance in the sample. Within 
Table 6.2 A-G the results have been assessed further using the following 
criteria: (1) Is the molecular weight of the identified protein in line with the 
band's position on the coomassie gel? (2) Is the identified protein present in 
adult brain tissue? And (3) Is the ion score high in relation to the other proteins 
identified? For this last criteria the ion scores were placed in numerical order 
(not shown) and the cut-off for removing the lowest 5% determined (ion score 
>775). For each of the three criteria met a score of one was given, resulting in a 
score range of 0-3, with 3 indicating the highest confidence score. Information 
on protein location, Tyr content and function was obtained from the UniProt 
database (Consortium, 2015). 
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Figure 6.11: Western blot for nitrated proteins in human brain tissue from dementia and dementia free controls 
This blot is representative of all the western blots performed (n=5). Lane 1 - molecular weight marker, Lanes 2 and 3 - AD samples, Lanes 4 and 5 - VaD samples, 
Lanes 6 and 7 - Control (no dementia) samples and Lane 8 - positive control; BSA-NO2 (blue arrows show the monomer and an aggregate). Western blotting was 
performed as per the protocol described in section 6.1.2. (A) Tyr-NO2 only staining. (B) Dual staining; red for actin binding, green for Tyr-NO2. (C) Actin only staining 
(red arrows show the bands for the whole protein and cleaved products).  
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Figure 6.12: Location of nitrated bands excised for mass spectrometry 
Seven Tyr-NO2 positive bands were selected (as indicated, A-G) across the three groups, along with an 
actin positive band (loading control, not marked on blot), and excised from a corresponding Coomassie 
stained gel (protocol Chapter 2, section 2.4). These bands were then digested and underwent mass 
spectrometry analysis as described in section 6.1.3. 
1 2 3 4 5 6 7 8 
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Table 6.2A: Mass spectrometry protein identification data for band A (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location Proteins identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
AD >170 kDa 
(resolver/stacker 
interface) 
Band A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectrin-β, non-
erythrocytic 
49 8,240 274,439 3 
Interacts with calmodulin in a 
calcium-dependent manner and is 
thus a candidate for the calcium-
dependent movement of the 
cytoskeleton at the membrane. 
(Masliah et al, 
1990; Sihag and 
Cataldo, 1996; 
Fernandez-Shaw 
et al, 1997) 
Pyruvate kinase 9 3,742 57,900 2 
A glycolytic enzyme that catalyses the 
transfer of a phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP, 
generating ATP. Plays a general role in 
caspase-independent cell death of 
tumour cells. The ratio between the 
highly active tetrameric form and nearly 
inactive dimeric form determines 
whether glucose carbons are channelled 
to biosynthetic processes or used for 
glycolytic ATP production. 
(Butterfield et al, 
2006b) 
Spectrin-α, non-
erythrocytic 
41 3,654 284,364 3 
Interacts with calmodulin in a 
calcium-dependent manner and is 
thus a candidate for the calcium-
dependent movement of the 
cytoskeleton at the membrane. 
(Masliah et al, 
1990; Sihag and 
Cataldo, 1996; 
Fernandez-Shaw 
et al, 1997) 
Serum albumin 19 20,012 69,321 2 
Has a good binding capacity for water, 
Ca2+, Na+, K+, fatty acids, hormones, 
bilirubin, and drugs. Its main function is 
the regulation of the colloidal osmotic 
pressure of blood. Major zinc transporter 
in plasma typically binds about 80% of 
all plasma zinc. 
(Altunoglu et al, 
2015) 
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Band location Proteins identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
AD >170 kDa 
(resolver/stacker 
interface) 
Band A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keratin type II 
cytoskeletal 
24 689 65,999 0 
May regulate the activity of kinases such 
as PKC and SRC via binding to integrin 
beta-1 (ITB1) and the receptor of 
activated protein kinase C 
(RACK1/GNB2L1). In complex with 
C1QBP is a high-affinity receptor for 
kininogen-1/HMWK. 
 
Haemoglobin-α 3 107 15,248 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et al, 
2011; Chuang et 
al, 2012) 
Creatine kinase 9 1,751 42,617 1 
Reversibly catalyzes the transfer of 
phosphate between ATP and various 
phosphogens (e.g. creatine phosphate). 
Creatine kinase isoenzymes play a 
central role in energy transduction in 
tissues with large, fluctuating energy 
demands, such as skeletal muscle, 
heart, brain and spermatozoa. 
(Bürklen et al, 
2006) 
Myelin proteolipid 
protein 
14 259 30,057 1 
This is the major myelin protein from the 
central nervous system. It plays an 
important role in the formation or 
maintenance of the multilamellar 
structure of myelin. 
(Roher et al, 
2002; Barker et 
al, 2013) 
Dihydropyrimidinase-
related protein 
14 626 62,255 1 
Plays a role in neuronal development 
and polarity, as well as in axon growth 
and guidance, neuronal growth cone 
collapse and cell migration. Necessary 
for signalling by class 3 semaphorins 
and subsequent remodelling of the 
cytoskeleton. May play a role in 
endocytosis. 
(Castegna et al, 
2002) 
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Band location Proteins identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
AD >170 kDa 
(resolver/stacker 
interface) 
Band A 
V-type proton 
ATPase 
18 544 56,465 1 
Non-catalytic subunit of the peripheral 
V1 complex of vacuolar ATPase. V-
ATPase is responsible for acidifying a 
variety of intracellular compartments in 
eukaryotic cells. 
Mice 
(Chang et al, 
2013; Fu et al, 
2015) 
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Table 6.2B: Mass spectrometry protein identification data for band B (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location Proteins identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
 
VaD >170 kDa 
(resolver/stacker 
interface) 
Band B 
 
 
 
 
 
 
 
 
 
 
 
Spectrin-β, non-
erythrocytic 
49 7,710 274,439 3 
Interacts with calmodulin in a 
calcium-dependent manner and is 
thus a candidate for the calcium-
dependent movement of the 
cytoskeleton at the membrane. 
(Masliah et al, 
1990; Sihag and 
Cataldo, 1996; 
Fernandez-Shaw 
et al, 1997) 
Haemoglobin-β 3 165 15,988 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et al, 
2011; Chuang et 
al, 2012) 
Myelin proteolipid 
protein 
14 652 30,057 1 
This is the major myelin protein from the 
central nervous system. It plays an 
important role in the formation or 
maintenance of the multilamellar 
structure of myelin. 
(Roher et al, 
2002; Barker et al, 
2013) 
Tubulin-β4A 15 809 49,554 2 
Tubulin is the major constituent of 
microtubules. It binds two moles of GTP, 
one at an exchangeable site on the beta 
chain and one at a non-exchangeable 
site on the alpha-chain. 
(Brion et al, 2001; 
Boutte et al, 2005) 
Tubulin-β 16 776 49,639 2 As above 
Tubulin-β2A 16 738 49,875 1 As above 
Tubulin-α4A 19 497 49,892 1 As above 
Tubulin-α1A 19 551 50,104 0 As above 
Haemoglobin-α 3 127 15,248 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et al, 
2011; Chuang et 
al, 2012) 
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Band location Proteins identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
VaD >170 kDa 
(resolver/stacker 
interface) 
Band B 
Sodium/potassium-
transporting ATPase 
24 1,334 112,824 2 
Catalytic component of the active 
enzyme, which catalyzes the hydrolysis 
of ATP coupled with the exchange of 
sodium and potassium ions across the 
plasma membrane. This action creates 
the electrochemical gradient of sodium 
and potassium ions, providing the 
energy for active transport of various 
nutrients. 
(Adav et al, 2014) 
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Table 6.2C: Mass spectrometry protein identification data for band C (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass (Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control >170 kDa 
(resolver/stacker 
interface) 
Band C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectrin-β, non-
erythrocytic 
49 6,271 274,439 3 
Interacts with calmodulin in a calcium-
dependent manner and is thus a 
candidate for the calcium-dependent 
movement of the cytoskeleton at the 
membrane. 
(Masliah et al, 
1990; Sihag 
and Cataldo, 
1996; 
Fernandez-
Shaw et al, 
1997) 
Haemoglobin-β 3 147 15,988 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Spectrin-α, non-
erythrocytic 
41 3,186 284,364 3 
Interacts with calmodulin in a calcium-
dependent manner and is thus a 
candidate for the calcium-dependent 
movement of the cytoskeleton at the 
membrane. 
(Masliah et al, 
1990; Sihag 
and Cataldo, 
1996; 
Fernandez-
Shaw et al, 
1997) 
Haemoglobin-α 3 156 15,248 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Serum albumin 19 2,928 69,321 2 
Has a good binding capacity for water, 
Ca2+, Na+, K+, fatty acids, hormones, 
bilirubin, and drugs. Its main function is 
the regulation of the colloidal osmotic 
pressure of blood. Major zinc transporter 
in plasma typically binds about 80% of all 
plasma zinc. 
(Altunoglu et al, 
2015) 
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Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass (Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
Control >170 kDa 
(resolver/stacker 
interface) 
Band C 
Keratin type II 
cytoskeletal 
24 433 65,999 0 
May regulate the activity of kinases such 
as PKC and SRC via binding to integrin 
beta-1 (ITB1) and the receptor of 
activated protein kinase C 
(RACK1/GNB2L1). In complex with 
C1QBP is a high-affinity receptor for 
kininogen-1/HMWK. 
 
Keratin type I 
cytoskeletal 
27 339 62,027 0 Epidermal  
Myelin 
proteolipid 
protein 
14 227 30,057 1 
This is the major myelin protein from the 
central nervous system. It plays an 
important role in the formation or 
maintenance of the multilamellar structure 
of myelin. 
(Roher et al, 
2002; Barker et 
al, 2013) 
Tubulin-α1B 19 83 50,120 1 
Tubulin is the major constituent of 
microtubules. It binds two moles of GTP, 
one at an exchangeable site on the beta 
chain and one at a non-exchangeable site 
on the alpha-chain. 
(Brion et al, 
2001; Boutte et 
al, 2005) 
Keratin type II 
cytoskeletal 2 
18 154 65,393 0 Epidermal  
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Table 6.2D: Mass spectrometry protein identification data for band D (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control approx. 60 
kDa 
Band D 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pyruvate kinase 9 16,908 57,900 3 
A glycolytic enzyme that catalyses the 
transfer of a phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP, 
generating ATP. Plays a general role in 
caspase-independent cell death of 
tumour cells. The ratio between the 
highly active tetrameric form and 
nearly inactive dimeric form 
determines whether glucose carbons 
are channelled to biosynthetic 
processes or used for glycolytic ATP 
production. 
(Butterfield et 
al, 2006b) 
Rab GDP 
dissociation 
inhibitor 
25 6,336 50550 2 
Regulates the GDP/GTP exchange 
reaction of most Rab proteins by 
inhibiting the dissociation of GDP from 
them, and the subsequent binding of GTP 
to them. Promotes the dissociation of 
GDP-bound Rab proteins from the 
membrane and inhibits their activation. 
Promotes the dissociation of RAB1A, 
RAB3A, RAB5A and RAB10 from 
membranes. 
(Owen et al, 
2009) 
Dihydropyrimidi
nase-related 
protein 2 
14 7,730 62,255 3 
Plays a role in neuronal development 
and polarity, as well as in axon growth 
and guidance, neuronal growth cone 
collapse and cell migration. Necessary 
for signalling by class 3 semaphorins 
and subsequent remodelling of the 
cytoskeleton. May play a role in 
endocytosis. 
(Castegna et 
al, 2002) 
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Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
Control approx. 60 
kDa 
Band D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V-type proton 
ATPase 
18 3,254 56,465 2 
Non-catalytic subunit of the peripheral V1 
complex of vacuolar ATPase. V-ATPase 
is responsible for acidifying a variety of 
intracellular compartments in eukaryotic 
cells. 
Mice 
(Chang et al, 
2013; Fu et al, 
2015) 
Haemoglobin-β 3 235 15,988 1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Haemoglobin-α 3 382 15,248 1 As above 
Syntaxin-binding 
protein 1 
23 1,974 67,526 2 
May participate in the regulation of 
synaptic vesicle docking and fusion, 
possibly through interaction with GTP-
binding proteins. Essential for 
neurotransmission and binds syntaxin, a 
component of the synaptic vesicle fusion 
machinery probably in a 1:1 ratio. Can 
interact with syntaxins 1, 2, and 3 but not 
syntaxin 4. May play a role in determining 
the specificity of intracellular fusion 
reactions. 
 
Glucose-6-
phosphate 
isomerase 
14 2,461 63,107 3 
Besides its role as a glycolytic 
enzyme, mammalian GPI can function 
as a tumour-secreted cytokine and an 
angiogenic factor (AMF) that 
stimulates endothelial cell motility. GPI 
is also a neurotrophic factor 
(Neuroleukin) for spinal and sensory 
neurons. 
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Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
Control approx. 60 
kDa 
Band D 
Heat shock 
protein (60kDa) 
7 1,795 61,016 3 
Implicated in mitochondrial protein 
import and macromolecular assembly. 
May facilitate the correct folding of 
imported proteins. May also prevent 
misfolding and promote the refolding 
and proper assembly of unfolded 
polypeptides generated under stress 
conditions in the mitochondrial matrix. 
 
Alpha-
aminoadipic 
semialdehyde 
dehydrogenase 
14 984 58,450 2 
Multifunctional enzyme mediating 
important protective effects. Metabolizes 
betaine aldehyde to betaine, an important 
cellular osmolyte and methyl donor. 
Protects cells from oxidative stress by 
metabolizing a number of lipid 
peroxidation-derived aldehydes. Involved 
in lysine catabolism. 
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Table 6.2E: Mass spectrometry protein identification data for band E (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
AD approx. 15 kDa 
Band E 
 
 
 
 
 
 
 
 
 
 
Haemoglobin-β 3 14,423 15,988 3 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Haemoglobin-δ 3 9,272 16,045 2 As above (foetal subunit). 
Haemoglobin-α 3 7,804 15,248 3 As above 
Histone H4 4 1,018 11,360 2 
Histones play a central role in 
transcription regulation, DNA repair, DNA 
replication and chromosomal stability. 
(Narayan et al, 
2015) 
Fatty acid binding 
protein 
2 760 14,849 2 
FABP are thought to play a role in the 
intracellular transport of long-chain fatty 
acids and their acyl-CoA esters. 
(Desikan et al, 
2013; Olsson et 
al, 2013) 
Cytochrome C 5 507 11,741 1 
Electron carrier protein. Plays a role in 
apoptosis. Suppression of the anti-
apoptotic members or activation of the 
pro-apoptotic members of the Bcl-2 family 
leads to altered mitochondrial membrane 
permeability resulting in the release of 
cytochrome c into the cytosol. Binding of 
cytochrome c to Apaf-1 triggers the 
activation of caspase-9, which then 
accelerates apoptosis by activating other 
caspases. 
 
 189 
 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
 
AD approx. 15 kDa 
Band E 
Profilin-1 5 406 15,045 1 
Binds to actin and affects the structure of 
the cytoskeleton. At high concentrations, 
profilin prevents the polymerization of 
actin, whereas it enhances it at low 
concentrations. By binding to PIP2, it 
inhibits the formation of IP3 and DG. 
Inhibits androgen receptor (AR) and HTT 
aggregation and binding of G-actin is 
essential for its inhibition of AR. 
 
Cystatin B 3 378 11,133 1 
This is an intracellular thiol proteinase 
inhibitor. Tightly binding reversible 
inhibitor of cathepsins L, H, and B. 
Conflicting 
results 
(Žerovnik, 
2009) 
Galectin 1 2 364 14,706 2 
May regulate apoptosis, cell proliferation, 
and cell differentiation. Binds beta-
galactoside and a wide array of complex 
carbohydrates. Inhibits CD45 protein 
phosphatase activity and therefore the 
dephosphorylation of Lyn kinase. Strong 
inducer of T-cell apoptosis. 
 
Profilin-2 7 654 15,036 2 
Binds to actin and affects the structure of 
the cytoskeleton. At high concentrations, 
profilin prevents the polymerization of 
actin, whereas it enhances it at low 
concentrations. By binding to PIP2, it 
inhibits the formation of IP3 and DG. 
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Table 6.2F: Mass spectrometry protein identification data for band F (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
Control approx. 18 
kDa 
Band F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptidyl-prolyl 
cis-trans 
isomerase 
2 4,457 18,001 3 
PPIases accelerate the folding of 
proteins. It catalyses the cis-trans 
isomerization of proline imidic peptide 
bonds in oligopeptides. 
(Thorpe et al, 
2004; Blair et 
al, 2015) 
Histone H2B type 
1C 
5 1,429 13,898 2 
A core component of nucleosome. DNA 
accessibility is regulated via a complex 
set of post-translational modifications of 
histones, also called histone code and 
nucleosome remodelling. 
Has broad antibacterial activity. May 
contribute to the formation of the 
functional antimicrobial barrier of the 
colonic epithelium, and to the bactericidal 
activity of amniotic fluid. 
(Narayan et al, 
2015) 
Histone H2B type 
1B 
5 1,358 13,942 2 
A core component of nucleosome. DNA 
accessibility is regulated via a complex 
set of post-translational modifications of 
histones, also called histone code and 
nucleosome remodelling. 
Haemoglobin-β 3 
 
341 
 
15,988 
1 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Peroxiredoxin-V 2 1,443 22,073 2 
Reduces hydrogen peroxide and alkyl 
hydroperoxides with reducing equivalents 
provided through the thioredoxin system. 
Involved in intracellular redox signalling. 
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Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
Control approx. 18 
kDa 
Band F 
 
 
 
 
 
 
 
 
 
 
Nucleoside 
diphosphate 
kinase 
4 494 17,287 2 
Major role in the synthesis of nucleoside 
triphosphates other than ATP. Negatively 
regulates Rho activity by interacting with 
AKAP13/LBC. Acts as a transcriptional 
activator of the MYC gene; binds DNA 
non-specifically. Exhibits histidine protein 
kinase activity 
 
Visinin-like 
protein 
5 
 
355 
 
22,128 
1 
Regulates (in vitro) the inhibition of 
rhodopsin phosphorylation in a calcium-
dependent manner. 
(Lee et al, 2008; 
Luo et al, 2013) 
Gamma-
synuclein 
1 291 13,323 1 
Plays a role in neurofilament network 
integrity. May be involved in modulating 
axonal architecture during development 
and in the adult. In vitro, increases the 
susceptibility of neurofilament-H to 
calcium-dependent proteases (By 
similarity). May also function in 
modulating the keratin network in skin. 
Activates the MAPK and Elk-1 signal 
transduction pathway (By similarity). 
(Mukaetova-
Ladinska et al, 
2008) 
Destrin 4 243 18,493 2 
Actin-depolymerizing protein. Severs 
actin filaments (F-actin) and binds to actin 
monomers (G-actin). Acts in a pH-
independent manner. 
 
Tubulin-β2A 16 1,108 49,875 2 
Tubulin is the major constituent of 
microtubules. It binds two moles of GTP, 
one at an exchangeable site on the beta 
chain and one at a non-exchangeable site 
on the alpha-chain. 
(Brion et al, 
2001; Boutte et 
al, 2005) 
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Table 6.2G: Mass spectrometry protein identification data for band G (see Figure 6.12). Proteins ordered by emPAI score. 
Protein information from UniProt (Consortium, 2015). 
Band location 
Proteins 
identified 
No of Y 
residues 
Ion 
Score 
Protein 
mass 
(Da) 
Confidence 
score 
Protein function 
Information from UniProt 
Affected in 
dementia 
 
 
 
 
 
 
 
 
 
 
 
Control approx. 15 
kDa 
Band G 
 
 
 
 
 
 
 
 
 
 
 
 
Haemoglobin-β 3 11,795 15,988 3 
Involved in oxygen transport from the 
lung to the various peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Haemoglobin-δ 3 7,201 16,045 2 As above (foetal subunit). 
Haemoglobin-α 3 6,266 15,248 3 As above 
Histone H4 4 1,132 11,360 2 
Histones play a central role in 
transcription regulation, DNA repair, DNA 
replication and chromosomal stability. 
DNA accessibility is regulated via a 
complex set of post-translational 
modifications of histones, also called 
histone code and nucleosome 
remodelling. 
(Narayan et al, 
2015) 
Cytochrome b-c1 
complex 
7 288 13,522 1 
This is a component of the ubiquinol-
cytochrome c reductase complex 
(complex III or cytochrome b-c1 
complex), which is part of the 
mitochondrial respiratory chain. This 
component is involved in redox-linked 
proton pumping. 
 
Cytochrome c 
oxidase 
4 76 8,776 1 
This protein is one of the nuclear-coded 
polypeptide chains of cytochrome c 
oxidase, the terminal oxidase in 
mitochondrial electron transport. 
(Parker et al, 
1990; Kish et al, 
1992; Maurer et 
al, 2000; 
Cottrell et al, 
2002) 
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Control approx. 15 
kDa 
Band G 
Cytochrome c 5 362 11,741 1 
Electron carrier protein. Plays a role in 
apoptosis. Suppression of the anti-
apoptotic members or activation of the 
pro-apoptotic members of the Bcl-2 family 
leads to altered mitochondrial membrane 
permeability resulting in the release of 
cytochrome c into the cytosol. Binding of 
cytochrome c to Apaf-1 triggers the 
activation of caspase-9, which then 
accelerates apoptosis by activating other 
caspases. 
 
Haemoglobin-γ1 2 1,082 16,130 2 
Sub-unit of foetal Hb. Involved in oxygen 
transport from the lung to the various 
peripheral tissues. 
(Ferrer et al, 
2011; Shah et 
al, 2011; 
Chuang et al, 
2012) 
Haemoglobin-γ2 2 1,036 16,116 2 As above 
Galectin 1 2 378 14,706 2 
May regulate apoptosis, cell proliferation, 
and cell differentiation. Binds beta-
galactoside and a wide array of complex 
carbohydrates. Inhibits CD45 protein 
phosphatase activity and therefore the 
dephosphorylation of Lyn kinase. Strong 
inducer of T-cell apoptosis. 
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6.3. Discussion  
Dementia affects 35 million people worldwide and this figure is expected to rise 
to 65.7 million by 2030 (Sosa-Ortiz et al, 2012). New biomarkers are needed to 
help identify AD pathology in the early stages and to assess drug efficacy in 
clinical trials (Hampel et al, 2010). 
Increased oxidative stress has been observed in dementia, though its precise 
role in pathology is unknown.  Some oxidative stress pathways thought to play a 
role in either initiating or maintaining the damage seen in the brain are: (a) H2O2 
generation by amyloid-β plaques (Bush, 2003; Milton, 2004; Tabner et al, 2005), 
(b) reduced activity of SOD (Marcus et al, 1998; Omar et al, 1999; Esposito et 
al, 2006; Murakami et al, 2011), with increased O2 ˙¯  linked with AD (Guo et al, 
1999), (c) increased ˙NO production (stimulated by amyloid-β (Akama et al, 
1998)) and (d) Increased expression of MPO, which can lead to the generation 
of hypochlorous acid (Crawford et al, 2001; Green et al, 2004). Tyr-NO2 
generation has been reported in AD (Good et al, 1996; Hensley et al, 1998; 
Calabrese et al, 2006; Butterfield et al, 2007b), and the pathways activated 
above are all involved in its production, e.g. the increased O2˙¯ and ˙NO react 
to produce peroxynitrite and MPO catalyses nitration in the presence of NO2¯. 
The data collected from the ‘proof of concept’ mouse study suggests that a 
statistically significant difference in Tyr-NO2 levels can be observed when 
comparing WT and Tg mice (Figure 6.2). This suggests that the AD pathology 
exhibited in these animals leads to an increase in ROS and thus nitration. Other 
authors have reported increased oxidative damage in the brains of animal AD 
models (Smith et al, 1998; Pratico et al, 2001; Sultana et al, 2009).  
There was also a significant difference between the Tau35 model and the Tas-
TPM model (Figure 6.3), with Tau35 producing a higher median nitration. As 
detailed previously, these models produce different pathologies associated with 
AD. The Tau35 model has an expression of insoluble tau and Tas-TPM has 
amyloid pathology. This result needs to be investigated further with a larger n 
number but, it could be hypothesised that the tau pathology is the main 
contributor to increased oxidative stress, rather than amyloid plaques. Given 
that oxidative damage is implicated in AD pathology and can affect multiple 
cellular pathways this would be a very important difference, with implications as 
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to which model is the most relevant. There is evidence that in AD amyloid-β and 
tau interact to increase the others toxicity (Bloom, 2014). Amyloid-β is upstream 
of tau which then feeds back to amyloid-β, creating a toxic loop (Castillo-
Carranza et al, 2015). However, tau has a greater association with cognition 
and memory deficit and is increasingly being considered a more important 
target for AD therapy (Giacobini and Gold, 2013). Therefore, if increased 
oxidative/nitrative stress is associated with tau pathology, rather than amyloid-β 
aggregation, oxidative damage may be an important part of the neurotoxicity 
shown by tau and a target for treatment.  
When separating the samples by all factors, e.g. different models, transgenic, 
wildtype and brain region the number in each group becomes very small. 
However, as a preliminary study, it shows that nitration is detectable within the 
mouse brain for both the wild type and transgenic models.  
The pilot study, on human tissue, did not find a significant difference in nitration 
of frontal lobe brain samples when comparing AD with VaD or non-demented 
controls (Figure 6.6). This challenges the current consensus that AD patients 
are more prone to Tyr-NO2 formation in the brain (Good et al, 1996; Castegna 
et al, 2003; Butterfield et al, 2006a; Sultana et al, 2006; Butterfield et al, 2007b; 
Sultana et al, 2007; Reed et al, 2009). The results reported here also show a 
higher concentration of NO2¯ in the AD brain tissue (Figure 6.9) compared to 
non-demented controls (p<0.05). This contradicts DiCiero Miranda et al (2000), 
who found NOx to be decreased in the frontal cortex of the AD brain compared 
to non-demented age-matched controls. The NOx levels reported by DiCiero 
Miranda et al (2000) are 30.66 ± 3.10 (n = 5) and 56.85 ± 8.26 (n = 7) nmol/g 
tissue for AD and controls respectively. If it is assumed that each of the samples 
measured in our study were exactly 200mg/ml tissue (see homogenization 
protocol, section 6.1), then the levels observed in AD brain tissue were 4 times 
higher than found by DiCiero Miranda et al (2000): 135 nmol/g compared to 31 
nmol/g respectively. DiCiero Miranda et al (2000) used cadmium to reduce 
NO3¯ to NO2¯, followed by measurement using the Griess reagent. However, 
the study reported here used vanadium (III) chloride (at 95°C) to reduce the 
NO3¯, and ozone-based chemiluminescence for measurement. This difference 
in methodology could account for the vast difference in NO3¯ levels measured 
in brain tissue.  
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As both MPO and H2O2 have been shown to be increased in AD (Crawford et 
al, 2001; Bush, 2003; Green et al, 2004; Milton, 2004; Tabner et al, 2005) and 
MPO/H2O2/NO2¯ is a possible pathway for Tyr-NO2 formation (see Chapter 1, 
section 1.5) the increase of NO2¯, in AD, but not Tyr-NO2 would seem 
contradictory. However, there are a few possible explanations: (a) the increased 
MPO expression has not translated to an increase in MPO activity and/or (b) the 
MPO is being inactivated by high levels of H2O2 (Kettle et al, 1993; Olorunniji et 
al, 2009; Paumann-Page et al, 2013).  
Previous methods that have shown a difference in nitration between AD and 
controls groups (mild cognitive impairment  and no dementia) have used 
immunoblot or immunochemistry  to analyse Tyr-NO2 in the brain (Castegna et 
al, 2003; Butterfield et al, 2006a; Sultana et al, 2006; Butterfield et al, 2007b; 
Sultana et al, 2007; Reed et al, 2009). Immunochemistry is not quantitative in 
terms of overall nitration but does highlight tissue localization of Tyr-NO2, which 
may go some way towards explaining the differences in the literature and the 
results reported here.  
The brain region most commonly investigated is the hippocampus, whilst this 
region has shown high rates of atrophy in the early (pre-symptomatic) stages of 
AD (Scahill et al, 2002) other hallmarks such as amyloid deposits and 
neurofibrillary changes are not observed here until later stages (modest in stage 
3, numerous in stage 4) (Braak and Braak, 1991). The progression of AD 
through the brain has been shown to happen in a defined pattern, with different 
regions affected at different stages (Braak and Braak, 1991; Ohm et al, 1995; 
Scahill et al, 2002). Different levels of nitration have also been observed in 
different brain regions of AD patients, with the hippocampus showing very high 
levels (Hensley et al, 1998). Therefore, it may be that the nitrative burden was 
not significantly different between dementia and healthy aged brains within the 
frontal lobe but is within different regions, as shown in other studies.  
Some of the immunoblot studies used trichloroacetic acid (TCA) protein 
precipitation (Sultana et al, 2006; Sultana et al, 2007; Reed et al, 2009) which, 
in light of the increased NO2¯ we have observed in AD, risks increased artefact 
formation during sample preparation in AD (due to the possibility of nitration 
under acidic conditions in the presence of NO2¯) (Ohshima et al, 1990; 
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Shigenaga et al, 1997). A study using HPLC-electrochemical detection 
considered the effect this treatment may have during sample preparation and 
report that incubating tyrosine with NO2¯  and 6% TCA led to less than 0.01% 
Tyr-NO2 formation (Hensley et al, 1998). In vivo levels of serum protein nitration 
is thought to be around 0.01% (Radi, 2004), therefore this level of artefact 
formation in immunoblots (where up to 15% TCA was used) could have a large 
impact on the relative levels of Tyr-NO2 observed between groups. However, 
within this study, brain nitration levels are far higher than serum levels (Chapter 
3), so 0.01% artefact nitration would have a smaller impact on the results. 
Artificial nitration may also affect which proteins are observed to be nitrated, as 
different nitration methods have shown different protein selectivity (Souza et al, 
1999).  
As mentioned, the mouse study (section 6.2.1) found a significant difference in 
brain tissue nitration levels between wildtype mice and transgenic mouse 
models of AD (Figure 6.2). There was also a statistically significant difference in 
median brain tissue nitration when comparing the human and mouse samples 
(Figure 6.8), with the mouse brain showing a higher median Tyr-NO2 levels. 
This disagreement between the human and mouse studies may be due to 
species differences and/or due to the shorter delay in collecting and freezing the 
mouse samples. Protein degradation, for some proteins, will increase over time. 
Therefore, a sample with a long post-mortem interval (PMI) will have more 
degradation than a sample with a small PMI (Ferrer et al, 2008; ElHajj et al, 
2016). However, as results are adjusted for protein content this would only 
affect the results if nitrated proteins were preferentially degraded post-mortem. 
PMI has also been found to effect post-translational modification of proteins, 
though Ferrer et al (2008) found that nitration levels increased after 20 hours. If 
this effect were seen here then the human samples would have had higher 
levels of Tyr-NO2, than the mice, as the mean PMI in humans was 44 hours. 
Additionally, there was no correlation between Tyr-NO2 levels and PMI in the 
human brain tissue. 
Within the human study, western blotting revealed some bands that were 
consistently nitrated in brain tissue; this was also seen in the mouse western 
blots (Figure 6.5). The main Tyr-NO2 positive bands in the human tissue were 
approximately 15 kDa and 18 kDa in size (Figure 6.11). The mouse western 
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blots need to be run with a biotin blocking step, prior to primary antibody 
incubation, due to endogenous biotin. However, the absence of the low 
molecular weight bands, in the blot run without the anti-Tyr-NO2 antibody 
(Figure 6.5), suggests that they are truly nitrated in this tissue as well. When 
analysing the human tissue western blots the median signal ratio (Tyr-
NO2/actin) for the ~15 kDa band was slightly higher in the dementia groups but 
this did not reach significance (Kruskal-Wallis, p = 0.06). The ~18 kDa band had 
a similar median value between groups (Kruskal-Wallis, p= 0.41). 
Several nitrated proteins have been identified in AD by others, such as α-
enolase, triose phosphate isomerase, ATP synthase,  voltage-dependent anion 
channel protein 1 and β-actin (Butterfield et al, 2011).  Here mass spectrometry 
was used to identify the proteins within a selection of human Tyr-NO2 positive 
bands, including the two bands discussed above (Figure 6.12). Due to the 
crude nature of the sample, numerous proteins were identified within each 
band. The data was therefore organised by the emPAI score (score of 
abundance) and the data of the top ten assessed. 
As can be seen from Table 6.2E/G the most abundant protein for bands E and 
G (Figure 6.12 ~15 kDa band, AD and control) was haemoglobin, with multiple 
subunits listed. The haemoglobin (Hb) subunits contain 3 Tyr residues each, are 
the right molecular weight for the band and had high ion scores. Hb has been 
shown to be nitrated by the H2O2/ NO2¯ pathway (Chen et al, 2008) and is 
thought to be a good indicator of overwhelmed anti-oxidant defences in 
erythrocytes (Xiang et al, 2013). α and β neuronal Hb chains have been found 
to be expressed in mouse, rat, and human brain tissue, the functions of this 
neuronal Hb are unknown but its expression is lowered in neurodegenerative 
diseases such as AD (Ferrer et al, 2011). Additionally, both anaemia and 
clinically high levels of Hb have been associated with increased risk of AD and 
cognitive decline in older populations (Shah et al, 2011). Hb has also been 
shown to bind to amyloid-β peptide (Chuang et al, 2012), a site of H2O2 
production (Bush, 2003; Milton, 2004; Tabner et al, 2005). As altered Hb has 
been associated with AD, can be nitrated and is an abundant protein in the 
band, it would suggest that the signal in the western blot is from nitrated Hb. 
However, this makes the assumption that the most abundant protein is the 
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protein that is nitrated when it could be a low abundance protein that is highly 
nitrated. 
If it is Hb that has been nitrated this opens up the possibility that this could be 
measured as a peripheral marker, i.e. in erythrocytes. This has the advantage 
of being a sample that is not only available prior to death but readily available 
through routine practice, where any differences could potentially be used as a 
tool for prognosis, or monitoring disease progression. There has been 
contradictory data regarding the oxidant/antioxidant balance in erythrocytes 
from AD patients, with studies reporting: decreased activity for copper 
containing SOD (Snaedal et al, 1998), increased activity of glutathione 
peroxidase (Annerén et al, 1986) and no differences in activity for copper-zinc 
SOD, seleno-dependent glutathione peroxidase or glutathione reductase 
(Ceballos-Picot et al, 1996), when comparing AD to non-demented controls. 
Delibas et al (2002) measured erythrocyte antioxidant enzyme levels in the 
same dementia patients (described as dementia of the Alzheimer type) 5 years 
apart and found that copper-zinc SOD levels increased and glutathione 
peroxidase levels decreased, they also reported a significant negative 
correlation between erythrocyte malondialdehyde (a measure of lipid 
peroxidation) and a mental state examination. Although contradictory these 
studies suggest that an oxidative imbalance can occur in the erythrocytes of AD 
patients and that therefore Tyr-NO2 may be present, and measurable, in these 
cells. 
Actin was used as a loading control for the western blotting, the main actin band 
is at 45 kDa (expected weight). However, faint staining for actin is also 
observed under the 35 kDa and 15 kDa markers. Cleavage of actin by caspase 
1 is known to produce 31 and 15 kDa fragments, and this cleavage has been 
linked to apoptosis (Mashima et al, 1999). Therefore, the proportion of actin 
cleavage was calculated for each human sample to see if there was a 
difference in cleavage/apoptosis between groups. No significant difference in 
actin cleavage was observed between the groups (Kruskal-Wallis p=0.74).  
A limitation to this study is the use of a single time point, rather than measuring 
nitrative stress over the course of the disease. This is impossible in humans due 
to the use of post-mortem tissue but mouse models can be studied from a time 
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point prior to disease manifestation right through to the advanced stages. 
Additionally, the measurement of other oxidative stress markers, such as 
carbonyls, in combination with Tyr-NO2, nitrite and nitrate would have given a 
more complete picture of oxidative damage occurring in dementia.  
6.4. Conclusion 
Mouse models give insight into underlying pathology during disease 
progression and the testing of potential therapeutic strategies. Identifying a 
marker of oxidative stress that is increased in the transgenic mice, compared to 
wild-type, would allow more information of the disease process to be collected 
and antioxidant drug efficacy to be assessed. 
Although the human study did not show any difference in nitration between the 
three groups (AD, VaD, and no dementia) the fact that particular proteins are 
responsible for the majority of the nitration seen leads us to believe that further 
investigation into what these proteins are, and how they are affected by nitration 
would be worthwhile. Mass spectrometry analysis suggests that one of these 
proteins is Hb. It would be of particular interest if Hb were the nitrated protein 
seen at ~15 kDa, as nitration of Hb in the blood could be measured at different 
stages of AD, in the same person, via a routine blood test. Interestingly there is 
a small amount of evidence that this protein is nitrated in mouse models of AD 
too and could therefore be a marker in animal studies as well. Currently, 
nitration differences in humans with AD have only be measured in brain tissue 
collected post-mortem and in cerebrospinal fluid, a difficult sample to obtain 
(Tohgi et al, 1999). Dildar et al (2010) measured plasma nitration and found no 
difference between AD, VaD, and no dementia. However, it could be that the 
protein of interest had been removed from the blood during sample preparation 
(i.e. the Hb in the erythrocytes). Further work could involve adaption of the 
sandwich ELISA so that the capture Ab binds Hb and the detection Ab binds to 
Tyr-NO2 within the Hb. This would allow for the measurement of nitrated Hb only 
(rather than total) and show if there are any quantitative differences in nitration 
between sample sets, something that cannot be done accurately with a western 
blot. 
As well as identifying the nitrated proteins, future study should determine 
whether, when looking at different brain regions, a difference between AD and 
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non-demented controls does become apparent when quantifying overall Tyr-
NO2 levels by ELISA in humans. 
 
 
 
6.5. Acknowledgments 
The mouse brain tissue samples were supplied by Professor Andrew Randall 
and Dr Francesco Tamagnini (University of Exeter Medical School). 
The project measuring ˙NO metabolites and protein nitration in human brain 
tissue was funded by University of Exeter Research Knowledge Transfer and 
was in collaboration with the South West Dementia Brain Bank.  
We would like to thank the South West Dementia Brain Bank (SWDBB) for 
providing brain tissue for this study. The SWDBB is part of the Brains for 
Dementia Research programme, jointly funded by Alzheimer’s Research UK 
and Alzheimer’s Society and is supported by BRACE (Bristol Research into 
Alzheimer's and Care of the Elderly) and the Medical Research Council. 
Dr Miranda Smallwood performed the ozone-based chemiluminescence for 
NO2¯ and NO3¯ measurement and assisted with the western blots on human 
samples. 
Mass spectrometry (TOF-MS/MS) was done by Professor A Pitt, Dr C Spickett 
and Dr K Tveen-Jensen (Aston University). 
 
 
 
 
 
 
 202 
 
Chapter 7  
General Discussion and Future Work 
Oxidative/nitrative stress has been studied in many diseases and it is becoming 
increasingly evident that ROS/RNS mediated damage plays a role in the 
pathology of many, diverse conditions e.g. cardiovascular disease (Shishehbor 
et al, 2003; Eleuteri et al, 2009), neurodegenerative disease (Beal et al, 1997; 
Butterfield et al, 2007a) and dysfunctional immune responses, i.e. autoimmunity 
(Khan et al, 2006; Eggleton et al, 2008) and sepsis (Fukuyama et al, 1997; 
Ohya et al, 2002). Despite many years of research, the accurate measurement 
of oxidative stress is still an area in need of analytical improvement, with many 
markers being non-specific or requiring expensive/time-consuming techniques, 
such as mass spectrometry, for accurate measurement (Frijhoff et al, 2015). 
More clinical studies, such as randomised drug trials or prospective studies, are 
also needed to be able to assess the sensitivity and specificity of oxidative 
stress biomarkers (Frijhoff et al, 2015).  
RNS such as ˙NO and ONOO¯ are upregulated during inflammation and 
damaging levels have been associated with inflammatory diseases (e.g. 
sepsis), chronic diseases with an inflammatory component (e.g. Alzheimer’s 
disease) and tissue insult (e.g. surgery). Tyr-NO2 is becoming an increasingly 
popular marker of RNS production but accurate and valid measurement has 
faced several methodological issues (Herce-Pagliai et al, 1998; Duncan, 2003). 
The gold standard of measurement for Tyr-NO2 is mass spectrometry but this is 
low-throughput and expensive. Commercial ELISAs are available but they have 
low sensitivity, limiting their usefulness when applied to diseased human 
plasma samples. Within this project, a new sensitive ELISA for Tyr-NO2 
measurement was developed. ˙NO production is also measured as a marker of 
nitrative stress, this is often done by measuring its metabolites, NO2¯ and NO3¯. 
Measurement of NO2¯ and NO3¯ is frequently performed using the Griess 
reaction. However, the more sensitive highly validated method of ozone-based 
chemiluminescence was utilised here. 
Within in this project, the aims have been to measure nitrative stress in samples 
with varying inflammatory conditions and to assess the clinical utility of Tyr-NO2. 
A Tyr-NO2 ELISA was developed, based on an electrochemiluminescence 
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(ECL) platform, ECL uses an electrically stimulated chemical reaction to 
produce light and this is then measured. This platform improves the sensitivity 
of the assay, when compared to colorimetric platforms, due to a decreased 
background (Figure 3.2). An ELISA method offers high throughput and requires 
little sample preparation but is semi-quantitative. The method developed within 
this project provided an assay with high sensitivity (LLOQ 0.04 nM BSA-NO2) 
and high reproducibility within and between runs (intra-assay CV 6.5% and 
inter-assay CV 14%). Additionally, the relative nitration of three BSA samples 
(non-modified, nitrated and dithionite treated) was measured by mass 
spectrometry and supported the ELISA results.   
The assay was applied for the measurement of Tyr-NO2 in serum samples from 
patients pre- and post-surgery. The surgery was viewed as an instigator of an 
acute inflammatory response, and this was confirmed by serum CRP 
measurements. Following the surgery/initiation of inflammation a significant 
increase in Tyr-NO2 levels was observed (median (IQR): 0.59 (0 – 1.3) and 0.97 
(0 – 1.7) Tyr-NO2 fmol BSA-NO2 equiv./mg protein for pre- and post-surgery 
respectively). These results are in keeping with the production of ROS during 
inflammation and confirm the assay’s sensitivity, as many of these samples 
were below the LOD of commercial ELISAs for Tyr-NO2 measurement. The 
assay was also successfully applied for the measurement of Tyr-NO2 in blood 
cell lysates. The intracellular levels of Tyr-NO2 were far higher than the 
extracellular serum levels, with the highest levels being found in the cell line 
U937: median Tyr-NO2 levels – serum 0.59, erythrocytes 11.18, mononuclear 
cells 742.96 and U937 cells 3160 fmol BSA-NO2 equivalents/mg protein.  
Our research group has previously performed extensive studies on NO3¯ rich 
supplementation, due to its potential beneficial physiological effects that are 
thought to be a result of the reduction of NO3¯ to ˙NO (Duncan et al, 1995; 
Gilchrist et al, 2010; Jones, 2014). Based on the fact that NO3¯ can be reduced 
to NO2¯ and ˙NO in vivo (Duncan et al (1995); Figure 4.1) we were interested 
in whether increased dietary intake of NO3¯ led to nitration of proteins (i.e. Tyr-
NO2 formation), in the saliva or in plasma. This was studied with a focus on 
smokers, as inflammatory reactions have been shown to be stimulated by 
cigarette smoking, e.g. elevated serum MPO has been observed in smokers 
compared to non-smokers (Martins et al, 2013). Nitration of proteins can affect 
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their function, and oxidative post-translational modifications of proteins can 
create neo-epitopes that have been linked to autoimmune reactions (Ryan et al, 
2014). 
Both plasma and saliva, from healthy individuals, were measured for nitrated 
protein, NO2¯, and NO3¯. Following the NO3¯-rich supplementation both plasma 
and saliva NO2¯ and NO3¯ levels increased significantly (Figure 4.5 and Figure 
4.8). Plasma showed very low levels of Tyr-NO2 (often near the LLOQ) 
regardless of whether the participant was a non-smoker or smoker, or taking 
NO3¯-rich supplementation (non-smokers and smokers after NO3¯-rich 
supplementation: median (IQR) 0.97 (0.57 – 1.92) and 1.13 (0.69 – 2.23) Tyr-
NO2 fmol BSA equiv./mg protein respectively, Figure 4.3). However, saliva 
showed 1000-fold higher levels of nitrated protein compared to the plasma and, 
interestingly, salivary Tyr-NO2 levels were decreased with NO3¯-rich 
supplementation: median (IQR) before and after supplementation: 0.67 (0.31 – 
1.14) and 0.42 (0.10 – 0.59) Tyr-NO2 pmol BSA equiv./mg protein respectively, 
non-smokers and smokers combined. One possible explanation is ˙NO 
production in excess of O2˙ ¯ (so it is not all used in ONOO¯ formation). 
Salivary ˙NO was previously shown to have anti-microbial activity (De Groote 
and Fang, 1995; Duncan et al, 1995) which would lead to less inflammation and 
therefore less MPO activity and O2˙¯ formation, resulting in decreased Tyr-NO2 
formation.  
Future work should investigate whether, following NO3¯-rich supplementation, 
decreased salivary Tyr-NO2 levels did correlate with decreased salivary 
inflammatory markers, such as IL1-β. 
Sepsis is a dysregulated immune response to infection involving pro- and anti-
inflammatory components, e.g. increased levels of circulating pro-inflammatory 
cytokines and reduced lymphocyte numbers (Adib-Conquy and Cavaillon, 
2008). Tyr-NO2 was previously measured in septic shock (Fukuyama et al, 
1997; Ohya et al, 2002), with results suggesting that Tyr-NO2 could have a 
prognostic value (Ohya et al, 2002). To investigate whether increased Tyr-NO2 
levels are seen prior to diagnosis a time course of serum samples was 
collected, from a cohort of patients with and without postoperative sepsis, with 
samples being collected one day before surgery and every day subsequently 
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until diagnosis. At one day prior to diagnosis, the levels of Tyr-NO2 were 
significantly higher in the sepsis group compared to the group which did not 
develop sepsis (controls); the median values were 4.5 and 1.2 fmol BSA-NO2 
equiv./mg protein respectively (Figure 5.4). As far as we are aware, this is the 
first time Tyr-NO2 has been measured prior to a clinical diagnosis of sepsis and 
demonstrates that elevated oxidative/nitrative stress can already be observed at 
this time point when compared to non-septic controls.  
The diagnostic potential of serum Tyr-NO2 was also assessed. When compared 
to serum CRP concentrations, an established marker of inflammation, the Tyr-
NO2 was not as sensitive at differentiating patients who would develop sepsis 
from those who would not (as determined by ROC analysis). Tyr-NO2 levels did 
not show a statistically significant correlation with CRP concentrations. 
Furthermore, when the markers were combined, there was no additive effect on 
specificity and sensitivity (net reclassification index –0.2).  
Sepsis is a highly heterogeneous disease and future work, on a larger number 
of samples, would allow for stratification of samples into groups based on 
factors such as the type of surgery being undertaken or patient outcome. This 
approach has been put forward to improve sepsis definition, with the PIRO 
(Predisposition, Infection, Response and Organ dysfunction) staging model 
suggested as a means of creating more informative groupings (Vincent et al, 
2009; Howell et al, 2011; Granja et al, 2013).This refined grouping would 
provide information on which individuals experience the highest levels of 
oxidative stress. The relationship, if any, between Tyr-NO2 levels prior to 
diagnosis and prognosis should also be assessed.  
Oxidative stress has been implicated in Alzheimer’s disease (AD) pathology and 
Tyr-NO2 has been observed in brain tissue (Castegna et al, 2003; Butterfield et 
al, 2007b; Sultana et al, 2007). We measured Tyr-NO2 in mouse brain tissue 
homogenates and observed that transgenic mouse models of AD had higher 
median values than wildtype mice: median (IQR) 1.36 (1.07 – 1.97) and 1.04 
(0.72 – 1.53) Tyr-NO2 pmol BSA equiv./mg protein respectively.  
We also investigated nitrative stress in human brain tissue homogenates, of 
patients with dementia, compared to age-matched control individuals without 
dementia. Mean NO2¯ levels in the brain tissue were significantly higher in the 
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AD brain compared to the controls (AD and non-demented: 0.12 ± 0.05 and 
0.09 ± 0.03 nmol/mg protein respectively). This suggests an increase in ˙NO 
formation. However, contradictory to published studies (Castegna et al, 2003; 
Butterfield et al, 2007b; Sultana et al, 2007), the data reported here showed no 
difference in total nitration between AD and controls (Figure 6.6). This could be 
due to methodological differences; here a semi-quantitative ELISA was used 
when many investigators have reported differences based on 
immunohistochemistry. The type and range of brain regions investigated could 
also impact on the results achieved by different groups as Hensley et al (1998) 
has shown oxidative damage to vary between different brain regions, for 
example the hippocampus has higher levels than other brain regions. In the 
study reported in this thesis, the levels of nitrated protein in the brain tissue 
were far higher than seen in serum from patients with sepsis, suggesting that 
nitrative modification is at its greatest in tissue rather than in circulation. 
Western blotting of the human brain tissue revealed that much of the nitration 
was in a band at approximately 15 kDa (as well as in a band at approximately 
18 kDa). Mass spectrometry analysis of the bands revealed that haemoglobin 
subunits were abundant within the ~15kDa band (Table 6.2).  
Future work, utilising mass spectrometry, should confirm that the haemoglobin 
within the western blot band is nitrated. If it is, then a further study, using the 
ECL ELISA, would look at red blood cell Tyr-NO2 levels. A blood biomarker of 
oxidative stress in AD would be of huge benefit to the field as (a) it could allow 
monitoring of the disease/treatment efficacy and (b) it could aid diagnosis as, 
currently, a definitive diagnosis can only be obtained upon post-mortem 
examination.  
During this project nitrative stress was measured in multiple sample types, in 
health and disease, using ozone-based chemiluminescence and a new ECL 
assay. These methods were selected for a more robust and validated approach 
to measuring nitrative stress as this field of study has been hindered by 
methodological problems. Further improvements to the Tyr-NO2 ECL assay are 
envisioned. In particular, the generation of a fully quantified standard. The 
current standard is a commercial preparation of nitrated BSA (BSA-NO2). The 
number of nitrated residues on each molecule of BSA is unknown. Therefore, 
results cannot be quantified in terms of the absolute Tyr-NO2 concentration. 
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Instead, the results are displayed as an equivalence to the BSA-NO2 
concentration. While there are further modifications and improvements that can 
be made to the assay, this ‘version 1.0’ has still proven to be useful in 
comparing sample sets and highlighting future directions of study.  For example, 
this project has shown that Tyr-NO2 is increased prior to a diagnosis of post-
surgery sepsis. A further study, with patients staged using the PIRO model, 
would determine if this could be an additional marker of diagnosis/prognosis in 
certain patient populations. Analysis of brain tissue nitration contradicted the 
published literature but, when combined with the blood cell lysate analysis, 
highlighted that the study of intracellular (e.g. blood cells) Tyr-NO2 levels may 
be an overlooked area of research.  
Another important consideration is whether oxidative stress should be 
measured in a ‘broader’ way, i.e. measuring a panel of oxidative stress markers 
in combination rather than just one or two. This approach, whilst time 
consuming and more expensive, would allow for a more complete overview of 
what is happening in different diseases, as different oxidative 
stress/inflammatory pathways will be activated to varying levels and analysing 
just one marker may miss crucial information.  
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Maxillofacial surgery
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Large bowel resection
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Radical cystectomy
0 1 2 3 4 5 6 7
0.1
1
10
100
Day
T
y
r-
N
O
2
 (
fm
o
l 
B
S
A
-N
O
2
 e
q
u
iv
./
m
g
 p
ro
te
in
)
Large bowel resection
(low anterior resection)
0 1 2 3 4 5 6 7
0.1
1
10
100
Day
T
y
r-
N
O
2
 (
fm
o
l 
B
S
A
-N
O
2
 e
q
u
iv
./
m
g
 p
ro
te
in
)
Aabdominoperineal resection
0 1 2 3 4 5 6 7
0.1
1
10
100
Day
T
y
r-
N
O
2
 (
fm
o
l 
B
S
A
-N
O
2
 e
q
u
iv
./
m
g
 p
ro
te
in
)
Large bowel resection
0 1 2 3 4 5 6 7
0.1
1
10
100
Day
T
y
r-
N
O
2
 (
fm
o
l 
B
S
A
-N
O
2
 e
q
u
iv
./
m
g
 p
ro
te
in
)
 212 
 
 
Large bowel resection
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Abdominal aortic aneurysm repair
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Cholecystectomy
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Post-surgery sepsis 
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Lung resection
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Biliary procedure
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Lung resection
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Cystectomy & reconstruction
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Small bowel resection
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